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Abstract 
 The research described here focuses on the molecular variations, clinical significance 
and structural interactions of the innate immune protein, C-reactive protein (CRP). 
Monomeric CRP (mCRP) was produced through urea-induced dissociation, at an 
optimum concentration of 3M urea over a 10-week period. Dissociated samples were 
purified via size exclusion chromatography and confirmation was provided via Western Blot 
analysis. In contrast with previous published works, this mCRP retained the ability to 
reversibly bind to phosphocholine. Furthermore, the binding of mCRP with cell wall 
polysaccharide does not result in the generic precipitation trend as that seen with pentameric 
CRP (pCRP). 
 Human serum samples with raised CRP levels (>100mg/L) were analysed (n =40) to 
determine whether circulating mCRP could be detected in vivo. All 40 samples tested 
positive for pCRP via Western Blot and ELISA analysis, with further quantification via the 
UV Spectrophotometer supporting the calculated pCRP levels. Monomeric CRP was 
identified in all the 40 patient samples tested, with an average value recorded of 0.88mg/L 
(SE = ±0.142). Informed by the results from in vitro mCRP studies, the mCRP displayed a 
molecular weight of approximately 25kDa based on size exclusion chromatography and 
Western Blot analysis and demonstrated an ability to reversibly bind phosphocholine. To 
our knowledge, we are the first to successfully purify and identify a monomeric form of CRP 
from human serum through these procedures. 
Crystallisation trials of in vitro produced mCRP and the complex of pCRP with 
C1qGHR and CWPS did not result in the growth of any protein crystals of sufficient 
diffraction quality. One crystal from the complex crystallisation trials diffracted to 9Å with 
follow up conditions currently being pursued. Furthermore, additional crystallisation trials 
  
 
 
from both experiments have generated potential conditions which may be refined in future 
research to produce high-quality diffraction grade crystals. 
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Chapter 1.0 – Introduction  
1.1 Overview 
C-reactive protein belongs to a family of proteins known as the pentraxins and has 
been highly conserved throughout evolution. The pentraxin family is named for its 
appearance in electron micrograph from the Greek words penta (five) and ragos (berries) 
(Pepys et al. 1978b; Pepys & Hirschfield, 2003).  
When the human body becomes infected with an invading pathogen, liver cells will 
begin synthesising C-reactive protein rapidly as part of the innate immune response. Due to 
this acute rise of the plasma protein’s levels within serum, it is routinely used worldwide as 
a biological marker for infection, inflammation and tissue damage. 
C-reactive protein has been identified within a whole range of species including the 
mammalian class, fish and even within the primitive Atlantic horseshoe crab, Limulus 
polyphemus (Pepys et al., 1978b). Additionally, there is no record of any human being 
identified as having a deficiency of C-reactive protein Coupled with a persistence to resist 
evolutionary change, this underlies the importance of C-reactive protein to the host’s innate 
immune function (Pepys & Baltz, 1983). 
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1.2 The Human Immune System 
 
The study of the human immune system is a relatively new science, thought to 
originate from Edward Jenner, who observed in the late 18th century that the relatively mild 
disease of cowpox seemed to confer protection against the often-fatal disease of smallpox. 
In 1796, Jenner demonstrated that inoculation with cowpox protected from smallpox, and 
named this procedure a ‘vaccination’. It was not until the 19th century that Robert Koch 
proved that infectious diseases are caused by microorganisms, each responsible for their own 
disease. In modern-day medicine, we now recognise four broad categories of disease-causing 
microorganisms, more commonly known as pathogens: viruses, bacteria, fungi and 
unicellular & multicellular eukaryotic organisms (collectively known as parasites) (Berg et 
al., 2011; Murphy et al., 2008).  
 The human immune system can be split into two different sub-categories. These two 
categories are; the innate immune system, a short lasting, non-specific primary line of 
defence, and the adaptive immune system, which provides a ‘tailored’ response specific to 
the pathogen it targets. Both systems contain proteins, cells and organs that are concerned 
with defence of the individual, primarily against the threat of disease caused by these 
infectious organisms. The animal or human that an infectious organism (or pathogen) 
invades is known as the host. Not all infectious organisms are harmful to the host they 
invade, with some being beneficial. Bacteria living within our gut aid in the digestion of 
food and are known as commensal organisms. However, there are many pathogens to which 
we as a species are constantly in danger of infection, and the diseases caused by them. 
Without the protection from our immune system, we would be vulnerable to these pathogens 
that we are exposed to daily (Wood, 2006).  
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 The function of the human immune system is primarily to protect the host against the 
threat of disease. This defence can be further split into four main tasks. The first is known 
as immunological recognition; the presence of an infection must be detectable by the 
immune system. This immediate response is carried out by white blood cells of the innate 
immune system, and lymphocytes of the adaptive immune system. The second task is to 
contain the infection, eventually removing the pathogen from the host completely. This is 
known as immune effector functions. The human body has a whole range of defence 
mechanisms within its arsenal; activation of one of the three complement cascades through 
a system of blood proteins, production of antibodies, recruitment of lymphocytes and other 
white blood cells (Murphy et al., 2008). The third task is immune regulation; the ability of 
the immune system to regulate itself to prevent causing harm to the host. Dysfunction of this 
system can result in exacerbation of the immune response, thus exploiting conditions such 
as allergies and auto-immune disease (Muphy et al., 2008). Finally, the fourth point is 
immunological memory, a unique feature of the adaptive immune system. Memory from the 
immune system is paramount if preventing recurrence of disease from the same pathogen. 
Having already been exposed to that same pathogen previously in a person’s life, allows the 
human body to generate an immediate and stronger response against subsequent exposure 
(Berg et al., 2011). 
 The human body has two main different forms of protection barriers which prevent 
invasion of pathogens which may cause disease. Physical barriers include skin and mucosa, 
cilia lining the respiratory tracts and mucus secreted in the epithelial cells of the gut. 
Chemical and biochemical barriers include the acidic conditions, fatty acids, lysozymes 
present in sweat and tears and collectins which can bind to sugars of microbial surfaces and 
promote elimination. Despite these primary defences, pathogens are constantly developing, 
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and adapting to these barriers, meaning more complex defence features are required from 
the human immune system (Berg et al., 2011; Muphy, et al 2008; Wood, 2006).  
1.2.1 Inflammation and the Immune System 
 
 When the host’s initial defences are breached, the invading pathogen will encounter 
cells that will recognise the organism as ‘foreign’. This results in the initiation of the 
immediate innate immune response. One of the main functions of the innate immune system 
is to propagate an inflammatory response at the site of infection (Berg et al., 2011). 
Physiological changes within the body, including vasodilation, endothelial cell activation, 
increased vascular permeability and the secretion of chemotactic factors, are all contributing 
factors. Immune cells, such as macrophages engulf these pathogens and present fragmented 
pieces of the pathogen on their surface. This phagocytosis of the invading organism also 
results in the release of proteins known as chemokines and cytokines, alongside other 
immune-stimulating biologically active molecules (Alberts et al., 2014; Wood, 2006).  
Chemokines are chemotactic agents which are responsible for the migration of 
certain immune cells. Furthermore, they can also indirectly increase the expression of cell 
adhesion molecules, such as selectins and integrins. Alteration in these cell adhesion 
molecules allows immune cells (neutrophils, macrophages) to bind to the epithelium at a site 
around the body and enter the tissues. The process by which these cells leave the bloodstream 
is known as extravasation (Wood, 2006). This is usually carried out in four main stages, the 
first being ‘rolling’. Vasodilation of blood vessels reduces blood flow and allows immune 
cells to ‘roll and bump’ along the endothelial cell wall, interacting with ‘E’ and ‘P’ selectin. 
Attachment then occurs through adhesion molecules such as the intercellular adhesion 
molecule 1 (ICAM-1), which allows cells to migrate across the epithelium towards the site 
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of inflammation, where concentrations of certain chemokines will be higher, usually 
interleukin (IL) 8 (Wood, 2006).   
Whereas chemokines function as chemo-attraction proteins, cytokines function as 
signalling molecules between cells. They are secreted through a broad range of cells from 
the immune system through interactions with receptors on the cell surface. Chemokines are 
responsible for regulation of the immune response, and can also evoke biological activities 
through binding to certain receptors. Although inflammation is a natural response of the 
human immune system to toxins or foreign substances, more commonly known as antigens, 
aggressive immune responses can occasionally inflict undue harm to the host. Diseases such 
as rheumatoid arthritis, cardiovascular disease and diabetes mellitus are all thought to 
contain an element of immune dysregulation. This occurs when immune cells fail to 
recognise the host’s cells and start destroying them. In addition, the uncontrolled release of 
inflammatory cytokines can further result in damaging levels of inflammation at localised 
sites throughout the body (Alberts et al., 2014; Berg et al., 2011; Murphy et al., 2008; Wood, 
2006).  
1.2.2 The Innate Immune System 
 
 The innate immune system is a part of a host’s defence, which has been passed down 
through the generations. Unlike the adaptive immune system which is ‘learnt’, organisms 
are born with innate immunity, with vertebrates, invertebrates, plants, and even the most 
primitive of organisms being recorded to display this line of defence (Alberts et al., 2014; 
Janeway & Medzhitov, 2002). These pre-existing defence mechanisms are designed to 
prevent infection and mount an immediate, primary defence against invading infectious 
agents. The innate immune response is not specific to a pathogen in the way the adaptive 
immune system is, and can generate a response within a matter of hours. The system depends 
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on a group of proteins and phagocytic cells that recognise conserved features of pathogens 
and become activated quickly to help destroy and remove pathogens (Alberts et al., 2014; 
Wood, 2008).  
 The innate immune system can be sub-divided into the humoral arm and the cellular 
arm of defence. The humoral arm of the innate immune system is extremely diverse and is 
so named as it involves substances which are found in the humorous or bodily fluids. 
Macromolecules such as antibodies (adaptive immunity), blood proteins and antimicrobial 
peptides are secreted into the extracellular space upon recognition of a foreign stimulus. 
Once infectious agents have breached anatomical barriers, or penetrated tissues, acute 
inflammation is stimulated, typically manifesting symptoms such as redness, swelling, heat 
and possible pain. Blood proteins responsible for these pathological changes include 
collectins (surfactant protein A and D, C1q, mannose-binding lectin), ficolins and pentraxins 
(C-reactive protein, PTX3, serum amyloid protein) (Garlanda et al., 2005). Activation of the 
complement system also occurs, enhancing the immune response through recruitment of 
immune cells and antibodies, whilst also promoting intensified states of inflammation. These 
immune components play a crucial role in the discrimination between host and foreign cells 
through recognition of highly conserved motifs called pathogen-associated molecular 
patterns (PAMPS) (Berg et al., 2011). PAMPS often occur in repeating patterns of microbial 
molecules, including nucleic acids, proteins, lipids and polysaccharides. Special receptor 
proteins, shown through the above listed examples, can recognise PAMPS, and are known 
as pattern recognition receptors (PRRs). PRRs can be expressed on the surface of immune 
cells (including macrophages and dendritic cells), in addition to intracellularly. There are 
four main classes of PRR families which have been identified. These include transmembrane 
proteins, such as toll-like receptors (TLRs), C-type lectin receptors as well as cytoplasmic 
proteins such as retinoic acid-inducible gene receptors and nucleotide oligomerisation 
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domain (NOD)-like receptors. Upon detection of PAMPs by PRRs, an inflammatory 
immune response is triggered, which leads to the destruction and removal of invading 
pathogens from the host (Alberts et al., 2014; Murphy et al., 2008; Takeuchi & Akira, 2010; 
Wood, 2006).   
 The cellular arm of the innate immune system involves the recruitment of immune 
cells to a site of infection and production of intensified states of inflammation, through the 
secretion of inflammatory mediators such as cytokines (interleukin-6) and chemokines 
(interleukin-8). These are produced by immune cells such as macrophages and mast cells 
(Janeway & Medzhitov, 2002). Among these recruited cells are phagocytes. Phagocytes are 
a group of cells, including dendritic cells and mast cells. The most commonly recruited 
phagocyte during an inflammatory response are neutrophils, which are capable of ingesting 
foreign particles such as bacteria, parasites, dead host cells and foreign debris and digesting 
their contents. This process is known as phagocytosis (Berg et al., 2011). Harmful pathogens 
(or peptides) which have been opsonised, agglutinated, neutralised or rendered harmless 
through interactions with antibodies or alternative immune proteins are engulfed by 
phagocytes. These are then digested through lysosome killing mechanisms (usually digestive 
enzymes). Alternative lysosome-independent killing mechanisms also exist, which involve 
the generation of oxygen radicals and the production of nitric oxide (Janeway & Medzhitov, 
2002, Wood, 2006). Although the innate immune system differs in specificity, response time, 
memory to the adaptive immune response, there is a large amount of overlap, with both arms 
of the immune system working together to protect the host.  
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1.2.3 The Adaptive Immune System 
 
 Occasionally, a microorganism will infect a host, which requires a stronger immune 
response than that provided through innate immunity. Complex creatures, such as vertebrates 
can elicit a more sophisticated and specialised response, known as the adaptive immune 
response. This system contains an extensive range of diverse cells, which can mount an 
augmented defence against one pathogen (Berg et al., 2011). Although the response time 
takes longer than that seen for the innate system, the adaptive immune system also provides 
long-lasting protection, or ‘memory’ against specific pathogens. A person who has recovered 
from a measles infection, for example, will be protected for life against that virus which 
invaded the body, although not against other common viruses. For the adaptive system’s 
memory to work, the host must have meet the organism previously and initiated an adaptive 
immune response (Alberts et al., 2014; Berg et al., 2011).  
 Part of the innate immune system’s role is the initiation of the adaptive immune 
response. Cytokines and chemokines released through the first line of defence results in the 
migration of immune cells to the site of infection. Lymphocytes play a crucial role within 
this adaptive response. There are two different types of lymphocytes; B and T cells (Murphy 
et al., 2008). The main role of B lymphocytes within the human body is the production of 
immunoglobulin proteins called antibodies. Antibodies circulate within the human blood 
stream, permeating other bodily fluids where they will bind to specific antigens (or epitope) 
which stimulated their production. B cells contain membrane-bound immunoglobulins (B-
cell receptors) which serve as the cell’s receptors for antigens. Cells known as antigen 
presenting cells (APC) will engulf pathogens upon contact, and present peptide fragments 
of the pathogen on the surface of their cell membrane through major histocompatibility 
complexes (MHC) (type 1 and 2). The presentation of these antigens allows interaction with 
T lymphocytes to further elicit an adaptive immune response. APC include dendritic cells, 
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macrophages and B cells (Murphy et al., 2008; Wood, 2006). Activation of these B cells 
occurs through this antigen presentation to T-helper cells. The T-helper cells bind to the 
presented antigen via T cell receptors which results in the release of cytokines, inducing the 
proliferation of B cells into memory cells and antibody-secreting plasma cells. Antibodies 
have two main roles within the body; the first is binding to a specific antigen, rendering the 
pathogen harmless via neutralisation, agglutination or precipitation. Secondly, antibodies 
propagate the immune response, to recruit other cells and molecules which can destroy the 
pathogen once the antibody has bound to it (Berg et al., 2011s; Murphy et al., 2008).  
 T lymphocytes provide the cell mediated response of the adaptive immune system. 
The main role of T cells within the immune system involves the killing and removal of 
foreign pathogens from the human body (Alberts et al., 2014). There are several types of T 
cells which make up this cell mediated response. T helper cells, as described previously, are 
responsible for the activation of several other immune cells through MHC proteins expressed 
on the surface of APC. Activation of B cells results in the production of antibodies, whilst 
macrophages are stimulated to further release inflammatory cytokines (Berg et al., 2011; 
Murphy et al., 2008). Cytotoxic T cells aid in the destruction of virus-infected cells or 
cancerous cells. Cells which are infected with a foreign pathogen will present fragments of 
foreign antigens on their surface which allows T cells to distinguish between healthy and 
infected cells. In addition, there are also T memory cells, which are antigen- specific cells 
which provide long-lasting immunity post infection, and regulatory T cells which provide 
crucial maintenance of the adaptive immune system (Alberts, et al., 2014; Wood, 2006).   
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1.3 Components of the Immune System 
 
1.3.1   Monocytes & Macrophages 
 
 Monocytes are a type of leukocyte (more commonly known as white blood cell) 
which, when matured, differentiate into macrophages or dendritic cells. Monocytes are an 
integral part of the innate immune system and participate within the first line of response 
against invading pathogens (Kinne et al., 2007). Located within the circulating blood stream 
of the human body, they can be recruited to localised sites of inflammation, through 
monocyte chemotactic protein 1 (MCP-1). Increased transcription of cell adhesion 
molecules at inflamed sites, through the release of cytokines and chemokines promotes 
transmigration of monocytes from the lumen of blood vessels into the arterial intima. Once 
infiltrated, monocytes can differentiate into macrophages in the presence of macrophage 
colony-stimulating factor (M-CSF) produced through endothelial cells and smooth muscle 
cells (Lundberg & Hansson, 2010).  
 Macrophages are matured monocytes, which engulf and digest cellular debris, 
foreign substances and microbes through phagocytosis. Foreign material is broken down and 
rendered harmless via digestive enzymes contained within the cells lysosomal sacks. In 
addition to phagocytosis, macrophages are also involved in the recruitment of additional 
immune cells, such as lymphocytes, to localised sites of infection and inflammation, and 
regulation of the immune response, by the release of anti-inflammatory cytokines when 
necessary.  
 
 
 
Chapter 1. Introduction  Introduction 
 
11 
 
1.3.2  Neutrophils  
 
 Neutrophils are the most abundant type of granular leukocyte within the human 
immune system. They are known as granulocytes due to the presence of granules in their 
cytoplasm. Formed in the stem cells of bone marrow, neutrophils are an integral part of the 
innate immune system, participating in the first line of defence upon infection and 
inflammation. Their primary function within the immune system is to phagocytose and 
eliminate foreign microorganisms that are recognised as harmful to the host. In addition, 
they participate in the breakdown and elimination of dead or damaged tissues (Springer, 
1995). Neutrophils also contribute towards the inflammatory response through the 
production of immune-stimulating components including lipids, cytokines, proteases, 
microbial products and reactive oxygen intermediaries (Murphy et al., 2008; Sampson, 
2000; Wood, 2006).  
1.3.3  Lymphocytes 
 
 Lymphocytes are a type of white blood cell, found in the immune system of 
vertebrates and are derived from pluripotential stem cells within the bone marrow. Types of 
lymphocytes include natural killer (NK) cells, T cells and B cells. Natural killer cells are a 
form of cytotoxic lymphocyte which is critical to the functioning of the innate immune 
system. They provide rapid responses to viral-infected cells, alongside combatting tumour 
formation from cancerous cells. NK are unique in the sense that they do not need to recognise 
antigens presented on the surface of a cell’s MHC protein to elicit an immune response. 
Their role within the immune system also extends to regulation, through the release of 
cytokines and chemokines during an immune response which helps recruit further immune 
cells to localised sites. Their main role however, is their ability to lyse target cells, usually 
infected with foreign pathogens. Upon proximity to the target cell, NK cells releases 
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enzymes such as perforin and proteases which form a pore in the target cells membrane, 
creating an aqueous channel into the cell. This therefore allows further enzymes to enter 
target cells and induce apoptosis or osmotic lysis (Alberts, et al., 2014; Berg et al., 2011; 
Murphy et al., 2008). 
 T lymphocytes are also derived from the bone marrow, but mature within the thymus 
of the body (hence the name ‘T’). They are distinguishable from NK cells and B lymphocytes 
as they display T cell receptors on their surface. T cells can multiply into various sub-
categories including: T helper cells, cytotoxic T cells or memory cells. The role of T cells 
within the immune system is widespread, ranging from the facilitation of the immune 
response, destroying virus-infected cells and providing the immune system with a ‘memory’ 
of previous antigens which have infected the host. Additionally, T cells are involved in the 
activation of B lymphocytes upon presentation of antigens on their T cell receptors. The 
resulting consequence is the production and release of antigen specific antibodies from mast 
cells which are crucial in the neutralisation of harmful invading pathogens. B cells, unlike T 
cells derive and mature within the bone marrow. They are part of the humoral arm of the 
immune system and are mainly responsible to produce antibodies. B cell receptors are 
expressed on their cell surface, which can ingest, process and present antigen sequences, 
which results in the initiation of an immune response. B cells can also be divided into sub-
categories, with each B cell derivative responsible for a different role within the adaptive 
immune system. The most common types of B cells are plasma cells and memory cells. 
Plasma cells, usually T cell-dependent upon activation, are responsible for the formation of 
antibodies. Memory cells, like those seen for T cells, provide host defence against pathogens, 
or antigenic sequences, which have previously invaded the host (Alberts, et al., 2014; Berg 
et al., 2011; Wood, 2006).  
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1.3.4   Eosinophils & Basophils 
 
 Eosinophils and basophils are forms of white blood cells found within the human 
immune system. Eosinophils are responsible for combating invading parasites and various 
infections within the body, alongside the regulation of mechanisms involved in allergies. 
Eosinophils develop in the bone marrow, and circulate the body for sites of infection or 
inflammation once they have fully matured (Murphy et al., 2008). Upon activation, these 
cells are involved in the production of inflammatory cytokines, release of granular proteins 
through degranulation and the production of RNases to help fight viral infections. Basophils 
are the most uncommon of all white blood cells; however, they display the largest 
morphology. Alongside eosinophils, they are also involved in allergic reactions. Basophils 
contain relatively large amounts of the vasodilator histamine, which is released from the cell 
when activated (Alberts, et al., 2014; Berg et al., 2011; Wood, 2006).  
1.3.5  Platelets  
 
 Platelets, also known as thrombocytes, are highly abundant haematopoietic cells; 
stem cells which give rise to blood cells including white and red blood cells. They are 
produced from large bone marrow cells, known as megakaryocytes, constituting a minority 
fraction of the total blood volume. Within the bone marrow, megakaryocytes undergo a 
fragmentation process which results in the release of thousands of platelets per cell, 
controlled by the hormone thrombopoietin. Platelets contain no nucleus, and are commonly 
not classed as true cells, but merely fragments of cells within circulation. Their main role 
within the human body is focused around wound repair to prevent continuous bleeding when 
tissue is damaged.  
 Damaged endothelium results in the exposure of fibrous proteins such as collagen, 
allowing platelets to bind through glycoprotein surface receptors. Adhesion to the 
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endothelium wall is further strengthened through the release of Von Willebrand factor, from 
both platelets and the endothelium. Platelets are activated by the release of integrins into the 
circulating plasma, which results in alterations to their shape, structure and membrane-bound 
glycoproteins. Activation of intracellular enzymes and the recruitment of additional platelets 
are also processes which occur (Murphy et al., 2008). In addition, the coagulation cascade 
is initiated, promoting the conversion of fibrinogen to fibrin; crucial for blood clotting. 
Together with platelets, a clot or thrombus will eventually form (providing the damage is 
not too severe), and prevent the host from bleeding to death (Alberts, et al., 2014; Berg et 
al., 2011; Wood, 2006).  
1.3.6  Antibodies 
 
 Antibodies, also known as immunoglobulins, are glycoproteins of the immune 
system which are involved in the identification and elimination of foreign pathogens from 
the human body. Bacteria, fungi and other harmful invading organisms are eliminated 
through processes such as agglutination, neutralisation or precipitation. These integral 
members of the adaptive immune system can be located either bound to the surface of B 
cells, ready to bind and interact with invading pathogens, or circulating within the blood 
(Murphy et al., 2008).    
 Antibody molecules are roughly ‘Y-shaped’, composed of four polypeptide chains. 
Each ‘Y’; contains two identical ‘light’ chains, and two identical ‘heavy’ chains. Held 
together by disulfide bonds, they both differ in their sequence and length, with a hinge region 
within the middle of the ‘Y’ promoting flexibility upon binding. The light chains can be 
classified as either κ or λ based on differences in their primary protein sequence. It is the 
composition of the heavy chain however, which determines the overall class of the antibody. 
Antibodies can be categorised into five main isotypes based on the number of ‘Y’ units and 
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the type of heavy chain: IgG, IgM, IgA, IgD and IgE. Each isotype differs in their biological 
properties and their functional ability when dealing with foreign antigens (Murphy et al., 
2008).    
 The ‘Y’ shape of antibodies can be divided into three sections: two Fab regions and 
one Fc region. The F(ab) regions contain variable domains and are located at the apex of the 
‘Y’ shape. It is this region which recognises and binds specific antigen sequences which 
simulated their initial production. The Fc region provides a binding site for endogenous Fc 
receptors on the surface of lymphocytes. The region is also the site for the binding of 
secondary (usually non-specific) antibodies. Dyes and enzymes can be covalently bound to 
the Fc region of antibodies for visualisation of specific proteins/antigens, a technique 
commonly used in clinical assays (Alberts, et al., 2014; Berg et al., 2011; Wood, 2006).  
1.4 Human C-reactive Protein 
 
1.4.1  Overview of C-reactive Protein 
 
 CRP was discovered by Tillett & Francis in the 1930’s in the sera of patients with 
various infectious and inflammatory diseases. They discovered that mixing acute human sera 
from patients with pneumonia containing a fraction of the pneumococcus bacteria (fraction 
‘C’), would result in the precipitation of the C-polysaccharide (CPS) that is expressed on the 
cell wall surface of the Streptococcus pneumoniae (McCarthy, 1982; Pepys & Hirschfield, 
2003; Tillett & Francis, 1930; Volanakis & Kaplan, 1971). Subsequently Abernethy & 
Avery characterised this protein and identified the protein’s need for calcium ions to interact 
with CPS (Abernethy & Avery, 1940). They and others went on to establish that the 
appearance of CRP within serum is the result of a non-specific reaction in response to 
infection, inflammation and tissue damage (Abernathy & Avery, 1940; Ash, 1933; Baltz et 
al., 1982; Tillett & Francis, 1930). CRP was the first acute-phase protein to be described and 
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subsequently the term; ‘acute phase protein’, was applied to many other plasma proteins, 
whereby their concentrations would rise in acute phase sera (Baltz et al., 1982; Pepys & 
Hirschfield, 2003). Because of these findings, CRP is now routinely used as an extremely 
sensitive systemic marker of infection, inflammation or tissue damage (Gewurz et al., 1982; 
Pepys & Hirschfield, 2003).  
The acute-phase response comprises both nonspecific physiological and biochemical 
reactions in endothermic animals in response to most forms of tissue damage, infection and 
inflammation (Pepys & Hirschfield, 2003). Acute-phase proteins, such as CRP, are rapidly 
upregulated under these conditions, most commonly within hepatocytes, under the control 
of cytokines produced at the site of pathology. One acute phase protein which displays 
similar characteristics to CRP is Serum Amyloid-P component (SAP). SAP is a pentraxin 
serum protein, involved in the handling of chromatin and resistance to bacterial infection. It 
is also a universal constituent of amyloid deposits commonly observed in Alzheimer’s 
disease. The pentameric protein displays an ability to form decamers in the absence of 
calcium with two cyclic disk-like pentamers interacting face to face (Emsley et al., 1994; 
Hutchinson et al., 2000). 
CRP, alongside SAP, is an oligomeric, calcium binding protein which demonstrates 
high sequence homology with a family of proteins known as the pentraxins (Osmand et al., 
1977; Pepys & Hirschfield, 2003). Based on the primary structure of their subunit, the 
pentraxins can be divided into two groups: the short pentraxins and the long pentraxins. CRP 
and SAP are classed as short pentraxins which are produced in the liver, whereas PTX3 is 
an example of a long pentraxin. PTX3 is produced from both vascular and immune cells in 
response to pro-inflammatory stimuli, binding to ligands including growth factors, 
pathogens and complement proteins (Luchetti et al., 2000).  
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CRP and SAP show substantial homology of amino acid sequence and subunit 
composition and both proteins are characterised by their cyclic pentameric assembly of 
generally non-covalently associated subunits. CRP displays only one pentameric ring, 
whereas SAP exists in a pentameric form, but can also aggregate to form a decamer of two 
pentameric rings, which interact through their double-calcium ligand binding sites 
(Hohenester et al., 1997). SAP is known to be present within amyloid deposits due to its 
calcium dependent binding to amyloid fibrils and like CRP, SAP serum levels rise during an 
acute phase response (Pepys et al., 1978b).  
1.4.2  Structure of Human C-reactive Protein  
 
Human CRP displays a five-membered ring structure, all non-covalently bound 
around a central pore, with each subunit containing 206 amino acids folded into two 
antiparallel β-sheets with a flattened jellyroll topology (Shrive et al., 1996). Each protomer 
contains two calcium ions, which help coordinate the binding of ligands, such as 
phosphocholine (PC), expressed on the surface of pathogens and dead or damaged cells, as 
shown in Figure 1.1 (Shrive et al., 1996; Thompson et al., 1999). CRP interprotomer 
contacts consists of three salt bridges; Glu101 – Lys201, Lys123 – Glu197 and Asp155 – 
Arg118 involving the 115 – 123 loop of one protomer and 40 – 42 and 197 – 202 on the 
adjoining loop. An effector face of CRP is located on the opposite side of the ligand binding 
face which contains a cleft-like region, situated around the middle of each protomer and 
extending to the central pore of the pentamer (Shrive et al., 1996; Thompson et al., 1999). 
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Figure 1.1 The three-dimensional structure of pentameric C-reactive protein.  The α-helix is 
displayed in red, with the β-sheets displayed in turquoise. Calcium ions bound to each 
protomer are displayed as purple spheres. CRP contains five protomers, all non-covalently 
bound, arranged around a central pore. Levels of this acute phase protein rise rapidly in 
response to infection, inflammation or injury. Image of 1GNH (Shrive et al., 1997) created 
with CCP4mg (McNicholas et al., 2011). 
 
1.4.3  Ligands of C-reactive Protein 
 
The pentraxin family of proteins are mainly characterised by their five identical 
subunits and their calcium dependent interaction with phosphate-containing ligands, such as 
phosphocholine and phosphoethanolamine (PE) (Schwalbe et al., 1992). CRP has been 
documented to interact with a wide range of autologous and extrinsic ligands in a calcium 
dependent manner. Modified plasma lipoproteins, small ribonucleoprotein particles and 
apoptotic cells within the human body have all been shown to interact with CRP. Foreign 
pathogens to the human body, including parasites, fungi, bacteria and microorganisms 
present ligands such as PE and various glycans to which CRP will bind to elicit an immune 
response (Clos, 1989; Gershov et al., 2000; Pepys & Hirschfield, Volanakis & Narkates; 
1981). The main principal ligand for CRP is PC which can be found in teichoic acids, 
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capsular carbohydrates and lipopolysaccharides of bacteria, galactan polysaccharides, the 
polar head group of phospholipids and microorganisms such as Streptococcus pneumoniae 
(Narkates & Volanakis, 1982; Gotschlich, 1982).  
PC is a major constituent of cell membranes from both prokaryotic and eukaryotic 
cells. In normal, healthy eukaryotic cells within the human body, PC is inaccessible, as the 
PC unit is usually part of a larger structure such as phosphatidylcholine. Any damage to 
these cell membranes results in the cleavage of phospholipids by the enzyme phospholipase 
A2, which exposes PC and enables CRP to distinguish between damaged and healthy cells 
(Hack et al., 1997; Narkates & Volanakis, 1982). The PC unit to which CRP binds contains 
a choline group alongside a phosphate atom, which is double bonded to one oxygen atom 
and two hydroxyl groups, as shown in Figure 1.2. 
 
Figure 1.2. The chemical structure of phosphocholine. PC is CRP’s main ligand and a major 
constituent in most cell membranes. PC is expressed on the surface of dead or dying cells, 
which allows CRP to distinguish them between healthy cells.  
PC units to which CRP will bind on the surface of bacteria are usually bound to larger 
structures, such as the C-polysaccharide present on Streptococcus pneumoniae. Since the 
first description of ‘fraction C’ of the pneumococcus by Tillett & Francis (1930), structural 
studies have shown C-polysaccharide to be a teichoic acid, comprising repeating units of 
ribitol phosphate, N-acetylgalactosamine, N-acetyldiaminotrideoxyhexose, choline 
phosphate and glucose residues. Teichoic acids are gram-positive (contain a thick layer of 
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peptidoglycan within their cell wall) bacterial co-polymers of either glycerol phosphate or 
ribitol phosphate and carbohydrates, linked via phosphodiester bonds. The results showed 
that these repeating units can display molecular weights from 65,000Da to over 200,000Da. 
Furthermore, it was noted that all fractions analysed contained the same hexosamine and 
amino acid components but in markedly different proportions (Gotshclich & Liu, 1966; 
Poxton et al., 1978). Chemical composition analysis had previously established C-
polysaccharide to originate from the bacterial cell wall, with the molecule containing four 
main amino acids (lysine, serine, glutamic acid and alanine) and four main sugars (D-
glucosamine, D-galactosamine 6-phosphate, muramic acid and muramic acid phosphate) 
(Liu & Gotschlich, 1963). 
1.4.4  The Calcium Binding Site 
 
There are two calcium ions located within each of the five subunits of CRP (Shrive 
et al., 1996). Both calcium ions are crucial in both the stability of the protein and the 
interaction between CRP and its ligands. The absence of calcium induces conformational 
changes within the protein. Residues 140-150 form a large loop away from the body of the 
molecule, exposing hidden sites which are susceptible to proteolysis (Ramadan et al., 2002). 
The first calcium ion is coordinated by Asp60, which presents an acidic oxygen, along with 
residues Asn61, Glu138, Asp140 and the main chain carbonyl of Gln139 (Shrive et al., 1996; 
Thompson et al., 1999). The second calcium ion is bound to residues Gln138, Asp140, 
Gln150 and Glu147. Glutamic acid-147 extends sufficiently so it can close the pocket when 
the addition calcium is bound (Shrive et al., 1996). 
1.4.5  The Phosphocholine Binding Site 
 
The binding of PC is mediated by a phosphate-calcium interaction at the calcium 
binding site. The two calcium ions, displayed as red spheres in Figure 1.3, interact with two 
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oxygen atoms of PC, positioning the third oxygen towards the solvent, allowing PC to form 
an ester linkage with other, larger molecules within the vicinity. 
 
Figure 1.3 A stick model of PC interacting with CRP which is coordinated by two calcium 
ions. The nitrogen in the choline moiety is displayed in blue with carbon atoms displayed as 
green. The phosphate is displayed in pink, with oxygen atoms coloured red. The two calcium 
ions are displayed as maroon spheres. Image of 1B09 (Thompson et al., 1999) created with 
CCP4mg (McNicholas et al., 2011). 
The choline moiety is then extended away from the calcium binding site and runs along the 
surface of the CRP molecule where the side chains from Phe66, Thr76 and Leu64 in CRP 
(see figure 1.3) form a large hydrophobic pocket (Shrive et al., 1996; Thompson et al., 1999). 
Hydrophobic interactions occur between three choline methyl groups and the exposed face 
of Phe66 and Glu81, as shown in in figure 1.3. The aromatic face of Phe66 is shifted away 
from the calcium site and exposed in an ideal position for the hydrophobic interaction with 
the tertiary methyl groups of the choline moiety (Agrawal, 2004; Thompson et al., 1999). 
 
1.4.6  The Effector Face 
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The effector face of CRP is located on the opposite site of the ligand binding face. A 
cleft-like region is situated around the middle of each protomer and extends to the central 
pore of the pentamer (Shrive et al., 1996). A long α-helix, from residues 168 – 176 lies 
folded against one of the two β-sheets. The carboxyl terminal end of the helix, including the 
loop from residues 177 – 182, form one of the two sides of the cleft that extend from about 
the centre of the protomer, to its edge and the central pore of the pentamer (Shrive et al., 
1996; Thompson et al., 1999). The opposite side of the cleft is formed by the amino and 
carboxyl termini of the protomer, giving a deep and narrow origin, but becoming shallower 
towards the pore of the pentamer, with residues His38, His95 and Trp205 protrude from the 
cleft floor (Thompson et al., 1999). The outer part of the cleft is positively charged with 
inner parts of the cleft halfway through, such as Asp112, providing a ring of negative charges 
lining the pore (Volanakis et al., 2001).  
It is suggested that this region is where CRP interacts with the complement protein 
C1q to activate, in a PC dependent manner, the classical complement pathway (Agrawal et 
al., 2001; Kaplan & Volanakis, 1974; Shrive et al., 1996; Thompson et al., 1999; Volanakis, 
1982).  
1.4.7  Levels of C-reactive Protein 
 
 In normal, healthy individuals, baseline levels of CRP range from 1-3mg/L (Pepys 
& Hirschfield, 2003). There are some associations which have been suggested between the 
production of CRP and genetic polymorphisms in IL-1 and Il-6, whereby an individual’s 
CRP baseline level is raised (>3mg/L). Furthermore, a polymorphic GT repeat in the intron 
on the CRP gene is reportedly associated with the differences in the baseline of CRP 
concentrations in normal individuals (Berger et al., 2002; Pepys & Hirschfield, 2003; 
Vickers et al., 2002). Clearance of human CRP from the blood depends on its half-life; 
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calculated to be at 19 hours, and is constant, regardless of synthesis rate and severity of 
disease (Pepys & Hirschfield, 2003). Raised baseline levels of CRP have also been linked as 
an indicator for the development of disease and will be discussed in further sections.  
1.4.8  C-reactive Protein as a Clinical Biomarker 
 
During infection and inflammation within the human body, CRP levels will rise 
acutely to elicit a sufficient immune response. Interleukin 6, 1 and transforming growth 
factor-β are responsible for the rise in plasma levels of the acute phase protein, due to the 
accelerated transcription of their genes within the liver (Mackiewicz et al., 1990). The 
general baseline level of CRP in a healthy patient’s serum is around 1-2mg/L. This can 
increase up to 100-fold within 24-72 hours of infection or inflammation. It is due to this 
rapid increase in serum levels that CRP is routinely used as a clinical biomarker for injury, 
infection and inflammation (Pepys & Baltz, 1983; Shine et al., 1981). The plasma half-life 
of CRP is about 19 hours and is constant under all conditions of health and disease, meaning 
the sole determinant of circulating pCRP is the synthesis rate, which directly reflects that 
intensity of pathological processes stimulating the pCRP production (Pepys & Hirschfield, 
2003).  
In a clinical setting, the most common technique to obtain a fast analysis of CRP 
levels is through automated laboratory analysis. Machines which incorporate the Enzyme-
linked Immunosorbent Assay (ELISA) concept of antigen to antibody complexes can 
determine CRP concentrations within a sample. This is due to their ease of use, sensitivity 
to the assay, biochemical stability and result in international standards and inter-assay 
prevision. Unfortunately, these are limited to detecting elevated concentrations of CRP 
(Algarra et al., 2013). There are several analytical methods which have been developed for 
the measurement of CRP levels within the blood. These tests vary in their use, with some 
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measuring more sensitive changes in lower CRP levels, compared to those which detect in 
larger rises; indicating an infection of the body. These clinical tests utilise methods such as; 
immunoturbidimetry, immunosorbent assays, surface plasmon resonance, 
chemiluminescence, impedimetry, beads, reflectometric interference spectroscopy, 
electrochemistry and microfluids (Choi et al., 2012; Bryan et al., 2013; Deegan et al., 2003; 
Islam & Kang, 2011; Kim et al., 2008; Kjelgaard-Hansen et al., 2007; Lee et al., 2011; 
Punyadeera et al., 2011; Vashist et al., 2014; Vashist et al., 2015; Vermeeren et al., 2011). 
These highly sensitive methods for measuring CRP levels are nephelometric assays (light 
scattering assays). Light scattered from antigen-antibody complexes is measured based on 
the principle that higher concentrations of antigen result in an increase in the scattered light. 
This highly sensitive method is used for measuring lower levels of CRP (<3mg/L) and to 
assess the risk of developing diseases such as cardiovascular disease in an apparently healthy 
population, which is further discussed in section 1.8.3 (Koivunen & Krogsrud, 2006; Rifai 
et al., 2006). 
1.5 Genetics of C-reactive Protein 
 
1.5.1  Production of C-reactive Protein 
 
 The degree to which an amino acid mutates within a protein sequence depends 
largely on its structural and functional importance. Amino acids involved in maintaining the 
structural integrity of the protein, or crucial to the proteins overall function, are unlikely to 
change over time (Mayrose et al., 2004). The evolutionary rate of an amino acid is therefore 
indicative of how conserved that site is, allowing evaluation of that amino acid, or sequence 
within the protein (Mayrose et al., 2004). Analogues of the same protein can be traced 
through various species, with the conservation of specific amino acids and/or sequences 
highlighting areas important in functionality. Furthermore, it can highlight residues which 
Chapter 1. Introduction  Introduction 
 
25 
 
may endure change throughout evolution, whilst resisting a change in the proteins overall 
structure and function (Mayrose et al., 2004). Proteins which show a high percentage of 
homogeneity through a wide range of species, even down to the most primitive of animals, 
suggests a crucial importance in not only specific regions in their amino acid sequence, but 
their contribution to the organism’s survival.  
 The gene sequence for human CRP is located on chromosome 1 (Whitehead et al., 
1983). Regulators of the gene are located 1 kilo base (KB) upstream, with two inducible 
elements located closer to the site of transcription (Li et al., 1990). There are also two 
enhancer-line elements located distal to the protomer, with a negative regulatory region 
located between the two (Li et al., 1990). The primary translation product is larger than 
native serum CRP by an 18-amino acid terminal extension, which forms the signal peptide 
(Tucci et al., 1983). Sequence analysis indicates that after the signal peptides lies two amino 
acids of the mature, serum protein, followed by an intron of 278 base pairs, with the 
remaining 204 amino acids following that (Lei et al., 1985). The CRP gene displays a typical 
protomer which contains the sequences TATAAAT (TATA) and CATT box 29 and 81 
nucleotides upstream. The mRNA cap site is located 104 nucleotides from the start of the 
signal peptide with a 3’ polyadenylated noncoding region (AATAAA), 1.2 kilo base pairs in 
length and the 5’ non-coding region at 0.1kilo base pairs (Lei et al., 1985)  
 Once transcription has occurred, the individual 206 amino acid protomers are 
assembled into their pentameric, quaternary structure within the endoplasmic reticulum of 
hepatocytes (Yue et al., 1996). Here the CRP protein can be stored until needed through an 
interaction with two carboxylesterases (gp60a and gp60b), which themselves are restricted 
to the endoplasmic reticulum (ER). During an acute phase response within the body, the 
synthesis of CRP within hepatocytes is dramatically increased, coupled with a decrease in 
the retention of the protein within the ER (Yue et al., 1996). To help fight off infection, the 
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acute phase response must be extremely fast and efficient. Ciliberto et al (1987) 
demonstrated that levels of CRP RNA are detectable, within hepatocytes, 2 hours after 
stimulation, with mature protein being detected after only just 6 hours. Furthermore, larger, 
intense and prolonged periods of an acute phase stimulus, results in the production of higher 
levels of CRP, among other proteins, to aid the body’s defences (Ciliberto et al., 1987).  
1.5.2  Induction of the C-reactive Protein Gene 
 
 The acute phase response is a normal, physiological reaction to tissue injury or 
infection and is therefore a fundamental aspect of many disease processes. During this 
response, in addition to protein synthesis upregulation, pre-formed proteins are released to 
limit damage and promote cellular repair or apoptosis (Pepys & Baltz, 1983). All hepatic 
cells within the liver are thought to be capable of synthesising acute phase proteins 
simultaneously, in response to infection or inflammation. However, the location of hepatic 
cells producing the acute phase proteins depends on the timescale of the acute response. At 
early periods of the inflammatory reaction, cells synthesising acute phase proteins were 
detected in the periportal zone, but later (24 hours), synthesising cells were detected 
principally in the hepatic lobule (Courtoy et al., 1981).  
 The primary inducer of the CRP gene was initially hypothesised to be IL-1, although 
since then, several other hormones, known to be involved within the acute phase response 
have also been linked. These include IL-6, interferon-γ, tumour necrosis factor α (TNFα) 
and transforming growth factor β (Pied et al., 1989; Steel & Whitehead, 1994). Despite IL-
1 having a large role in the induction of the inflammatory response, experimental research 
by Ganapathi et al., (1991) has shown that on its own, the hormone is unable induce the 
production of certain acute phase proteins, including CRP. Furthermore, they demonstrated 
that the induction of CRP required more than one inducer to be present; larger levels of IL-
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1 with even lower levels of IL-6 were required (Ganapathi et al., 1991). Since this study, 
additional experimental research has established that IL-6 is the major inducer of the CRP 
gene, with IL-1 and other compounds acting as synergists (Li et al., 1996; Mackiewicz et 
al., 1990; Szalai et al., 2000).  
1.6 Human C-reactive Protein within Additional Species 
 
1.6.1   Mammalian C-reactive Protein 
 
 CRP is a physiologically highly conserved protein, which can be found within a 
variety of species across the animal kingdom. Mammalian species in which CRP has been 
confirmed include; monkey, rat, dog, cat, horse, goat, cow, rabbit and sheep (Mitra & 
Bhattacharya, 1992). Throughout these species, there are several consistencies in CRP’s 
structure, amino acid composition and role within the host. The most common between all 
CRP analogues, is a primary role within the host’s innate immune system, through binding 
to phosphocholine-containing ligands, in a calcium dependent manner (Baltz et al., 1982). 
CRP levels will rise rapidly during the acute phase response in all CRP-containing species 
(Schwalbe et al., 1992). CRP serum levels in mammals are known to differ slightly, with 
concentrations in healthy rats ranging from 300-600ug/ml – much greater than in other 
species (de Beer et al., 1982a). Levels in rat sera will increase about 2-3-fold during their 
acute phase response, therefore rat CRP being described as a minor acute phase protein 
(Schwalbe et al., 1992). Most mammalian CRP molecules display five identical subunits, all 
non-covalently formed around a central pore (de Beer et al., 1982a).  
 The high percentage of sequence homology observed for CRP throughout various 
species is a testament to the protein’s resilience to evolutionary change. This similarity 
between protein sequences is displayed in Figure 1.4, whereby four other CRP sequences 
are compared against that of the human sequence. Residue Phe66 aids in the formation of 
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the hydrophobic pocket to which phosphocholine binds. Furthermore, Glu81 is crucial in 
interaction with the choline group upon binding. These ligand binding regions are 
highlighted within Figure 1.4 to display their homology between the various species. 
Similarity is also observed in the amino acids which are known to bind calcium; Glu138, 
Asp140 and Gln150 (Shrive et al., 1996).  
 
Figure 1.4 A comparison of CRP sequences from several different species to highlight the 
high percentage of sequence homology. Areas which are shaded dark blue display identical 
amino acids for all five species. The lighter shades of blue indicate identical amino acids for 
four out of the five species. The sequence comparison was obtained from 
http://www.uniprot.org/.   
Rabbit CRP, like humans also retains the ability to bind PC in a calcium dependent 
manner (Syin et al., 1986). Its half-life is much shorter than human CRP, at approximately 
five hours, and is can be located within areas of localised inflammation and necrosis 
(Kushner & Kaplan, 1961). CRP subunit composition does differ slightly throughout 
species, mice CRP subunits are roughly 25-27kDa in size, compared to human CRP at 
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roughly 22-23kDa. Interestingly, dissimilar to most mammals, the major acute phase protein 
in mice is SAP and not CRP, despite the fact it contains both (Schwalbe et al., 1992).  
1.6.2  C-reactive Protein within Fish 
 
Homologues of CRP have been detected in fish species including Plaice 
(Pleuronectes platessa L.), the Common Carp (Cyprinus carpio), Snapper Fish (Pagrus 
auratus, S.) and Rainbow Trout (Oncorhynchus mykiss). The CRP analogues within plaice, 
alongside other fish species, share substantial homology in amino acid sequence, similar 
subunit composition, and a similar molecular appearance when observed through an electron 
microscope when compared to human CRP (Pepys et al., 1978a; Pepys et al., 1982). 
Although, plaice CRP differs from human CRP in that it contains subunits of two different 
molecular weights, as one is glycosylated (Baltz et al., 1982). Fish pentraxins, like those 
identified within other species can bind to phosphocholine, displayed on the surface of 
bacterial cell walls, in a calcium dependent manner (Cartwright et al., 2004). Currently, there 
is rather limited information regarding the in vivo function of pentraxin-like molecules 
within fish, although studies have established their ability in both complement activation and 
opsonisation of particles (Cook et al., 2005; Nakanishi et al., 1999) 
1.6.3   Limulus C-reactive Protein 
 
 The Atlantic horseshoe crab, Limulus polyphemus, is one of the oldest surviving 
multicellular organisms on the planet, being over 500 million years old in existence (Enghild 
et al., 1990). In Limulus, CRP and SAP have been identified and described as an important 
component of the innate immune response and host defence (Armstrong, 1996; Pepys et al., 
1978a; Robey & Liu, 1981). The molecular mass of Limulus CRP was first estimated to be 
approximately 300kDa, with each subunit around 22.5kDa. The subunits are arranged in 
cyclic pentameric symmetry and amino acid sequence homology with a range of species 
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(Nguyen et al., 1986; Tennent et al., 1993) Experimental evidence has reported several 
different forms of Limulus CRP with numerous genes (Nguyen et al., 1986). These genes 
give rise to three different subunit types, which are identical in N- and C- termini.  
 Unlike human CRP, Limulus CRP has been documented to be a glycosylated protein, 
with an N-linked oligosaccharide on each subunit. The structure of this oligosaccharide is 
unknown, but several different structures have been suggested (Amatayakul-Chantler et al., 
1993). At the glycosylation site of Asn123, the cysteine residues involved in the formation 
of disulfide bridges appear to be the same in all Limulus CRP genes. Furthermore, these 
disulfide bridges are still present within human CRP, SAP and rabbit CRP (Nguyen et al., 
1986). All forms of Limulus CRP display the ability to bind to PC in a calcium dependent 
manner. PC-binding sites display homology with that of the human CRP binding site, with 
ten out of sixteen residues identical. Furthermore, nine out of fifteen residues are also 
conserved in the calcium binding site. Sequence comparison of both Limulus and human 
CRP revealed a 25% identity, although Limulus does not contain the intron between the 
signal peptide and mature protein like human CRP (Nguyen et al., 1986).  
1.7 Interaction of C-reactive Protein with Components of the Immune 
System  
 
1.7.1  Macrophages and Monocytes 
 
 Alongside the activation of the inflammatory response, through the binding of dead 
or damaged cells, CRP plays a role in the recruitment and modulation of several other 
immune components within the human body. During the inflammatory response, levels of 
monocytes rise rapidly, which mature into macrophages at the site of infection or 
inflammation. It has been hypothesised that CRP can play a role in the recruitment, 
maturation and regulation of macrophages; although there is a debate among researchers as 
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to which cellular receptors are involved in these interactions (Tron et al., 2008). The 
maturation of monocytes has been shown to be susceptible to CRP-dependent inhibition, 
through binding to Fc receptors on their cellular surface. Although this can be inhibited via 
IgG, which further supports the theory of CRP binding via Fc receptors. Furthermore, CRP 
is known to be a negative regulator of macrophage activation, via binding to lymphocyte-
derived apoptotic DNA (Mortensen et al., 1982; Zhang et al., 2011).  
 Flow cytometry studies involving monocytes has established the presence of CRP-
binding receptors on their surface. The study by Ballou & Cleveland, demonstrated that there 
is specific low-affinity binding of CRP to phagocytic cells, which occurs in a calcium 
dependent manner (Ballou & Cleveland, 1990). As early as 1977, it was reported that CRP 
interacts with Fcγ receptors. This was however, later disputed, due to inconsistencies within 
experimental research involving inhibition of binding CRP to Fc receptors by use of 
antibodies, and the inability of CRP receptor modulation to inhibit IgG binding to monocytes 
(Gewurz et al., 1982; Mortensen & Duszkiewicz, 1977). Although it is not certain which 
receptors are involved within these interactions. The primary contenders which have been 
proposed are various subclasses of Fcγ-receptors known as FcγRI and FcγRIIa, which are 
expressed on the surface of various haematopoietic cells. FcγR contain tyrosine-based 
motifs, which are activated through clustering on the cellular surface, caused by ligand 
binding (Marnell et al., 2005; Tron et al., 2008). These receptors function through the 
recognition of the Fc portion of IgG and provide a link between the humoral and cellular 
responses. The binding of CRP to these FcγR is proposed to have a similar effect to that seen 
with IgG. 
 CRP is thought to share several functional activities with IgG in relation to 
interactions with macrophage cells. These include; complement activation, opsonisation, 
cytokine secretion for the recruitment of additional immune cells, facilitation of 
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phagocytosis of CPS-coated cells, and the induction of the release of tissue factor, a potent 
pro-coagulant within the body (Cermak et al., 1993; Mortensen & Duszkiewicz, 1977; Stein 
et al., 2000; Torzewski et al., 2000; Zhang et al., 2011). The cytokine response to CRP is 
like that observed for IgG and includes the production of IL-1β, IL-6 and TNF-α (Gewurz 
et al., 1982). These immunological responses highlight not only a role of complement 
activation and promotion of the inflammatory response, but a more regulatory role with other 
immune components. The role of monocytes and macrophages in the immune response is 
typically known for their recruitment of further immune cells and phagocytosis of harmful 
pathogens within the body. The functional relationship between these two immune cells and 
CRP highlighted here demonstrates one of regulation and synergistic actions, when initiating 
the acute phase response. 
1.7.2  Lymphocytes 
 
 The interaction between CRP and lymphocytes was first suggested by Abernathy & 
Francis in 1937 (Abernathy & Francis, 1937). Early investigations of CRP interactions with 
cells showed that the binding of CRP to immune cells, such as lymphocytes, could be readily 
inhibited by IgG, thus suggesting a CRP-type receptor, like that seen with Fc receptors. 
Eventually, these findings were disregarded, with interactions now thought to occur through 
certain Fc receptors, like that observed with monocytes and macrophages (Gewurz et al., 
1982). CRP has been found to bind human T lymphocytes, and inhibit their functions, 
preventing T cell proliferation. Mortensen & Gewurz found that this CRP-induced inhibition 
was prevented by the addition of CPS (Mortensen & Gewurz, 1976). This thus suggests CRP 
may exert a regulatory effect of cellular immune responsiveness during inflammatory 
reactions (Mortensen & Gewurz, 1976). CRP has also been shown to selectively bind to T 
lymphocytes, inhibiting their ability to form spontaneous rosettes with sheep erythrocytes 
and their response to allogenic cells in mixed lymphocyte reactions. In contrast with these 
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results, CRP was not shown to bind B lymphocytes, and does not alter B cell functions such 
as binding and activation of complement components (Mortensen et al., 1975).  
 More recent experimental research has revealed that CRP can bind specifically to 
Jurkat T cells and to mouse naïve cells, modulating their activity during an immune response 
(Zhang et al., 2015). Furthermore, CRP inhibited differentiation of the T helper 1 cells, 
whilst augmenting the differentiation of the T helper 2 cells, derived from native CD4+ T 
cells. These results additionally portray CRP acting as a tonic regulator of the immune 
system (Zhang et al., 2015). CRP, alongside complexes of CRP with CPS increases 
lymphocyte toxicity in addition to enhancing the mixed lymphocyte culture reaction (Vetter 
et al., 1983). Furthermore, low levels of CRP have been shown to increase lymphocyte 
blastogenesis, thus increasing their numbers within serum (Hornung, 1972), as well as 
stimulating lymphocytes to destroy myeloma cells. Patients also suffering with diseases such 
as rheumatic fever are thought to promote the interactions between CRP and lymphocytes, 
to elicit a greater immune response (Hornung, 1972; Williams et al., 1978).  
1.7.3  Platelets 
 
  During an immune response, inflammation at sites throughout the body will cause a 
rise in the level of circulating platelets (Crosby, 1971; Skoglund et al., 2008). Their primary 
role is clotting of the blood and wound repair, through activation of the coagulation cascade 
(Sato et al., 2014). Dysregulation of lipids can exacerbate the physiological events that are 
commonly observed in numerous inflammatory diseases. Platelet activating factor (PAF) is 
involved in the activation of platelets, thrombotic cascades and triggering inflammation 
(Sato et al., 2014). PAF is specifically enhanced, upon binding with CRP, which results in 
platelet activation & degranulation, dysregulation of and the inflammatory response and the 
recruitment and mediation of various leukocytes (Sato et al., 2014). Further to this, 
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experimental evidence demonstrates CRP enhancing the aggregation between monocytes 
and platelets during an immune response. Mediated through cell adhesion molecule P-
selectin (among others), these findings suggest a more pro-inflammatory role for CRP 
(Danenberg et al., 2007). In contrast to these results, Skoglund et al., conclude that CRP, in 
conjunction with the complement protein C1q, provide an immunoregulatory role for 
platelets during inflammatory conditions through the reduction of thromboxane B2, a lipid 
known to induce platelet aggregation. Although it is worth noting, CRP alone had no 
regulatory effect on the platelets, and required the presence of C1q (Skoglund et al., 2008).  
1.7.4  Tissue Factor 
 
 Tissue factor (TF) is a transmembrane protein receptor for Factor VII/VIIa, which is 
commonly expressed in fibroblasts, monocytes and the sub-endothelial tissue layer (Cermak 
et al., 1993). One of TF main roles within the human body is the conversion of thrombin to 
prothrombin, initiating the coagulation cascade. The interaction between smooth muscle 
cells and endothelial cells with CRP, via FcγRIIIa receptors, has been documented to 
promote proliferation and TF expression, whilst decreasing the tissue factor pathway 
inhibitor protein (Cirillo et al., 2005; Wu et al., 2008). CRP also induces the production and 
activity of TF on the surface of peripheral blood monocytes, although these results have been 
contested (Cermak et al., 1993; Paffen et al., 2004). Cermak et al., proposed that CRP may 
be contributing towards the development and dissemination of intravascular coagulation and 
thrombosis at inflammatory sites throughout the body; although this is not conclusive 
(Cermak et al., 1993).  
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1.7.5  High and Low Density Lipoproteins 
 
 Lipoproteins are a soluble group of proteins that are bound to fat or lipids within the 
blood plasma. The main role of these proteins is to emulsify the lipid molecules to enable 
them to be transported around the body (Fredrickson et al., 1967). Common examples of 
lipoproteins include low density lipoproteins (LDL), very LDL (VLDL) and high density 
lipoproteins (HDL) (Fredrickson et al., 1967; Pepys & Hirschfield, 2003). CRP has been 
specifically shown to bind LDL and traces of VLDL when aggregated on a solid phase at a 
sufficient density, alongside damaged cell membranes which display these epitopes (de Beer 
et al., 1982b; Pepys et al., 1985). The form in which these lipoproteins must be present has 
been reported to be crucial though (Chang et al., 2002). Chang et al. demonstrated that CRP 
binds to oxidised LDL and oxidised phosphatidylcholine, but does not bind their non-
oxidised native forms. With binding mediated through the available PC head group, they 
hypothesise that PC becomes accessible upon oxidation (Chang et al., 2002), thus suggesting 
that oxidised LDL may potentially impose a pro-inflammatory stimulus upon the body. 
Further to this, enzymatically degraded products of LDL can activate the complement 
pathway in conjunction with CRP, with the degraded product being reported to have been 
found within atherosclerotic lesions (Bhakdi et al., 1999). Interactions between CRP and 
HDL display an alternative role within the immune system, with HDL being shown to 
neutralise the pro-inflammatory actions of CRP. HDL also demonstrated an ability to prevent 
CRP-induced upregulation of cell adhesion molecules and cytokine-induced expression 
from of endothelial cells, a common phenotype observed in atherosclerosis and other 
inflammatory diseases (McGrowder et al., 2010; Pepys & Hirschfield, 2003; Pepys et al., 
1985).  
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1.8 C-reactive Protein and Cardiovascular Disease 
 
1.8.1  Overview of Cardiovascular Disease 
 
 Cardiovascular disease is one of the leading causes of death and illness in developed 
countries, causing world-wide health problems and severe pressure for the funding and 
capacity of national health services (Libby, 2002). Atherosclerosis is one of the main factors 
which contribute towards cardiovascular disease, distinguishable by the formation of lesions 
in larger arteries throughout the body, characterised by inflammation, lipid accumulation, 
cell death and fibrosis (Hansson & Libby, 2006). Research that has been provided based on 
animal experiments and human specimens indicates a qualitative change in the monolayer 
of endothelial cells which line the inner arterial surface (Libby et al., 2011; Ross, 1999). 
Over time, these lesions, also known as atherosclerotic plaques mature and eventually result 
in severe clinical events including plaque rupture resulting in thrombotic material being 
exposed to the blood. Atherosclerosis within the heart can further lead to myocardial 
infraction and heart failure, whereas rupturing arteries within the brain can lead to ischemic 
stroke (Hansson & Libby, 2006).  
1.8.2  Atherosclerosis & Thrombosis Formation 
 
 Laboratory and clinical evidence has demonstrated that atherosclerosis is not a 
simple disease of lipid deposition as once thought, but rather a systemic inflammation which 
plays a significant role in atherothrombotic inception and progression. Cells such as 
mononuclear cells, macrophages and T lymphocytes are prominent in atheromatous plaques 
and within the arterial wall (Blake & Ridker, 2002; Rifai et al., 2001). The accumulation of 
these immune cells within the lesions typically presents an asymmetrical focal thickening of 
the intima, the innermost layer of the artery (Jonasson et al., 1986; Ross, 1999). The cells 
lining the artery are normally resistant to the attachment of white blood cells onto their walls. 
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When the artery walls are subject to an irritative stimulus, the expression of cell adhesion 
molecules are upregulated on their surface (Libby et al., 2011). The endothelial-leukocyte 
cell adhesion molecule has been proposed to be one of the first to be upregulated upon 
irritation. Mononuclear leukocytes migrate through the arterial endothelium through binding 
to vascular cell adhesion molecule 1 (VCAM-1) (Cybulsky & Gimbrone, 1991; Jialal et al., 
2004; Libby, 2002). LDL can also diffuse from the blood into the innermost layer of the 
artery. The extracellular pool of enzymes and oxygen free radicals modifies the LDL to form 
oxidised forms. Constituents of modified lipoprotein particles, such as oxidised 
phospholipids, and short chain aldehydes arising from this oxidation reaction, can induce 
transcriptional activation of the VCAM-1 gene. Pro-inflammatory cytokines, such as IL-1β 
and TNF-α, released from immune cells, can also induce the expression of VCAM-1 in 
endothelial cells (Cybulsky & Gimbrone, 1991; Libby, 2002; Ross, 1999; Yudkin et al., 
2000). 
 Once monocytes have migrated through the endothelial cell layer into the arterial 
intima, they can differentiate into macrophages. These macrophages are capable of engulfing 
accumulating free lipoprotein particles, eventually differentiating into foam cells (Chang et 
al., 2002; Fredrickson et al., 1967; Tabas, 2010). Furthermore, these macrophages within 
the atheroma are induced to produce and release pro-inflammatory cytokines, intensifying 
the localised state of inflammation and resulting in the recruitment of further immune cells 
(Libby et al., 2011). Additionally, smooth muscle cells (SMC) are recruited from the tunica 
media, the middle layer of the arterial cell wall. They are induced to proliferate in response 
to mediators such as platelet-derived growth factor, into the tunica intima. These SMC then 
produce extracellular matrix molecules, such as collagen and elastin, and form a fibrous cap 
which covers the plaque (Hansson & Libby, 2006; Yudkin et al., 2000).  
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 One of the first responses to vascular injury involves the adhesion of platelets to the 
damaged vessel wall, or to the exposed tissue components. This is mediated by flow-
regulated interactions, which have a key influence on subsequent thrombus growth; often 
cumulating in life threatening situations (Molins et al., 2008). Activation of endothelial cells 
plays an extremely important role in the development of atherosclerosis, and is accompanied 
by the up-regulation and exposure to cell adhesion molecules at the site of thrombosis or 
infarction. P-selectin, ICAM-1 and VCAM-1 are all strongly expressed on the endothelium 
overlying atherosclerotic plaques. Regulation of the VCAM-1 gene is thought to be coupled 
with the oxidative stress of endothelial cells, through specific reduction-oxidation sensitive 
transcriptional and post-transcriptional regulation (Mauri et al., 1993). Vascular endothelial 
growth factor is responsible for the induction of adhesion molecules, and the adhesiveness 
of leukocytes within circulation (Kim et al., 2001). Upon exposure to environmental signal 
such as cytokines, endothelial cells can undergo profound changes which allow them to 
participate within the inflammatory response (Mantovani et al., 1992). This activation results 
in the release of IL-8 and MCP-1, production of reactive oxygen specific and upregulation 
of adhesion molecules; all which indirectly contribute to thrombus formation.  
 Circulating platelets play a significant role in the pathology commonly seen in 
atherosclerosis. Activated platelets secrete chemotactic substances (cytokines, chemokines) 
which facilitate the binding and transmigration of leukocytes across the endothelium layer 
through the upregulation of VCAM-1 (Coppinger et al., 2004; Klinger, 1997). In addition, 
upon activation, P-selectin, a component of the platelet alpha granule membrane, is 
translocated to the platelet’s surface and meditates the binding of various leukocytes; 
forming aggregates within circulation. This response observed from platelets is a primary 
event that occurs in arterial thrombosis. Platelet activation is a multistep process, initiated 
through an interaction between platelets and the adhesive molecules collagen and Von 
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Willebrand factor upon the surface of the sub-endothelial extracellular matrix (Chen, et al., 
2001; Ruggeri, 2002). This activation of platelets results in the production of high affinity 
integrins, thus promoting thrombus growth, and the development of atherosclerosis within 
the body (Nieswandt & Watson, 2003; Chen et al., 2002).  
 This increased presence of activated immune cells within the plaque result in 
enzymes, such as proteases, being released within the local vicinity. These proteases attack 
the collagenous cap, resulting in a significantly weaker and unstable lining. This can lead to 
a severe cardiovascular event, known as thrombosis; the rupturing of the plaque from forces 
such as arterial blood pressure. Areas which usually rupture commonly have thin, collagen-
poor fibrous caps, with few SMC, but abundance in macrophages (or foam cells). These 
immune cells present within the plaque, produce the enzymes which degrade the collagen, 
alongside producing coagulant tissue factor which renders the lipid core thrombogenic. This 
indirectly contributes to a severe thrombotic event, causing the plaque’s contents to spill out 
into the lumen of the blood vessel, resulting in severe clinical complications, such as heart 
attack and stroke (Hansson and Libby, 2011; Rifai et al., 2001; Yudkin et al., 2000).  
1.8.3  C-reactive Protein levels and Risk of Heart Disease 
 
 Traditionally levels of CRP are clinically measured to assess the level of infection, 
inflammation or tissue damage within the body (Pepys & Hirschfield, 2003; Zhang et al., 
2012). Increasing experimental evidence suggests an alternative, pro-inflammatory role for 
native CRP in the progression of disease. Deposition of CRP within the arterial wall is a 
common pathological feature in early atherosclerotic lesions. Inflammatory mediators 
released as a direct result of CRP include; monocyte chemoattractant protein, ICAM, 
VCAM-1, tissue factor and the release of cytokines (Pasceri et al., 2000; Pasceri et al., 2001; 
Pepys & Hirschfield, 2003; Torzewski et al., 1998; Zhang et al., 1999; Zhang et al., 2012). 
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Levels of IL-10, a major anti-inflammatory cytokine, are also decreased as a direct result of 
CRP; all pathological features common to atherosclerosis (Singh et al., 2006). This CRP-
dependent response has been recorded in endothelial cells, vascular smooth muscle cells and 
macrophages. Fcγ receptors expressed on these immune and vascular cells, is thought to 
mediate this binding of CRP, which can also result in opsonisation of ligands and the release 
of prothrombic factors at localised sites of inflammation and aortic plaques (Pepys & 
Hirschfield, 2003; Zhang et al., 2012). Local CRP synthesis through macrophages and 
smooth muscle cells has been reported within these atherosclerotic plaques, due to the 
detection of mRNA for CRP. However, this has been contested, with doubt still existing on 
whether CRP within atherosclerotic lesions originates from circulation or is locally 
synthesised (Dong & Wright, 1996; Jabs et al., 2003). 
 As previously discussed, CRP is known to selectively bind to LDL and to a lesser 
extent, VLDL from whole serum. Additionally, native CRP binds to oxidised and partially 
degraded LDL, components commonly found within atheromatous plaques. Localisation of 
CRP within premature atherosclerotic plaques aids in the formation of foam cells in vivo, 
with cell culture experimental work supporting this (Bhakdi et al., 1999; Chang et al., 2002; 
Fredrickson et al., 1967; Pepys & Hirschfield, 2003; Zhang et al., 2012; Zwaka et al., 2001). 
Alternative to human CRP, experimental research with rat CRP demonstrates an inability to 
bind to damaged cells and activate the complement pathway. Rats which have also been 
subjected to middle cerebral artery occlusion, and then treated with human CRP developed 
significantly larger cerebral infarcts compared to the control cohort receiving serum albumin 
(Gill et al., 2004; Griselli et al., 1999). In contrast with previous results, a study carried out 
Khera et al., recorded that subjects with higher CRP levels, had a modest increase in the 
prevalence of subclinical atherosclerosis, with their conclusions suggesting CRP is a poor 
predictor of an atherosclerotic burden (Khera et al., 2006). Collectively, these studies are 
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consistent with the current theory that CRP may exert a pro-atherogenic stimulus within the 
human body through the expression of cell adhesion molecules, release of inflammatory 
mediators and activation of complement (Zhang et al., 2012).  
Therapeutic inhibition of CRP has been suggested to be a promising new approach 
to cardio-protection in acute myocardial infarction, per an experimental study headed by 
Pepys et al (2006). The administration of 1,6-bis(phosphocholine)-hexane to rats which were 
undergoing acute myocardial infarction, abrogates the increase in infarct size and cardiac 
dysfunction produced by the injection of human CRP (Pepys et al., 2006). They state that 
their rationally designed drug demonstrates that CRP inhibition is a valid therapeutic 
strategy, which is unlikely to result in adverse effects, and thus provides informative about 
the physiological and pathological roles of human CRP (Pepys et al., 2006). Currently, 
statins are a form of medication which is given to patients suffering with heart disease to 
reduce levels of CRP (Albert et al., 2001; Jialal et al., 2001; Ridker et al., 1999; Ridker et 
al., 2001). The administration of statins influences the status of an atherosclerotic plaque, as 
inflammation and CRP levels are reduced. Statins can also be used to reduce the levels of 
LDL-cholesterol in patients, as well as CRP. Patients who display generally lower levels of 
CRP consistently show a better response to statin treatment. Medication which is commonly 
used to reduce levels of CRP is pravastatin and simvastatin, which inhibit CRP production 
at the transcriptional level within hepatocytes (Ridker et al., 2005; Voleti & Agrawal, 2006).  
To improve global cardiovascular risk prediction, considerable interest has focused 
on CRP which has been shown in multiple epidemiological studies to predict an incident of 
myocardial infarction, stroke, peripheral arterial disease or sudden cardiac death (Koenig et 
al., 1999; Ridker, 2001; Ridker, 2003; Tracy et al., 1997). The hypothesis that testing CRP 
may have prognostic usefulness for patients with acute myocardial infarction dates to the 
1940’s, when levels of CRP were observed to increase as part of the acute phase response 
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associated with ischemia (Ridker 2001). In terms of clinical application, the measurement of 
CRP levels is suggested to be a stronger predictor of cardiovascular events later in a patient’s 
lifetime, than levels of LDL cholesterol. High-sensitivity CRP tests were developed to 
measure the desired levels of inflammation within a ‘normal’ range, as standard CRP assays 
lacked the required sensitivity, with a lower detection limit of 3-8mg/L (Danesh et al., 2000; 
Jialal et al., 2004; Ridker 2001). Table 1.1 highlights the general risk category patients are 
grouped in depending on their reading from a high sensitive CRP (hsCRP) test.  
CRP Level (mg/L) Risk 
<1 Low 
1-3 Moderate 
>3 High 
 Table 1.1 Levels of CRP which determine the risk category patients are placed in 
depending on their reading from the hsCRP test. The risks define the general likelihood of 
developing a severe cardiovascular condition later in life. 
It is worth noting that in clinical practice, results generated from a high sensitivity 
CRP measurement would not be used solely to define the patient’s likelihood of developing 
a certain condition; these results would be assessed alongside a variety of other clinical tests. 
Individuals with cholesterol below 130mg/L who have CRP levels >3mg/L represent high-
risk groups in clinical practice (Danesh et al., 2000; Jialal et al., 2004; Ridker 2003). This 
relationship between a patient’s baseline level of CRP and future vascular risk has been 
consistent in studies from the United States and Europe. Compared to novel risk factors, 
such as the Framingham score, hsCRP is set to be the most promising. The Framingham risk 
score is a gender specific algorithm commonly used to estimate the 10-year cardiovascular 
risk of an individual. Cohort studies have confirmed that hsCRP evaluation adds prognostic 
information beyond this test (Danesh et al., 2000; Jialal et al., 2004; Ridker et al., 2004). 
CRP is not the only biomarker that can be used to predict cardiovascular events. More 
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sophisticated measurements of cytokine activity, cellular adhesion and immunologic 
function have all been shown to be elevated among those at increased vascular risk. These 
approaches, however are unlikely to have clinical utility because the assays required for their 
assessment are either inappropriate for routine clinical analysis, or the protein of interest has 
too short a half-life for clinical evaluation (Danesh et al., 2000; Jialal et al., 2004; Ridker, 
2003).  
Despite the accumulating evidence suggesting a pro-inflammatory role for native 
CRP in the progression of disease, there is a continuous debate as to whether CRP plays a 
causal role in the development of disease, or whether it is simply an important clinical marker 
of inflammation.  
1.9 Monomeric C-reactive Protein 
 
1.9.1   Overview of Monomeric C-reactive Protein 
 
 Pentameric C-reactive protein (pCRP) is extremely stable under physiological 
conditions. There are increasing reports which suggest a biological role for a monomeric 
form of CRP named monomeric CRP (mCRP) or membrane-bound CRP (mbCRP) 
(Ciubotaru et al., 2005; Ji et al., 2009; Li et al., 2012; Zhao & Shi, 2010).  
 The in vitro production of mCRP, by treatment of pCRP with high concentrations of 
urea (up to 8M), was first described by Potempa et al., (1983). They showed that this 
monomeric form had decreased solubility, a difference in isoelectric point and a loss of 
calcium dependent binding to C-polysaccharide (Potempa et al., 1983). Interestingly, once 
pCRP has been dissociated into mCRP, it is unable to re-associate back into its native form, 
raising important questions as to whether the treatment in such harsh conditions results in a 
Chapter 1. Introduction  Introduction 
 
44 
 
conformational change in the protein’s structure, with unknown consequences for its 
function (Kresl et al., 1998).  
 There is some confusion within the literature concerning the definitions of CRP 
isoforms. ‘Monomeric CRP’ can be produced in vitro, but references are also made to a 
‘membrane-bound CRP’ or ‘modified CRP’. It is unclear whether this isoform is monomeric 
or pentameric, but it is suggested to form through membrane binding of pCRP, which 
induces dissociation. Furthermore, it is unclear whether the ‘modified’ or ‘membrane-
bound’ CRP can be located freely within human serum (Eisenhardt et al., 2009; 
Habersberger et al., 2012; Ji et al., 2007; Ji et al., 2009; Li et al., 2012; Molins et al., 2008; 
Slevin & Krupinski, 2009; Zhao & Shi, 2010).  
1.9.2  The Formation of Monomeric C-reactive Protein 
 
Several models have been proposed for the in vivo formation of mCRP, with cell 
membranes and liposomes being the more commonly accepted theories (Eisenhardt et al., 
2009; Habersberger et al., 2012; Ji et al., 2007; Ji et al., 2009; Li et al., 2012; Slevin & 
Krumpinski, 2009). Although, as previously stated, native CRP is known to be relatively 
stable under physiological conditions, evidence has been published which suggests 
dissociation may occur under a normal, physiological environment. Calcium dependent 
binding of circulating pCRP to liposomes or cell membranes can induce rapid dissociation 
of the pentamer with apoptotic THP-1 and Jurkat T cells, mediating this form of dissociation 
into a membrane bound form of CRP, thought to be monomeric (Eisenhardt et al., 2009; 
Filep, 2009; Ji et al., 2009; Sjowall and Wettero, 2007).  
The dissociation of pCRP has been proposed to occur through various epitopes 
presented on the cell surface of endothelial cells, including lipid raft domains. Lipid rafts are 
specialised membrane microdomains which are enriched with cholesterol and sphingolipids 
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which play an important role in cellular signalling. They also contain other saturated long-
chain lipids that create a dynamic ‘liquid-ordered’ zone in the bulk fluid membrane. These 
areas provide the capacity for rafts to sequester or exclude certain proteins and organise a 
signal transduction platform (Ji et al., 2009). Sequence analysis of CRP identified a region 
of amino acids 35-47 which displayed a sequence resembling the putative cholesterol 
recognition consensus. In its pentameric form, amino acids 35-47 would largely be buried 
within the apolar core of the subunits and overlap with the inter-subunit contacting sequence. 
Moreover, upon dissociation, this sequence would then become exposed and capable of 
binding to regions on the membrane of high cholesterol content (Ji et al., 2009). Alongside 
cholesterol, other key lipid components that have been identified as being able to induce 
dissociation of pCRP upon binding are Pneumococcal C-polysaccharide and polylysine. In 
addition to multipoint attachment of pCRP to induce dissociation, a hydrophobic 
microenvironment has been identified as a key determinant. This mild hydrophobic 
environment, such as the cell membrane, can lead to rapid dissociation of pCRP subunits, 
with partially retained native confirmation (Ji et al., 2007).  
1.9.3  Monomeric C-reactive Protein and Disease 
 
 Experimental work documented within the literature has hypothesised a link between 
the mCRP and the progression of certain diseases within the body. Monomeric CRP is 
documented to have reduced aqueous ability, with a tendency to aggregate into matrix-like 
lattices in various tissues, such as blood vessel walls (Slevin et al., 2009). As discussed 
previously, activation of endothelial cells and their dysfunction is a common event leading 
contributing to the development of cardiovascular disease. It is believed that CRP may 
contribute towards this dysfunction, through the production and recruitment of pro-
inflammatory cytokines, alongside the upregulation of cell adhesion molecules.  
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 It is suggested that pCRP may undergo some form of structural rearrangement to a 
modified version of CRP (usually denoted mCRP), for this activation and dysfunction of 
endothelial cells to occur alongside asserting pro-inflammatory stimuli upon vascular cells 
(Khreiss et al., 2004; Ji et al., 2009). A study carried out by Molins et al., demonstrated that 
mCRP, unlike pCRP was shown to induce thrombus growth on the collagen surface, and not 
only significantly increase the adhesion of platelets, but also the aggregate size and thrombus 
height (Molins et al., 2008). P-selectin up regulation by mCRP demonstrates an ability to 
stabilise platelet-platelet and platelet-leukocyte aggregates; a potential explanation for the 
increase in thrombus growth as mCRP has been linked to the recruitment of platelets and 
thrombus growth (Molins et al., 2008).  
 In human neutrophils, mCRP has been shown to stimulate rapid production of IL-8 
(<4 hours), required de novo synthesis and transcription of the IL-8 gene (Khreiss et al., 
2005). In addition to this study, Khreiss et al., showed that modified CRP, thought to be 
mCRP, induced the production of peroxynitrite, formed through the reaction of superoxides 
and nitric oxide. Peroxynitrite functions as an intracellular signalling molecule to produce 
IL-8 through the activation of transcription factors nuclear factor-κB and activator protein-
1 (Khreiss et al., 2005). The adhesion of neutrophils to endothelial cells in areas of 
intensified inflammation can also be increased because of mCRP. Dissimilar to pCRP, 
cellular adhesion molecules CD11b and CD18 are upregulated on the surface of neutrophils 
when they interact with mCRP (Zouki et al., 2001). The properties of fibrin in human artery 
endothelial cells have been shown to be altered upon interactions with mCRP. Incubation 
with mCRP on the cell surface resulted in increased fibrin polymerisation and tissue factor 
expression. This increase in tissue factor alters the formation of fibrin and its clotting 
properties, which may contribute towards potential pro-thrombotic events that can occur at 
injured vessel walls (Li et al., 2012). Furthermore, levels of IL-8 and monocyte 
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chemoattractant protein, alongside increased mRNA levels and expression of ICAM-1, E-
selectin and VCAM-1 were also observed (Khreiss et al., 2004). The physiological changes 
which have been recorded here could potentially translate into severe biological alterations 
within the pathology and, in turn, contribute towards the development and progression of 
inflammatory diseases.  
 Circulating platelets have also been documented to play a role in the mCRP-induced 
progression of inflammatory disease. Phosphatidylcholine is a major lipid contained within 
the membrane of eukaryotic cells, serving as a reservoir for several lipid messengers, 
including lysophosphatidycholine. On activation and cell death, cell membranes express 
derivatives of phosphatidylcholine, expressing phosphocholine residues to which CRP can 
bind too (Eisenhardt et al., 2009). This binding site has been hypothesised to be the region 
where CRP binds to activated platelets, present within atherosclerotic lesions, and induce 
the dissociation of pCRP into mCRP. This resulting formation of mCRP leads to increased 
expression of adhesion molecules, like that described during endothelial cell dysfunction 
(Eisenhardt et al., 2009). Verma et al proposed a method of pCRP dissociation in the 
peripheral circulation that would enhance the pro-inflammatory properties of CRP (Verma 
et al., 2004). This was backed up by Eisenhardt et al as they could demonstrate a dissociation 
process showing that activated platelet membranes exposing phosphocholine, which 
mediates this dissociation (Eisenhardt et al., 2009; Verma et al., 2004).  
 Upon platelet activation, lipids located within their membranes are known to undergo 
a change in morphology and composition; one of these changes being the exposure of 
binding sites for immune proteins such as CRP. This rapid change in the membrane structure 
of lipids also results in the shedding of microparticles (MP) (Owens & Mackman, 2011). A 
study by Habersberger et al., has hypothesised that circulating microparticles can bind and 
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induce dissociation of pCRP, in addition to act as a mode of transport around the body, to 
sites of intensified inflammation (Habersberger et al., 2012). More recently, an experimental 
study has highlighted the failure of standard clinical CRP tests to detect mCRP that is bound 
to MP. This could potentially have a devastating impact on the type and quality of treatment 
a patient could receive (Crawford et al., 2016). The experimental evidence highlighted here 
displays a damaging pro-inflammatory role of the elusive monomeric form of CRP, which 
may potentially exacerbate the progression of inflammatory diseases. 
1.10 Complement  
 
1.10.1  Introduction to Complement 
 
 The complement system is part of the innate immune system and is one of the key 
effector mechanisms of antibody-mediated immunity in the classical pathway. It was first 
identified as a process in serum that ‘complemented’ antibodies in the killing of bacteria 
(Walport, 2001). There is a total of three complement pathways; the classical pathway, 
mannose-binding lectin pathway and the alternative pathway (Walport, 2001). The C1 
complex is an initiator for the classical complement pathway by binding to immunoglobulins 
such as IgM, IgG or the acute phase protein CRP, bound on the surface of host cell walls 
(Carland et al., 2010).  
The C1 complex is a 790 kDa complex, which is formed by the association of the 
recognition protein, C1q, and a calcium dependent tetramer, comprising of two copies of the 
proteases C1r and C1s (Gaboriaud et al., 2004). The proteases are elongated tetramers that 
become more compact when they bind to the collagen-like domains of the C1q molecule 
(Girija et al., 2013). Binding of the C1q protein induces a conformational change which 
drives the activation of the proteases in a stepwise fashion: C1r first auto-activates, then 
activates C1s. C1s subsequently cleaves the additional complement proteins C4 and C4b-
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bound C2, forming the C3 convertase – a downstream component of the complement 
cascade (Girija et al., 2013). The role of the C1 complex within the human immune system 
is to activate the classical complement pathway, which results in the recruitment of 
inflammatory mediators and eventually the cell lysis through the formation of the membrane 
attack complex (MAC) (Black et al., 2004; Girija et al., 2013; Kishore et al., 2004; Mold et 
al., 1999). Most major complement components are synthesised within the hepatocytes of 
the liver; however, the C1 complex proteins are produced, primarily within the epithelium 
of the gut, along with a growing list of immune cells such as macrophages and endothelial 
cells (Arlaud & Colomb, 2001).  
1.10.2  C-reactive Protein and Complement 
 
 Activation of the complement system by CRP was first demonstrated by Kaplan and 
Volanakis in 1974 (Kaplan & Volanakis, 1974). They reported that the addition of 
pneumococcal C-polysaccharide to acute phase serum caused complement depletion, and 
that this process required the presence of both CRP and C1q. This activation was also shown 
by Sigel et al., using CRP-protamine complexes (Kaplan & Volanakis, 1974; Sigel et al., 
1974). These studies established that CRP, complexed with polyvalent or chemically cross-
linked ligands, binds to C1q and activates the classical complement pathway (Mold et al., 
1999).  
 The proteins C1-C9 are the major components of the classical complement cascade 
and are most commonly activated through the binding of various immune complexes to C1q. 
The initial stage of the classical complement pathway results in the cleavage of products C3 
and C4, which act as opsonins (Black et al., 2004; Mold et al., 1999). The later stage of the 
classical complement pathway involves activation of the C5-C9, generating highly 
inflammatory chemotactic peptides and the formation of the membrane attack complex 
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causing lysis of the bacteria or cell to which they bind. The complexing of the ligand-bound 
CRP to C1q leads to the formation of the C3 convertase protein which assembles in a 
formation like that initiated by antigen-antibody complexes (Mold et al., 1999). The 
examination of individual complement components suggests that CRP mediated 
complement activation is limited its initial stages, involving C1-C4, with little activation of 
late complement proteins C5-C9 (Black et al., 2004; Mold et al., 1999). This contrasts with 
the complement cascade which is initiated via the antibody-antigen complex, which recruits 
the later phase components of the complement cascade. This difference between 
complement activation through CRP and that resulting from other immune complexes is 
presumably down to CRP’s ability to interact and with factor H, leading to the inhibition of 
pathways that result from the formation of C5 convertases. Thus, strong inflammatory 
responses typically associated with C5a and the C5-9 membrane attack complexes are 
limited (Black et al., 2004; Clos & Mold, 2004; Mold et al., 1999; Zhu et al., 2005).  
 CRP has been shown to bind to artificial membranes, via the positively charged fatty 
acid derivatives, stearylamine, which results in the activation of the complement pathway 
(Mold et al., 1981; Richards et al., 1977). PC subunits protruding from liposomal 
membranes can interact and bind with CRP, and activate the complement cascade whilst 
simultaneously stimulating the release of glucose from the liposomes. Adequate membrane 
binding of CRP to PC is essential when activating the complement cascade, as lysis of the 
liposomal membrane was reduced when incorrect binding occurred (Richards et al., 1977). 
The complement components that were consumed during this experimental process 
demonstrated that activation occurred through the classical pathway. The interaction of CRP 
with protamines (arginine-rich, nuclear proteins) also appears to consume components of the 
classical complement pathway (Siegel et al., 1974). The consumption of classical 
complement components has also been described when CRP interacts with PC units present 
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of the surface of lecithin and sphingomyelin, both different types of phosphatides (Kaplan 
& Volanakis, 1974). 
1.10.3  Introduction to the Human C1q Protein 
 
 The importance of C1q as a biological molecule is shown by its wide range of 
biological processes. Activation of the classical complement pathway by C1q usually results 
in the formation of the membrane attack complex (MAC) on the target cell, including cell 
lysis (Kishore et al., 2002; Kishore et al., 2004; Kishore & Reid, 2000).  
The interlocking of antigens and antibodies in a complex is a natural and successful 
attempt to neutralise antigens. C1q plays a vital role in the solubilisation and clearance of 
these complexes (Kishore et al., 2004; Navratil et al., 1999). The complement protein, C1q, 
also acts as an opsonin in the removal of bacterial products by coating the bacteria and 
enhancing the uptake by phagocytic cells (Kishore et al., 2004).  
Production of pro-inflammatory cytokines such as IL-8, IL-6 and monocyte 
chemoattractant protein (MCP) 1 from endothelial cells is also an important role for the C1q 
protein. The interaction involving a collagen-like region of the C1q protein and calreticulin-
CD91 receptor complex enhances p38 MAPK activation, NF-κB activity and the production 
of pro-inflammatory cytokines in macrophages (Berg et al., 1998; Kishore et al., 2004).  
1.10.4  The Structure of Human C1q 
 
The human C1q molecule is composed of three different polypeptide chains, A, B 
and C. There is a total of 6 subunits, each containing one A, B and C polypeptide chain with 
a total of 18 polypeptide chains within the C1q protein. The protein, as shown in Figure 1.5 
is commonly described to take on the appearance of a ‘bouquet of flowers’.   
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Figure 1.5 Model of the three-dimensional structure of the C1q protein. The central collagen-
like region is shown at the apex of the image which diverges into six stems, eventually 
forming the globular head region. Each polypeptide chain is represented via a different 
colour; blue (A), red (B) and green (C). The glycosylated region attached to the globular 
head is shown in yellow. Figure has been adapted from Gaboriaud et al. (2004)   
Each chain has a short amino-terminal region, containing a half-cysteine residue, 
which is involved in inter-chain disulfide bond formation. This is followed by a collagen-
like region (CLR) of around 81 residues (comprising of Gly-X-Y repeats) which is linked to 
a C-terminal globular head region (GHR) of approximately 135 residues (Kishore & Reid, 
2000; Kishore et al., 2004).  
The GHR fragment of C1q has been crystallised and the structure determined to a 
1.9-Å resolution by Gaboriaud, et al (2003). The structure shows a tight, heterotrimeric 
assembly with non-crystallographic pseudo-3-fold symmetry (Gaboriaud et al., 2003). The 
N- and C- termini for each of the subunits, A, B and C of the GHR emerge at the base of the 
trimer. Each subunit has a 10-stranded β-sandwich with jellyroll topology, homologous to 
GHR 
CLR 
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the structure that has also been described for tumour necrosis factor (TNF). There is strong 
conservation shown within the β-sheets of the A, B and C subunits, with significant 
variability occurring within the loops protruding from the apex of globular head (Gaboriaud 
et al., 2003). There is a predominance of positive charge at the top of the C1q GHR, mainly 
due to lysine residues. The calcium ion at the apex of the GHR is coordinated by six oxygen 
ligands; the oxygen present on the side chain of AspB172, one from the main chain carbonyl 
of TryB173, two from the side chain carbonyls of GlnA177 & GlnB179 and two water 
molecules (Gaboriaud et al., 2003).  
Furthermore, there are exposed hydrophobic patches with several aromatic residues 
available to the solvent (Gaboriaud et al., 2003; Kishore et al., 2004). The subunits A and C 
both show a combination of basic and acidic residues scattered over their external face, 
whereas subunit B shows a predominance of positive charge, especially focused around a 
concentrated patch of arginine residues (Arg101, 112 and 129). This modular organisation 
of heterotrimer assembly, in addition with the diverse surface patterns around the three 
subunits of the GHR, allows C1q to interact with a diverse range of ligands (Kishore et al., 
2004).  
1.10.5  Interactions Between C-reactive Protein and C1q 
 
 The mechanical and structural interactions that occur between C1q and CRP on an 
atomic level are not fully understood. Two main theories exist, based on previous 
experimental evidence which suggest how this interaction occurs. The first theory 
hypothesises that C1q interacts with the effector face of CRP through its collagen-like 
region, with the alternative theory suggesting an interaction between CRP and the globular 
head region of C1q. Moreover, there is strong experimental evidence from both mutagenesis 
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and binding studies which supports the latter hypothesis (Agrawal et al., 2001; Gaboriaud et 
al., 2003; Kishore et al., 2004). 
 Previous binding studies carried out, to determine the location of the CRP binding 
site on the C1q molecule, demonstrated two regions of amino acids which originate from the 
A chain within the CLR (Jiang et al., 1992). To establish whether this region was crucial for 
binding, two C1q A chain peptides were synthesised, identical to the amino acids in regions 
76-92 and 14-26; regions which were predicted to bind to the CRP protein. The results 
demonstrated that the peptide fragment 76-92 partially and peptide 14-26 completely 
inhibited the binding of CRP to the fully intact C1q protein (Jiang et al., 1992). Further, 
replacement of amino acids within both sequences resulted in a complete loss of inhibition, 
which interestingly suggests sequence specificity, and binding does not just specifically rely 
on charge alone when forming a theoretical basis for the inhibitory effects of the peptide 
sequence (Jiang et al., 1992).  
 The immunoglobulin IgG is known to bind to the globular head region of the C1q 
protein. Experimental research by Jiang et al., 1991, showed that heat-aggregated IgG did 
not block the binding of CRP-trimers to C1q, nor did CRP-trimers block the binding of IgG 
to C1q, suggesting that the binding sites were located at different regions on C1q (Jiang et 
al., 1991). Monoclonal antibodies that were directed towards the CLR of C1q (anti-CLR 
mAb) could inhibit the binding of CRP towards C1q, whereas when using the anti-GHR 
mAb, it was unable to elicit the same effect. The results demonstrated here provide indirect 
evidence which supports the theory that binding occurs through the CLR of the C1q protein, 
thus initiating the classical complement pathway (Jiang et al., 1991; Jiang et al., 1992). 
However, it is now generally accepted that the interaction between CRP and C1q occurs 
through the globular head region of the protein.  
Chapter 1. Introduction  Introduction 
 
55 
 
 Alternatively, experimental evidence described by McGrath et al., supports the latter 
hypothesis (McGrath et al., 2005). McGrath et al., demonstrate how five monoclonal 
antibodies against the globular head region of C1q inhibited the binding of CRP to C1q, 
failing to initiate complement. Whereas four monoclonal antibodies, which were specific to 
the collagen-like region, failed to induce any inhibition at all. Furthermore, the five 
monoclonal antibodies which were specific to the globular head region inhibited the binding 
of C1q the solid-phase IgG, demonstrating the binding site for IgG is also located on the 
globular head. Finally, McGrath also showed that binding of C1q to CRP could also be 
inhibited by IgG, suggesting further evidence that both binding sites are located upon the 
globular head, as opposed to the collagen-like region (Gaboriaud et al., 2003; McGrath et 
al., 2005). 
 Modelling studies, researching potential structural and charge based interactions 
between the two proteins has also been carried out. The three-dimensional structure of CRP 
sports a deep cleft, which extends between each protomer on the face of the pentamer 
opposite to that of the phosphocholine binding site (Agrawal et al., 2001; Gaboriaud et al., 
2003; Shrive et al., 1996). Gaboriaud et al suggest that this cleft on the CRP molecules is 
where the interaction between the globular head region of C1q interacts. The apex of the 
globular head displays a predominantly basic charge, which could be accommodated by the 
negatively charged central pore of CRP; an interaction which involves the A and B subunits 
of C1q (Agrawal et al., 2001; Gaboriaud et al., 2003; Gaboriaud et al., 2004). Structural 
elements that are suggested to be involved in the interaction between CRP and C1q are more 
than likely to be located on the effector face of the pentamer, as shown in Figure 1.6. 
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Figure 1.6 Schematic illustration of the hypothesised interaction between the GHR of C1q 
with the effector face of pentameric CRP.  The globular head region A is shown in blue, B 
is shown in green and C is shown in red. The model was designed to facilitate the exploration 
of the potential interaction between the globular head region of C1q and CRP. Residues 
shown include Asp112 and Tyr175 of CRP, and Tyr175B, Lyc200A and Trp147A. The 
residues suggested to interact between the two proteins are highlighted as ball and stick 
models. Image adapted from Kishore et al. (2004).  
The residues Asp112 and Tyr174 from CRP, show striking shape complementarity 
between the two proteins and have been identified as major contact residues with C1q 
(Agrawal et al., 2001; Kishore et al., 2004). Asp112 from CRP is located within the open 
cleft, towards the centre of the pentamer; suggesting an important role for this region of the 
protein (Agrawal et al., 2001). Further mutagenesis studies to define the topology of the C1q 
binding site has also demonstrated the importance of Asp112 and Tyr175, although the 
positively charged reside of Lys114 hinders the binding of C1q as substitution, as a 
negatively charged residue enhanced the binding of C1q and complement activation 
(Agrawal, 2004; Gaboriaud et al., 2003). 
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 The structural interactions between C1q and CRP are extremely important when 
researching the activation of complement, and to a wider extent, the innate immune response. 
Determination of individual amino acid interactions, location of binding sites and structural 
changes to both proteins overall will help provide a greater overall understanding of how 
these two proteins work and interact. Furthermore, alternative physiological forms of CRP, 
such as mCRP, have been linked to binding and activating the classical complement pathway 
(Mihlan, et al., 2011). This ability of mCRP to interact with mCRP is thought to result in the 
exacerbation of inflammation in certain diseases. Further research into understanding 
providing detailed structural information of how the protein binds and interacts with its 
constituent immune proteins may help drive areas of research and understanding. 
1.11   Research Aims  
 
 The overall aims of this research were split into two areas. The first was to provide 
some insight into the current ambiguities around the molecular variations of CRP. This will 
involve the production, purification and characterisation of in vitro produced mCRP, 
alongside analysis of human serum samples for an in vivo form. The presence of a 
monomeric form of CRP within human serum may have an impact on both current clinical 
practice and the treatment and care a patient receives as it is not clear whether raised levels 
of the protein may indicate a different set of circumstances to that of its native counterpart, 
pCRP. Furthermore, it is unknown whether current clinical tests may be able to detect the 
presence of a monomeric form of CRP, or whether current clinical practice needs to be re-
evaluated to accommodate for its presence.  
The latter part of this research involved crystallisation studies of in vitro produced 
mCRP, alongside complex crystallisation trials involving native CRP, C1q and CWPS. 
Crystallisation trials involving the in vitro produced mCRP were initiated to identify a 
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potential structural map of the protein, should we identify it. Additionally, an atomic map of 
the monomer may highlight any structural differences between itself and the native 
pentameric form. Additionally, we wanted to visualise the structural interactions that 
occurred between CRP and its natural ligands; more specifically CPS and C1q. The 
crystallisation trials involving CRP, C1q and CWPS aimed at providing greater detail into 
the structural interactions within this complex on an atomic scale. It is not yet certain as to 
how CRP binds the C1q complement protein; does this occur via the globular head or the 
collagen-like region? Furthermore, it remains unclear why CRP can only activate 
complement when bound to a larger structure, and not just PC. The evidence suggests a 
conformational change may occur within CRP, once bound to both proteins. Solving the 
atomic structure of this complex will answer these questions, alongside providing a greater 
understanding to CRP’s role and function within the immune system 
Overall, this research will further the knowledge on CRP’s role within the immune 
system, both structurally and clinically. It will also provide insight into common 
misconceptions of the acute phase protein, whilst contributing to the quality assurance of 
current clinical practice, when measuring patient CRP levels.  
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Chapter 2.0 – Production & Characterisation of Monomeric C-reactive 
Protein 
2.1  Introduction 
  
2.1.1  Overview 
 
Native, pCRP is extremely stable under normal, human physiological conditions. 
However, there is increasing evidence within the literature which suggests a role for an 
isoform of pCRP, known as monomeric C-reactive protein (hereon referred to as mCRP). 
Although slightly unclear whether this protein is ‘modified’, or ‘membrane-bound’, the 
consensus suggests a pro-inflammatory role within the human body, compared to its native 
pentameric isoform (Ciubotaru et al., 2005; Eisenhardt et al., 2009; Ji et al., 2009; Li et al., 
2012; Zhao & Shi, 2010). 
 The described mCRP displays a reduction in solubility, a change in isoelectric point 
and a complete loss of the calcium dependent binding to C-polysaccharide (Potempa et al., 
1983). The biological relevance of mCRP is yet to be fully established, with some debating 
whether the protein exists in vivo and asking if mCRP is not just a product of in vitro 
dissociated pCRP which displays these pro-inflammatory properties. There is some 
experimental evidence that has recently been published which demonstrates a model for the 
production and transportation of mCRP in vivo, with some researchers claiming they have 
successfully detected the protein in vivo (Wang et al., 2015).  
 This chapter will discuss the production and characterisation of an in vitro produced 
form of mCRP, from native pCRP. The experimental work is based upon previous 
production of mCRP both within the literature and previous experimental work carried out 
within our own research lab. The aim of this research is to develop a sound methodology 
which allowed us to produce mCRP (in vitro) in the least harsh conditions possible.  
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2.1.2  Production of in vitro Monomeric C-reactive Protein 
 
 The production of a monomeric form of CRP was first described by Potempa et al., 
in 1983. They used methods including; heat treatment, altering the pH to extremely acidic 
conditions and dissociation through high concentrations of urea (Potempa et al., 1983). 
Interestingly, in addition to the characteristics previously described, once dissociated into 
mCRP, it was unable to re-associate back into its native form. This raises important questions 
as to whether treatment in such harsh conditions results in a conformational change to the 
structure and function of the protein. It is worth noting that many of the published works on 
the damaging pro-inflammatory effects exhibited by mCRP have produced their mCRP in 
the same way, bringing into question whether there is any physiological relevance to their 
work.  
2.1.3  Affinity Chromatography 
 
 The technique affinity chromatography separates out protein molecules based on a 
reversible interaction between a protein (or a group of proteins) and a specific ligand which 
is coupled to a chromatography matrix. Crude samples such as human serum can be passed 
through this chromatography matrix to which a specific ligand is immobilised. This is called 
a coupled ligand, as it is coupled to the matrix, and the protein in the sample binds to this 
(Wilchek & Chaiken, 2000). The technique offers a highly selective method of protein 
purification which displays a high capacity for the protein of interest. The purification of a 
specific protein can be in the order of several thousand-fold, with recoveries of active 
material generally very high. For successful purification, affinity chromatography relies on 
intact protein structure and function. Thus, the process can also be used to separate out active 
biomolecules from denatured or functionally different forms (Wilchek & Chaiken, 2000).   
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 The biological interactions that occur between the ligand and the target molecule can 
be a result of electrostatic or hydrophobic interactions, van der Waals’ forces or hydrogen 
bonding. It is these interactions which allow target molecules to be purified from complex 
biological mixtures. A ligand which displays binding to very few proteins, or even just one 
protein, will allow greater purification than a ligand which is less specific and can bind to 
many proteins (Amersham Biosciences, 2003).  
 The matrix of the column used in this project is Sepharose made from agarose sugar 
beads. This material is stable and not affected by changes in pH or ionic strength in addition 
to being relatively inert meaning it does not interact with the proteins within the sample. The 
column is tightly packed with the Sepharose matrix, arranged in a matrix structure with a 
rigidity allowing for varying flow rates. This is known as the ‘affinity medium’ (Amersham 
Biosciences, 2003).  
 The ligand which is bound to the column matrix is bound via a covalent bond, whilst 
still retaining the crucial binding properties for interaction with protein(s). The bound ligand 
possesses several important qualities which are crucial for affinity chromatography. Firstly, 
the ligand binds reversibly to the protein in question and does not alter the protein’s 
biological activity or properties in anyway. Secondly, the binding affinity between the ligand 
and the protein must be strong enough to ensure that most, if not all the target protein is 
bound providing a high purification yield from the crude sample. Thirdly, the interaction 
between the protein and ligand must not be too strong to prevent recovery once the whole 
sample has been passed through the column (Amersham Biosciences, 2003). 
 Once the entire sample has been run through the chromatography matrix, and the 
protein has bound to the coupled ligand, the sample must be recovered from the column. 
Elution of the sample can be performed specifically, by using a competitive ligand, or non-
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specifically, by altering the pH, ionic strength or polarity of the solution running through the 
column. The most common method of purifying a sample from the column is using a 
competitive ligand. The competitive ligand will display a higher binding affinity for either 
the protein in question, or the ligand bound to the chromatography matrix (Villems & 
Toomik, 1993). The concentration of the competitive ligand depends on the affinity of the 
protein for the competitor. A lower binding affinity of the protein to the competitive ligand 
usually results in a higher concentration being used, whereas a higher binding affinity can 
generally mean a lower concentration will suffice for the removal of the protein from the 
column.  
 Crude samples such as blood and serum can be purified by affinity chromatography, 
as can any liquid containing a mixture of proteins. Larger volume samples do not necessarily 
affect the purification process, although a larger sample will increase the time taken to load 
onto the column. It is the amount of protein within the initial sample that is crucial for 
purification as overloading the column with too much protein will result in protein being 
wasted and incorrect feedback values when calculating the recovery yield.  
 The flowrate used for applying and eluting the protein sample to the column should 
be optimised. Too high a flowrate and the proteins within the solution may not bind 
adequately, therefore losing valuable protein through washing steps. However, if there is 
high binding affinity between the protein and ligand, slightly higher flow rates are acceptable 
as this will save time with a negligible loss of protein from the sample. 
 Prior to the addition of the sample, the column is thoroughly cleaned, usually with a 
recommended wash buffer appropriate for the sample being used. The wash buffer will help 
remove any protein that failed to elute off from the previous run. Equilibration buffer is also 
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run through the column before and after each step in the purification process to wash through 
unbound material and to ensure a constant flow through the column.  
2.1.4  Gel Filtration Size Exclusion Chromatography 
 
 Gel filtration chromatography is the simplest and mildest of all chromatography 
techniques. It plays a key role in the purification of biological macromolecules including 
proteins, polysaccharides and nucleic acids. This robust technique is well suited to the 
handling of biomolecules that are sensitive to changes in pH, concentration of metal ions or 
harsh environmental conditions. Sample purification can be performed in the presence of 
harmful substances such as urea, guanidine, hydrochloric acid, alongside a range of 
temperatures. The main functions of gel filtration chromatography include; sample 
purification, buffer exchange and molecular weight determination. The separation and 
purification of these biomolecules is achieved by passing the solution through a gel filtration 
medium, which has been tightly packed into a column. Unlike affinity or ion exchange 
chromatography, the molecules within the sample do not bind to the chromatography 
medium, meaning buffer composition does not affect the resolution. This highlights an 
advantage over other chromatography techniques, as buffer conditions can be altered to suit 
each sample (Amersham Biosciences, 2003).  
 The gel filtration medium is tightly packed inside the column, forming what is known 
as the ‘packed bed’. This medium consists of a porous matrix of spherical particles which 
are used due to their chemical and physical stability, in addition to their inertness. There are 
several different types of gel filtration medium that can be used in size exclusion 
chromatography, each suited to a different type of protein purification. One common 
example of the medium used in size exclusion columns is Sephadex, which is ideal for rapid 
group separation of molecules, desalting and buffer exchange. Prior to the addition of the 
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sample, the column is equilibrated with buffer which fills the pores of the matrix and the 
space between each of the particles. The liquid within the matrix is known as the ‘stationary 
phase’, which is in equilibrium with the liquid outside of the matrix, known as the ‘mobile 
phase’ (Amersham Biosciences, 2003). 
 The sample is applied to the column via a syringe. To achieve the best possible 
resolution of the elution profile, a sample volume between 0.1-2% of the column volume is 
recommended. Once the sample has been applied to the column, the buffer (and sample) 
slowly migrates through the column tubing, towards the column. Optimum flow rates will 
increase the resolution of the elution profile in addition to conserving the yield of protein 
collected post-purification. Molecules within the sample diffuse in and out of the pores 
within the matrix. Smaller molecules can move further into the matrix, whereas larger 
molecules are restricted as to where they penetrate the pores due to their size. This ability to 
‘visit’ more areas of the porous matrix facilitates the separation of the molecules throughout 
the solution based on their molecular weight. As the buffer continuously passes through the 
column, larger molecules which are no longer able to move further into the matrix are eluted 
off into fraction collection tubes. As samples are eluted off the column, their ultra-violet 
(UV) absorbance is measured (wavelength will depend on the type of biomolecule) to create 
an elution profile. The entire separation process takes place over a total of one column 
volume (equivalent to the volume of the packed bed) of buffer passing through the column. 
Calibration graphs, constructed from the elution volumes of known molecular weight 
standards can be used to determine the molecular weight of unknowns, based on their elution 
volumes (Amersham Biosciences, 2003). 
 Samples such as blood and serum are advised not to be run through the column due 
to their crude composition. This could potentially block the size exclusion column and would 
require constant rigorous cleaning procedures after each run. Typically, samples will have 
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been initially purified via a different form of chromatography (such as affinity) before being 
applied to the size exclusion column. Unlike affinity chromatography, the amount of protein 
within the sample is not a crucial factor, whereas sample volume size is. Larger volumes can 
affect the resolution of the sample elution profile, providing inaccurate and unreliable 
results.  
 The flowrate for applying the sample should also be optimised. The flowrate cannot 
exceed 1.6ml/minute for the column used in these experiments. Exceeding this could damage 
the column matrix. The columns are typically stored in a 20% ethanol solution to prevent 
any bacterial growth when not in use. Prior to running a sample through the column, 
deionised water is flushed through at a high flowrate (1.6ml/min) to remove all ethanol and 
any potential proteins that may be residing within the column from the previous run. The 
removal of waste is monitored through UV absorbance. When the required volume of 
deionised water (and equilibration buffer) has been run through, and the UV absorbance 
reading has baselined, the column is then ready for use (Amersham Biosciences, 2003).  
2.1.5  Gel Electrophoresis 
 
 Electrophoresis is a relatively simple, rapid and highly sensitive tool which can be 
used to identify and characterise sample contents. Agarose gels are mainly used to separate 
out larger macromolecules, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), 
whereas polyacrylamide is used for the separation of proteins (Hames, 1998). 
Polyacrylamide gel electrophoresis can be used to analyse the size, amount, purity and 
isoelectric point of polypeptides or proteins. In both types of gels, a matrix is formed 
containing pores through which loaded samples on the gel will separate out when an 
electrical current is applied (Hames 1998). Components within the sample will be separated 
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out per their electrophoretic mobility, migrating from the negative anode, towards the 
positively charged cathode.  
 The components used to form the polyacrylamide gels are monomeric acrylamide 
and N, N’-methylene-bisacrylamide (bisacrylamide) (Hames, 1998). The polymerisation 
between acrylamide and bisacrylamide is initiated by either a chemical or photochemical 
free-radical generating system. Tetramethylethylenediamine (TEMED) initiates the 
chemical polymerisation with ammonium persulfate (APS), while photochemical 
polymerisation is initiated by riboflavin-5’-phosphate, or methylene blue (Hames, 1998). 
Dissolving APS in water causes the formation of free radicals, which in turn activates the 
acrylamide monomer. TEMED serves as a catalyst to accelerate the polymerisation reaction 
due to its ability to carry electrons. The activated acrylamide monomer can therefore react 
with inactivated monomeric units, producing a long polymer chain. Bisacrylamide subunits 
randomly cross-links with the elongating polymer chains forming a ‘net’ or matrix of 
acrylamide chains (Hames, 1998).  
 The ratio between the acrylamide and bisacrylamide, or the percentage used in the 
gel, determines the solidity/fluidity of the gel. The size of the pores within the polymerised 
gel is governed by the total amount of acrylamide used per unit volume and the degree of 
cross-linkage (Hames, 1998). The composition of acrylamide mixtures is defined by the 
letters T and C per Hjerten, 1962. ‘T’ denotes the percentage of both acrylamide and 
bisacrylamide in grams per 100ml, whereas ‘C’ denotes the percentage (by weight) of the 
cross-linker, relative to the total monomer (Hames, 1998; Hjerten, 1962). In practice, the 
suggested range for uniform acrylamide gels is between 5-20%. Samples containing larger 
molecular weight proteins require a lower percentage of acrylamide. High percentage 
acrylamide gels form smaller pores, meaning the gel would be unable to resolve these larger 
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molecular weight proteins (and visa-versa for small molecular weight proteins) (Hames, 
1998).  
When casting an acrylamide gel, two types of gel are cast; a stacking gel and a 
resolving gel. The stacking gel is where samples are loaded onto the gel and allows proteins 
to concentrate into a band prior to entering the resolving gel, increasing the resolution. The 
resolving gel is where proteins are separated out per their properties (Hames, 1998).  
 There are two types of systems that can be used to separate out proteins through 
electrophoresis; denaturing and non-denaturing systems. Non-denaturing systems are 
designed to separate out native proteins under conditions that preserve the proteins’ function, 
structure and activity (usually denoted native PAGE: polyacrylamide gel electrophoresis). 
Separation is based not only on the protein’s size, but its charge and shape. In a denaturing 
system, proteins are denatured to their constituent polypeptides, allowing examination of the 
composition, size and number of polypeptide units within the sample (usually denoted SDS 
PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis) (Hames, 1998). Unlike 
non-denaturing systems, SDS PAGE is easier to run, stain and de-stain, without 
compromising on resolution (Hames, 1998).   
 Prior to protein samples being loaded onto the gel, they are mixed with a sample 
buffer. The sample buffer components depend on the type of electrophoresis system that is 
being run. For the denaturing system, SDS is added. SDS is an anionic detergent which binds 
to the proteins within the sample giving an overall negative charge (Hames, 1998). Samples 
are heated at 95oC for 5 minutes to further denature the protein. The heating of the samples 
helps break the electrostatic forces that hold the three-dimensional protein structure together, 
except for disulfide bonds. The addition of β-mercaptoethanol reduces any disulfide bonds 
present in the protein. Under these conditions, all polypeptide units bind the same amount 
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of SDS, independent of their composition or sequence, and will migrate through the gel 
(when a current is applied) based only on their size (Hames, 1998). In addition to these 
components the sample buffer also contains bromophenol blue, a loading dye which allows 
visualisation of the dye front whilst the gel is running, as well as glycerol, a density reagent 
ensuring samples sink into the well during loading. Non-denaturing systems require no 
denaturing components in their sample buffer.  
2.1.6  Western Blotting 
 
 A blot in molecular biology is the process of transferring proteins, DNA or RNA 
onto a carrier surface. There are a variety of blotting methods which can be used, depending 
on the sample being transferred. Southern blotting involves the transfer of DNA onto a 
carrier for detection, whereas northern blotting involves RNA. Western Blotting is the 
process of detecting specific proteins by use of antibodies which have been transferred onto 
a membrane, post-gel electrophoresis. The method originated in the laboratory of Harry 
Towbin at the Friedrich Miescher Institute and is now used across the world in both clinical 
and research settings (Dunbar, 1994; Towbin et al., 1979). 
 Proteins within a sample are initially separated out, usually by SDS gel 
electrophoresis, as described in section 2.1.5. The proteins within the gel are then transferred 
onto a membrane. An electric current is applied, which ‘pulls’ the proteins from the gel and 
onto the membrane. Proteins that have been run on an SDS PAGE gel will have an overall 
negative charge due to the SDS; therefore, this will aid in the transfer of the proteins onto 
the membrane (Dunbar, 1994; Towbin et al., 1979).   
Typical membranes used in Western Blotting are either nitrocellulose or PVDF. 
Nitrocellulose is produced by treating cellulose with nitric acid and spreading the solution 
over a thin film. Each glucose unit in the cellulose polymer is esterified with three nitrate 
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groups, which are responsible for the negative charge of the membrane. Both electrostatic 
and hydrophobic interacts are thought to be the possible binding mechanisms between 
macromolecules, such as proteins, on the membrane. Nitrocellulose is widely used due to its 
high affinity and retention for protein, cost and ease of use (Johnstone & Thorpe, 1987; 
Towbin et al., 1979). PVDF is a highly non-reactive fluoropolymer produced by the 
polymerisation of vinylidene difluoride. It is also commonly used in Western Blotting 
procedures due to its non-specific binding capacity of amino acids (higher than 
nitrocellulose) and mechanical strength. PVDF is an extremely hydrophobic surface and 
therefore must be hydrated in methanol prior to use to improve transfer and binding (Dunbar, 
1994; Johnstone & Thorpe, 1987; Towbin et al., 1979). 
As the membranes used in Western Blotting are chosen for their ability to bind 
proteins, necessary steps are required to prevent interactions between the membrane and the 
antibody used for detection of the target protein. To prevent this non-specific binding, the 
membrane is blocked with non-fat dry milk powder or bovine serum albumin (BSA). 
Proteins within the milk powder bind to regions of the membrane where the target protein 
has not yet bound (Johnstone & Thorpe, 1987; Towbin et al., 1979). 
The primary antibody is then added to ‘probe’ the membrane. Primary monoclonal 
antibodies are generated when their host species, or cell culture, is exposed to the protein (or 
fragment of that protein) of interest. The primary antibody will therefore be specific to the 
target protein. Once a sufficient amount of time has passed, the primary antibody is removed, 
and a secondary, species specific, enzyme-conjugated antibody is added. If the primary 
antibody had been raised within a mouse, an anti-mouse secondary antibody will bind to 
almost any mouse-sourced primary antibody (Murphy, 2008; Johnstone & Thorpe; 1987; 
Towbin et al., 1979). The secondary antibody is conjugated to an enzyme, usually 
horseradish peroxidase (HRP) or alkaline phosphatase (AP). Once the secondary antibody 
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has been allowed sufficient time to probe the membrane, a substrate for the conjugated 
enzyme is added. The substrate usually depends on the type of conjugated enzyme used. 
Horseradish peroxidase can be used to cleave chemiluminescent agents. The product formed 
from the reaction produces light, which therefore confirms the presence of the target protein 
(Johnstone & Thorpe, 1987; Towbin et al., 1979). The emitted light is then detected on a 
charged coupled device camera, which captures digital images of the blot. Cheaper detection 
methods are also used; 4-chloronaphthol stain with 1% hydrogen peroxide is one example. 
The reaction of peroxide radicals with 4-chloronapthol produces a dark purple stain that can 
be photographed without using specialised equipment. Although cheaper detection methods 
are significantly cheaper, the sensitivity of the assay is reduced dramatically (Dunbar, 1994; 
Murphy, 2008; Johnstone & Thorpe, 1987; Towbin et al., 1979). 
2.1.7  The Enzyme-linked Immunosorbent Assay  
 
 An Enzyme-linked immunosorbent assay (ELISA) is a basic immunology concept of 
an antigen binding to a specific antibody, allowing detection of small antigens such as 
proteins, peptides, hormones or antibody in a fluid sample (Gan & Patel, 2013). ELISA 
utilises enzyme-conjugated antibodies for the detection of biological molecules. The three 
enzymes most commonly used are HRP, AP and β-D-galactosidase (Kemeny, 1991). The 
ELISA is a quantitative method that measures interactions through a colorimetric reading, 
serving to identify and determine the presence and concentration of specific biological 
molecules (Gan & Patel, 2013; Hornbeck, 2001).  
 The ELISA method was invented simultaneously by two research groups at the same 
time (Engvall & Perlmann, 1971; Van-Weemen & Schuurs, 1971). The method and 
technique of an ELISA was developed largely from modifying a radioimmunoassay (RIA), 
which dates back as far as 1941 (Coons et al., 1941). RIA is a sensitive method for measuring 
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small amounts of substance in biological fluids, with the method first being used by Yalow 
& Berson in the 1960s to measure endogenous plasma insulin levels (Yalow & Berson, 
1960). The use of ELISA is now routinely used method in research and diagnostic 
laboratories around the world (Aydin, 2015).  
 The antigen utilised in the ELISA is bound to a solid-phase carrier (Aydin, 2015). 
Carriers for ELISA can be divided into two broad categories based on their ability to bind 
the protein. High-capacity materials include cyanogen bromide-activated agarose, cellulose 
and nitrocellulose. The advantage being that they can make use of relatively impure antigen 
preparations and are stable for several months. Disadvantages include high background 
binding and difficult washing steps. Low-capacity materials such as polystyrene, polyvinyl 
and polypropylene are used which are easier to wash and give a lower background noise; 
although they can be more difficult to coat with antigen. The choice of carrier used depends 
on several factors, the most important of these being the purity of the coating material. 
Assays using immunoglobulin G (IgG) antibodies can display non-specific binding; 
therefore, a low-capacity material is preferable (Engvall & Perlmann, 1971; Kemeny, 1991; 
Van-Weemen & Schuurs, 1971).  
 Once the antigen has bound to the 96-well microplates, vacant binding sites are 
blocked with an excess of irrelevant protein, such as BSA. This blocking step prevents any 
unnecessary binding of the antibody to the plate, and only allowing binding to the antigen 
(Kemeny, 1991). A primary antibody, specific to the antigen, can bind, which is itself 
subsequently detected by a secondary, species specific, enzyme-conjugated, antibody. The 
use of secondary, enzyme-conjugated antibodies allows an amplification of the signal for 
when detecting the antigen, in addition to the beneficial economic costs. Conjugating an 
enzyme to a secondary antibody that possesses the ability to bind to multiple monoclonal 
specific primary antibodies is significantly more cost effective. Washing is performed after 
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each step, usually with phosphate-buffered saline at neutral pH, in order for the removal of 
any unbound antigen/antibody. Addition of the enzyme substrate yields a visible colour 
change or fluorescence, indicating the presence of the antigen (Gan & Patel, 2013). The 
reaction is usually completed within 30 minutes and can be stopped by using either sodium 
hydroxide or sulfuric acid (Gan & Patel, 2013). Unlike the Western Blotting technique, the 
sensitivity of the reaction is heightened within an ELISA, allowing for the detection of 
significantly smaller amounts of protein. In addition, the quantitative method of analysis also 
allows for antigen concentrations to be calculated. One downside compared to a Western 
Blot however, is that the molecular weight of the antigen (usually a protein) is unknown 
alongside sample purity and they are prone to false positive/negative results (Gan & Patel, 
2013; Murphy et al., 2008). There are several types of ELISA commonly used in scientific 
practice, each modified slightly for a quantitative analysis of the antigen-antibody 
interaction. Capture or sandwich ELISA can be used to detect secreted products such as 
cytokines, rather than binding the antigen directly to the plate (Murphy et al., 2008) These 
involve antigen specific antibodies (sometimes raised against different epitopes on the 
antigen) being bound to the base of the plate prior to the addition of antigen, to ‘capture’ the 
antigen in question (Murphy et al., 2008).  
2.1.8  Experimental Aims 
 
 Our aim here within this research is to implement our developed methodology, 
incorporating the discussed techniques, which can result in the production, purification and 
where possible, characterisation of in vitro produced mCRP. Furthermore, it was important 
that we aimed at reducing any damage to the proteins structural and biological integrity 
through these dissociation experiments. The techniques discussed within this chapter will 
help develop the groundwork needed in future studies when testing human serum samples. 
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2.2  Materials & Methods 
 
2.2.1  Preparation of C-reactive Protein 
 
 Native, pCRP was purchased from SCRIPPS at 2.48mg/ml in a standard storage 
calcium buffer (20mM Tris, 280mM NaCl, 5mM CaCl2, 0.01% Sodium Azide at pH 7.4). 
The samples provided were stored at 4oC and confirmed by the supplier to be >99% pure by 
SDS PAGE analysis.  
 Dissociation buffers were produced (20mM Tris, 280mM NaCl, and 1mM EDTA) 
with varying concentrations of Urea (2, 2.5, 3 and 4M Urea) from a stock of 8M Urea. 
Dissociation samples were mixed thoroughly in a vortex and stored in the cold room at 4oC 
for a minimum of 10 weeks.  
2.2.2  Calibration of the Size Exclusion Chromatography Column 
 
 Prior to running any samples through the column, it first needed to be calibrated for 
protein sizes to be accurately determined via elution volumes. The AKTA explorer 100, Fast 
Protein Liquid Chromatography (FPLC) system from GE Healthcare was used, with a 
HiLoad 16/60 Superdex 200pg Column. The system runs on the software UNICORN 5.11. 
To monitor the elution volumes of the proteins the UV absorbance is measured at 280nm, 
creating an elution profile (Amersham Biosciences, 2003). 
A Gel Filtration Calibration Kit of high and low molecular weight markers was 
purchased from GE Healthcare. The molecular weight markers included are shown in Table 
2.1. Blue Dextran was also included to determine the void volume of the column. All samples 
were provided in a lyophilised form and reconstituted to a 20mg/ml stock solution, as 
recommended via the product booklet.  
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Protein Standard Known Molecular Weight (Da) 
Ferritin 440,000 
Aldolase 158,000 
Conalbumin 75,000 
Ovalbumin 44,000 
Ribonuclease A 13,700 
Table 2.1 A Table of the protein standards and their respective molecular weights, which 
were used to construct the calibration graph for the HiLoad 16/60 Superdex 200pg size 
exclusion chromatography column. 
 
 The buffers and solutions used for preparing the column are outlined in Table 2.2. 
The column is stored in 20% ethanol. Three column volumes (120ml/column volume) of 
deionised water were used to remove the ethanol solution from the system tubing and the 
column. The column and tubing were equilibrated with three column volumes of elution 
buffer (see Table 2.2). Tris and NaCl were both purchased from Fisher Scientific and sodium 
azide was purchased from Sigma Aldrich. All buffers and solutions used on the column were 
filtered through a 0.2µm cellulose acetate filter (Sartorius Stedim Biotech, Geottingem, 
Germany) to remove any particulate matter that may clog the system and de-gassed, to avoid 
introducing air into the system. All buffers and solutions were stored at 4oC and allowed to 
equilibrate to room temperature before use. 
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Buffer/Solution Components pH 
Wash Solution Deionised H20 7.0 
Elution Buffer 50mM Tris, 150mM NaCl, 0.01% Sodium Azide 7.2 
Storage Solution 20% Ethanol 7.0 
Table 2.2 Buffers and solutions that were used to equilibrate the HiLoad 16/60 Superdex 
200pg size exclusion chromatography column.  
  
To achieve the most reliable results, the product booklet for the molecular weight 
standards contained a list of parameters that needed to be adhered to. An elution buffer with 
an ionic strength ≤ 0.15 (e.g. 0.15M NaCl, see Table 2.2) needed to be used. Suitable protein 
mixtures of the molecular weight standards also needed to be prepared; running incorrect 
samples together could cause either protein precipitation or the potential clashing of elution 
peaks on the chromatogram. This therefore resulted in two separate chromatography runs; 
the first containing Ferritin, Conalbumin and Ribonuclease A, and the second containing 
Aldolase and Ovalbumin. Blue dextran was run separately to determine the void volume of 
the column.   
 Molecular weight standards were prepared from stocks as shown in Table 2.3. The 
protein standards were diluted with the same elution buffer that was used to equilibrate the 
column (see Table 2.3). The total volume of the sample was recommended to be between 
0.1 to 2% of the total column volume to achieve the best resolution on the chromatogram, 
therefore a final volume of 500µl was used.  
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Protein Standard Required Final Concentration (mg/ml) 
Ferritin 0.3 
Aldolase 4 
Conalbumin 3 
Ovalbumin 4 
Ribonuclease A 3 
Table 2.3. A table listing the protein standards used to construct the calibration graph and 
their respective final concentrations that were required. 
 The prepared samples containing the molecular weight standards were loaded onto 
the column via a 2ml sample injection loop. A flow rate of 1ml/min was used, as 
recommended via the product booklet, with the absorbance measured at 280nm. Sample 
fractions of 5ml were collected up to a total volume of 120ml (one column volume). All size 
exclusion chromatography was carried out at room temperature. 
2.2.3  Purification of Pentameric and Monomeric C-reactive Protein 
 
 Once the column had been calibrated, the size exclusion column was used to assess 
the dissociation of pCRP into mCRP and to purify both isoforms from the sample. The 
system, column and software used for the size exclusion chromatography are the same as 
described in Section 2.2.2. All chromatography runs were carried out at room temperature. 
The buffer and solutions used for preparing the column are outlined in Table 2.4. The 
column is stored in 20% ethanol and was purged with 3 column volumes of deionised water, 
as described in section 2.2.2. The column and tubing were equilibrated with three column 
volumes of standard CRP storage buffer (Table 2.4). NaCl and CaCl2 were purchased from 
Fisher Scientific. Tris buffer and sodium azide were purchased from Sigma Aldrich. The 
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CRP storage buffer pH was adjusted by the addition of hydrochloric acid (HCl). All buffers 
and solutions used on the column were filtered through a 0.2µm cellulose acetate filter 
(Sartorius Stedim Biotech, Geottingem, Germany) to remove any particulate matter that may 
clog the system and de-gassed, to avoid introducing air into the system. All buffers and 
solutions were stored at 4oC and allowed to equilibrate to room temperature before use.  
Buffer/Solution Components pH 
Wash Solution Deionised H2O 7.0 
CRP Storage Buffer 
280mM NaCl, 20mM Tris, 5mM CaCl2, 0.01% Sodium 
Azide 
7.4 
Storage Solution 20% Ethanol 7.0 
Table 2.4. A table listing the buffers and solutions that were used to equilibrate the size-
exclusion column. All buffers were filtered through a 0.2µm filter and degassed before use. 
 Dissociation samples containing CRP were, as described in section 2.2.1, loaded onto 
the column via a 2ml sample injection loop. Based on the user guide recommendations, the 
sample volume did not exceed 0.1-2% of the column volume (120µL – 2.4mL) to obtain the 
best resolution. A flow rate of 0.5ml/min was used in all samples and the absorbance 
measured at 280nm. All experiments were carried out at room temperature. Sample fractions 
of 5ml were collected up to a total volume of 120ml (one column volume).  
2.2.4  Concentration of C-reactive Protein Samples 
 
 Eluted protein samples were concentrated using a Vivaspin Centrifugal 
Concentrator, 10kDa molecular weight cut off (MWCO), purchased through Fisher 
Scientific. The centrifugal concentrator was initially primed with deionised water and spun 
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at 1,000 x g, 4oC for 10 minutes. The protein sample was then spun at 1,000 x g, 4oC for 15 
minutes or until the desired concentration had been achieved.  
2.2.5  Protein Quantification 
 
 The protein content of the CRP samples was determined by using a 
spectrophotometer, which measures the absorbance unit for full scale deflection of the 
protein solution at UV280nm. A UV reading at 320nm was also taken as background 
absorbance, as proteins do not absorb at this wavelength. The protein concentration of the 
CRP samples was determined by Equations 2.1 and 2.2. 
 
Equation 2.1: Absorbance at UV280mm = UV280nm – UV320nm 
Equation 2.2: Concentration (mg/ml) = Absorbance at 280nm / Extinction Coefficient 
 
 Extinction coefficient values are worked out using the online programme ProtParam 
from Expasy (http://web.expasy.org/protparam/) which uses the protein sequence to 
calculate to the total absorbance of tyrosine and tryptophan and any disulfide bonds 
(Gasteiger et al., 2003). The extinction coefficient value of 1.7 for human CRP was used to 
give concentration values in mg/ml. 
2.2.6  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
 
SDS PAGE was used to assess the purity and size of the eluted protein from the size 
exclusion column. SDS PAGE gels usually consist of a 12.5%T resolving gel and a 4%T 
stacking gel. SDS, TEMED and 30%T acrylamide/bisacrylamide were all purchased from 
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Sigma. The stock acrylamide/bisacrylamide was stored at -20oC and was thawed at room 
temperature prior to use. APS (VWR) was made to a 10% solution prior to use. 
 Samples were added to either reducing or non-reducing sample buffer at a 1:1 ratio 
and the gel was run in a standard SDS PAGE running buffer (see Table 2.5). Glycine, 
glycerol and Tris were all purchased from Sigma. Reduced sample buffer requires the 
addition of β-Mercaptoethanol (Sigma) to 5% prior to use. Bromophenol blue (VWR) was 
used to visualise dye front whilst the gel was running. Low range molecular weight markers 
(BioRad) were ran alongside the samples for the estimation of band sizes. The molecular 
weight markers were stored in reducing buffer and kept at -20oC prior to use. All samples 
and markers were heated at 95oC for 5 minutes prior to being run on the gel. The typical well 
volume for each sample loaded was 10µL.  
 Gels were run vertically in a BioRad mini-PROTEIN II cell (BioRad), connected to 
a PowerPac 300 (BioRad). The gels were run at a voltage of 200V for approximately 45-50 
minutes, in 500mL of running buffer (see Table 2.5).  
Gel Type Components Amount 
12%T Resolving Gel 
Deionised Water 2.55ml 
30%T acrylamide/bisacrylamide 3.33ml 
1.5M Tris pH 8.8 2.0ml 
10% SDS 80µl 
10% APS 60µl 
100% TEMED 6µl 
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4%T Stacking Gel 
Deionised Water 3.0ml 
30%T acrylamide/bisacrylamide 670µl 
0.5M Tris pH 6.8 1.25ml 
10% SDS 60µl 
10% APS 60µl 
100% TEMED 6µl 
Sample Buffer 
Tris-HCl pH 6.8 125mM 
SDS 4% 
Glycerol 20% 
Bromophenol Blue 0.02% 
Reduced Sample Buffer β-Mercaptoethanol 5% 
Running Buffer 500ml 
SDS 0.5g 
Glycine 7.21g 
Tris 1.515g 
Table 2.5. Components for the casting and running of an SDS PAGE gel. The amounts given 
are enough to cast two identical 0.75mm SDS PAGE gels. Amounts are also given for sample 
and running buffers.  
 After 45 minutes, had elapsed, or the dye front had run off the gel, the gels were 
removed from the tank. Coomassie Brilliant Blue (BioRad), a total protein stain was used 
for SDS PAGE gel lanes containing molecular weight markers, whereas lanes containing 
eluted CRP samples were subject to Western Blot analysis. The section of gel containing the 
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molecular weight markers was immersed in Coomassie Brilliant Blue for a minimum of 
thirty minutes for the stain to penetrate the gel’s pores and stain the protein. Once a sufficient 
level of staining had been achieved for the protein bands, to reduce background staining, 
gels were gently washed in deionised water and then photographed on a Syngene GBOX 
image detector. Coomassie Brilliant Blue has a detection limit of around 1µg of protein; 
therefore, a sufficient volume of sample was added to avoid this limitation.   
2.2.7  Western Blotting of C-reactive Protein Samples  
 
Samples which were used within the Western Blot transfer had previously been 
subject to SDS PAGE, as described in section 2.2.6. All western blot analyses were 
performed in the absence of staining the SDS PAGE gel with Coomassie Brilliant Blue. A 
minimum of 1µg per sample was used in the SDS PAGE. Sample quantification was 
determined as described in section 2.2.5. Once 45 minutes had elapsed, or the dye front had 
run off the gel, the gel was removed from the tank and immersed into equilibration buffer 
(as shown in Table 2.6) for up to 30 minutes. Prior to running the SDS PAGE, nitrocellulose 
membrane blotting paper (0.2µm, 7x8.4cm, pre-cut) and filter pads (BioRad) were pre-
soaked for up to 1 hour in equilibration buffer (Table 2.6). Resolving gels were then added 
to the equilibration buffer for a further 30 minutes. 
 The gel, nitrocellulose blotting paper and filter pads were assembled in cassette cases 
of the Mini Trans-Blot Electrophoretic Transfer Cell (BioRad). Prior to the transfer, an ice 
pack, to prevent overheating, and a magnetic stirrer, to maintain a consistent flow of running 
buffer (Table 2.6) throughout the tank were added. The transfer cell was connected to the 
PowerPac 300 (BioRad) and run at 350mA for 1 hour at 4oC. Approximately 500ml of 
running buffer was added to the tank during protein transfer. 
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Buffer/Solution Components Amount 
Running 
Buffer/Equilibration Buffer 
SDS 0.5g 
Tris 7.21g 
Glycine 1.515g 
Table 2.6. A Table of components for the running and equilibration buffers needed for 
protein transfer during the Western Blot analysis. Amounts of each component are also 
given.  
 Once the transfer was complete, the nitrocellulose membrane was removed from the 
cassette and placed in a container with blocking solution (protein side facing up) and blocked 
overnight. Marvel dried milk powder was used with Tris-buffered saline (TBS) for the 
blocking solution (see Table 2.7). Marvel dried milk was purchased from the local 
supermarket. The membrane was then washed 5 times with BLOTTO solution (5 minutes 
for each wash, see Table 2.7). Triton-X-100 was purchased from Sigma. The primary 
antibody was added at a dilution of 1:1,000, made up in BLOTTO, and left for a minimum 
of 5 hours. The primary antibody used was a monoclonal anti-C-reactive protein antibody 
(Clone-8), produced in a mouse. The monoclonal antibody was purchased from Sigma and 
was provided in ascites fluid. The antibody concentration reading was 9.1mg/ml and was 
stored at -20oC, with the sample being thawed out prior to use. A volume sufficient to 
immerse the nitrocellulose membrane was used (>20ml). 
 The membrane was then washed 5 times with BLOTTO (5 minutes for each wash). 
The secondary antibody used was an anti-mouse IgG (whole molecule) HRP antibody, 
produced in a rabbit. The enzyme conjugated IgG antibody was purchased from Sigma and 
provided as a fraction of antiserum, buffered in aqueous solution. The antibody 
concentration reading was 10.6mg/ml and stored at -20oC, with the sample being thawed out 
prior to use. The secondary antibody was diluted in BLOTTO at 1:40,000 and added to the 
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nitrocellulose membrane for a minimum of 1 hour. A volume sufficient to immerse the 
nitrocellulose membrane was used (>20ml).  
Buffer/Solution Components Amount 
Tris-buffered Saline (TBS) 
pH 7.4 with HCl 
Sodium Chloride 150mM 
Tris 50mM 
Blocking Solution 
Marvel Dried Milk 1g 
TBS 40ml 
BLOTTO 
Marvel Dried Milk 0.5g 
Triton-X-100 1ml 
TBS 50ml 
Primary Antibody Dilution 
Monoclonal anti-CRP 
Antibody 
6µl 
BLOTTO 23.994ml 
Secondary Antibody 
Dilution 
Anti-mouse IgG (whole 
molecule) peroxidase 
Antibody 
1µl 
BLOTTO 39.999ml 
ECL Reagent Clarity peroxidase reagent 7ml 
Chapter 2. Production and Characterisation of Monomeric CRP          Materials & Methods  
 
84 
 
Clarity western 
luminol/enhancer reagent 
7ml 
Table 2.7. A Table of components for the staining of the nitrocellulose membrane during the 
Western Blot analysis. Amounts for each component are also given. 
 The membrane was then washed 7 times with BLOTTO (5 minutes for each wash). 
Chemiluminescence was used to enable visualisation of the bands on the nitrocellulose 
membrane. The reagent used was the Clarity Western Enzyme Chemiluminescence (ECL) 
Substrate, purchased from BioRad. The ECL reagent provided high sensitivity for detecting 
protein on a nitrocellulose membrane when using an enzyme-conjugated horseradish 
peroxidase antibody (secondary antibody). Two reagents were included in the ECL Clarity 
package; Clarity peroxide reagent and Clarity western luminol/enhancer reagent. For mini-
sized membranes (7x8.5cm), 7ml of each reagent was advised and made prior to use (see 
Table 2.7). All steps were carried out on the rocking machine to encourage gentle agitation 
of the solution with the nitrocellulose membrane.  
 The combined ECL reagents were added to the membrane and left for a minimum of 
5 minutes. The membrane was then removed from the reagent and was wrapped in Saran 
Wrap (protein side up) to prevent the membrane from drying out. The membrane was then 
viewed on a CCD digital image detector and exposed for up to 30 minutes, depending on the 
intensity of the band required.   
2.2.8 Binding Studies of Monomeric and Pentameric C-reactive Protein with 
Phosphocholine 
  
  Immobilised p-Aminophenyl Phosphoryl Choline (APC) was purchased from Fisher 
Scientific in the form of a gel, cross-linked with 6% beaded agarose. The gel had a constant 
storage temperature of 4oC, with 5ml provided. The binding capacity of the APC was >3mg 
of CRP per 1ml of gel. The sample was purified from ascites fluid by centrifugation and 
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filtration. All affinity chromatography experiments were run using the Biologic LP 
Chromatography System, purchased from BioRad. The software used was LP Data View 
(BioRad). The absorbance was measured at 280nm. Prior to mCRP being run through the 
column, 20 column volumes of equilibration buffer were run through the column at 
0.5ml/min (see Table 2.8). The UV absorbance baseline reading was blanked to a value of 0 
absorbance units (Au). 500µl of the CRP (both monomeric and pentameric) sample was 
diluted in 5ml of the equilibration buffer. Larger volumes of samples were used to prevent 
air bubbles entering the column whilst applying a sample. The mCRP sample was run 
through the column at 0.5ml/min. Once the entire sample had been applied, 5 column 
volumes of equilibration buffer were run through the column at a flowrate of 0.5ml/min.  
 The chelating buffer was then added to the column. Around 3-4 column volumes of 
chelating buffer were run through the column, or until the UV absorbance reading had 
returned to its baseline value of 0Au. The column was then washed with 10 column volumes 
of equilibration buffer, ready for storage.  
Buffer/Solution Components Concentration 
Equilibration Buffer pH 7.4 
Calcium Chloride 10mM 
Tris 50mM 
Sodium Chloride 150mM 
Sodium Azide 0.01% 
Chelating Buffer pH 7.4 
EDTA 10mM 
Tris 50mM 
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Sodium Chloride 150mM 
Sodium Azide 0.01% 
Table 2.8. A list of the components for the equilibration and chelating buffers required 
during a run of the phosphocholine-bound affinity chromatography column. Concentrations 
of each component used are also given.  
 
Following the PC-based purification of pCRP, the sample was subject to size 
exclusion chromatography as described in Section 2.2.3. Eluted affinity chromatography 
fractions were concentrated as described in Section 2.2.4 prior to application on the size 
exclusion column.   
2.2.9  Precipitation Studies with Cell Wall Polysaccharide 
 
 The precipitation experiment involving pCRP and mCRP was adapted from previous 
work carried out by Volanakis, (1982), when researching into how pCRP precipitates out 
with varying amounts of ligand. Native, pCRP (purchased from SCRIPPS) alongside mCRP 
(dissociated with 3M urea) were incubated with varying amounts of CWPS. Precipitation 
levels were calculated based on the remaining concentration of protein within the 
supernatant via an ELISA. Prior to this, calibration of both proteins was required, to calculate 
the precipitated levels of both proteins. All ELISA analysis was performed on 96-well 
microplates. Table 2.9 displays the amounts of CRP used (µg) for the calibration 
experiments using either pCRP (SCRIPPS) and in vitro produced mCRP (via 3M Urea).   
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  1 2 3 4 5 6 7 8 9 10 
A 
pCRP 
(µg) 
0.75 0.375 0.187 0.093 0.046 0.023 0.011 0.005 0.002 Blank 
B 0.75 0.375 0.187 0.093 0.046 0.023 0.011 0.005 0.002 Blank 
C 0.75 0.375 0.187 0.093 0.046 0.023 0.011 0.005 0.002 Blank 
D mCRP 
(µg) 
 
0.75 0.375 0.187 0.093 0.046 0.023 0.011 0.005 0.002 Blank 
E 0.75 0.375 0.187 0.093 0.046 0.023 0.011 0.005 0.002 Blank 
F 0.75 0.375 0.187 0.093 0.046 0.023 0.011 0.005 0.002 Blank 
Table 2.9 The varying amounts of both pCRP and mCRP used for the construction of 
calibration graphs via ELISA analysis. All samples were triplicated with the average value 
used when constructing the calibration graph.  
 
Samples for both pCRP and mCRP used in ELISAs were treated and developed as 
described in section 3.2.9. The primary monoclonal antibody dilution used was 40,000 as 
suggested by the supplier, as was the secondary antibody dilution. Samples were developed 
with TMB for 5-10 (2M sulphuric acid added to stop the reaction) and then read at 450nm 
on a BioTek EL800 plate reader using the Gen5 Software. 
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Pentameric CRP and in vitro produced mCRP (20µg per sample) were incubated 
with varying amounts of CWPS, as shown in Table 2.10. 
  Amount of CWPS (µg) 
  1 2 3 4 5 6 7 8 9 10 
A pCRP 
(20µg 
used) 
0.1 0.5 1 10 20 50 100 200 300 Blank 
B 0.1 0.5 1 10 20 50 100 200 300 Blank 
C 0.1 0.5 1 10 20 50 100 200 300 Blank 
D mCRP 
(20µg 
used) 
 
0.1 0.5 1 10 20 50 100 200 300 Blank 
E 0.1 0.5 1 10 20 50 100 200 300 Blank 
F 0.1 0.5 1 10 20 50 100 200 300 Blank 
Table 2.10 The varying amounts of CWPS used within the precipitation experiments. 
Precipitation levels for both pCRP and the in vitro produced mCRP were calculated by 
ELISA analysis of the remaining supernatant, once mixed with CWPS and centrifuged.  
 
 Samples were made up to 400µl using a standard storage calcium buffer (see section 
2.2.1). All samples were then incubated at 37oC for 1 hour whilst being gently agitated. The 
samples were then centrifuged at 6,500 x g for 15 minutes to pellet the precipitate within the 
sample. The supernatant from each sample was transferred to separate tubes.  
 The supernatant from each sample was then subject to an ELISA, as described in 
section 3.2.9. Primary and secondary antibody dilutions used were as per the calibration 
(40,000), with samples being developed in TMB (for the same period as the calibration). 
Samples were then read at 450nm. CRP concentrations were determined using the calibration 
line equations. Total level of precipitation was calculated by subtracting the total amount of 
CRP remaining from the initial amount (20µg). 
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2.3  Results 
 
2.3.1  Calibration of the Size Exclusion Chromatography Column 
 
Size exclusion chromatography was used to assess the level of dissociation of pCRP 
into in vitro produced mCRP and to purify out both protein forms from the sample. Prior to 
the use of this technique within our research, the column needed to be calibrated for us to 
determine/establish accurately where pentameric, monomeric and other possible CRP 
isoforms would be eluted. The gel filtration calibration kit purchased from GE Healthcare 
provided a range of proteins with known molecular weights. A calibration graph was plotted 
based on the elution volume of each protein standard. This calibration was used throughout 
our research to determine the molecular weight of protein which had been run through the 
size exclusion column.  
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For the calibration of the size exclusion column, three separate runs were carried out 
as suggested by the GE Healthcare Calibration User Guide. This was to avoid the clashing 
of peaks on the chromatogram and to avoid mixing protein standards which may cause 
precipitation within the sample. Figure 2.1 shows the chromatography trace for the 
molecular weight standards aldolase (158kDa) and ovalbumin (43kDa). The sample was 
injected into the column at 0ml and two peaks were observed at elution volumes of 76.37ml 
(55.98mAu) and 87.64ml (87.63mAu) for aldolase and ovalbumin respectively.  
 
Figure 2.1 A size exclusion chromatography trace of the molecular weight standards 
Aldolase (158kDa) and Ovalbumin (43kDa).  Aldolase, peak 1, has an elution volume of 
76.37ml. Ovalbumin, peak 2, has an elution volume of 87.64.  
 
 
 
The second chromatography run used molecular weight standards ferritin (440kDa), 
conalbumin (75kDa) and ribonuclease A (13.7kDa) (see Figure 2.2). Three main peaks were 
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observed (peaks 2-4, Figure 2.2) with elution volumes of 64.41ml (7.55mAu), 83.2ml 
(40.59mAu) and 100.32ml (38.49mAu), as expected. A fourth, smaller peak was observed 
at 46.07ml (1.01mAu). Based on the calculated molecular weight and absorbance reading of 
this fourth peak, it was unclear what it represented. It was therefore disregarded within our 
line of experiments as it did not contribute towards the calibration of the size exclusion 
column.  
 
Figure 2.2 A size exclusion chromatography trace of the molecular weight standards Ferritin 
(440kDa), Conalbumin (75kDa) and Ribonuclease A (13.7kDa).  Ferritin, peak 2, has an 
elution volume of 64.41ml. Conalbumin, peak 3, has an elution volume of 83.2ml. 
Ribonuclease A, peak 4, has an elution volume of 100.32ml. Peak 1 displayed an elution 
volume of 46.07, although it is unclear what this peak represents.   
 
 
The third calibration only used Blue Dextran, a high molecular weight glucose 
polymer which can be used to determine the void volume of the column. Blue Dextran was 
used to determine the void volume of the column. The chromatography trace of Blue Dextran 
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shows one sharp single peak (see Figure 2.3). The peak displays a slight ‘shoulder’ on its 
right-hand side and extends all the way to the end of the chromatography trace as expected, 
with UV absorbance not returning to baseline levels 
 
Figure 2.3 A size exclusion chromatography trace for Blue Dextran, a high molecular weight 
glucose polymer. Peak 1 is labelled on the graph, with an elution volume of 46.79ml. This 
is highlighted in the magnified graph of the elution region of 40-55ml. The absorbance was 
measured at 280nm.  
 
 
 
 
The elution profiles of the molecular weight standards were then used to construct a 
calibration graph for the size exclusion chromatography column. Based on each individual 
elution volume for the protein standards, a Kav value was determined. This was calculated 
from the following equation: 
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Equation 2.3: Kav = (Elution Volume – Void Volume)/(Total Column Volume – Void 
Volume) 
 
 The total column volume was calculated to be 120.63ml (π x radius x length) and the 
void volume of the column was calculated to be 46.79ml from the chromatography run with 
Blue Dextran, as shown in Figure 2.3.  
Protein 
Molecular 
Weight (Da) 
Elution Volume 
(ml) 
Kav Value 
Log of 
Molecular 
Weight 
Ferritin 440, 000 64.41 0.239 5.64 
Aldolase 158, 000 76.37 0.401 5.19 
Conalbumin 75, 000 83.20 0.493 4.87 
Ovalbumin 43, 000 87.64 0.553 4.63 
Ribonuclease A 13, 700 100.32 0.725 4.13 
Table 2.11 Elution volumes for all the molecular weight standards and their calculated Kav 
values. The Log of the molecular weight for all standards is also shown.   
 
 
Table 2.11 shows the calculated Kav values for each of the protein molecular weight 
standards in addition to the Log of each of the protein standards’ molecular weight. These 
two values for each molecular weight standard were plotted against each other to construct 
a calibration graph, as shown in Figure 2.4. 
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Figure 2.4 A graph of the Kav of each of the molecular weight standards plotted against the 
log of their molecular weight. The R2 value is 0.9968. The line equation for the graph is as 
follows: y = -0.3163x + 2.0311.  
The calibration graph displays an R2 value of 0.9968, indicating a strong negative 
correlation for the data points, which indicates an inverse relationship, where the larger the 
elution volume, the smaller the molecular weight of the protein. The line equation of the 
calibration graph is as follows: 
 
Equation 2.4: y = -0.3163x + 2.0311 
  
Equation 2.4 describes the relationship between the Kav of the molecular weight 
protein standards and the Log of their molecular weight. By running a protein through the 
size exclusion chromatography column, its molecular weight can therefore be determined 
through this equation. The ability to calculate a protein’s molecular weight based on its 
elution volume will enable reliable/accurate identification of CRP molecular variants based 
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on the number of monomers present in the molecule from in vitro-produced and purified 
serum samples – or some similar sentence.   
2.3.2  Purification of Monomeric C-reactive Protein 
 
 In addition to the calibration of the size exclusion chromatography column, a control 
sample of the pCRP (which was not subject to dissociation) was run through the column to 
establish an elution volume for the native protein. The chromatography trace for pCRP is 
shown in Figure 2.5. One peak is observed, at an elution volume of 79ml (8.2mAU). Based 
on the calibration graph, this elution volume corresponds to a size of around 110kDa for the 
eluted protein. This corresponds to the known molecular weight of pCRP of 115kDa (Shrive 
et al., 1996). 
 
Figure 2.5 A size exclusion chromatography trace for the pCRP control run. 200µg of the 
protein was run through the column. The one main peak on the chromatogram, labelled 1, 
has an elution volume at 79ml (8.2mAU).  
To dissociate native, pCRP into mCRP the protein was exposed to a dissociation 
buffer containing urea and the calcium chelator, EDTA. Research within the group (J Moran, 
unpublished results) has shown that removal of calcium is required to effectively dissociate 
pCRP with urea buffer. A period of 10 weeks for a dissociation trial with 2M urea and 5mM 
EDTA resulted in only approximately 10% of the pCRP to dissociate into mCRP (J Moran, 
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unpublished results). To determine whether moderate concentrations could be used to 
successfully dissociate all the pCRP in a 10-week period, several different dissociation trials 
were initiated with varying concentrations of urea. Figure 2.6 shows a size exclusion 
chromatography trace for a 2M urea dissociation trial after a 10-week period. Two peaks are 
observed on the chromatography trace, like that recorded from J. Moran’s unpublished 
results. The larger of the two peaks, peak 1, was eluted off at a volume of 79.02ml into the 
fraction collection tubes B4 and B5. Based on the calibration graph, the elution volume for 
peak 1 indicates a protein with a molecular weight of 108kDa. The elution profile and 
volume of peak 1 is like that of the pCRP (see Figure 2.6). Peak 2, which was significantly 
smaller, eluted at 95.65ml into the fraction collection tubes B7 and B8, corresponding to a 
calculated molecular weight of 21.3kDa, which corresponds to an expected monomer 
molecular weight. Fractions which corresponded to elution peaks for all size exclusion 
chromatography runs were combined respectively and concentrated to the appropriate 
protein concentration (as described in section 2.2.4) and stored at 4oC for further 
experimental analysis. All samples were injected at 0ml with the UV absorbance being read 
at 280nm.  
 
Figure 2.6 A size exclusion chromatography trace for the CRP 2M urea dissociation 
experiment. The sample was run through the system 10 weeks after the initiation of the 
 Chapter 2. Production and Characterisation of Monomeric CRP Results 
97 
 
experiment. Both peaks are labelled on the graph (1 and 2). The elution volume for peak one 
is 79.02ml and the elution volume for peak 2 is 95.65ml. Fractions that were collected for 
further experimental analysis are also labelled (B4, 5, 7 and 8).  
 
 Figure 2.7 shows the size exclusion chromatography trace for a 2.5M urea 
dissociation trial after 10 weeks. The chromatogram shows similarities to the 2M urea 
dissociation in that two peaks are observed at similar elution volumes. Peak 1 was eluted off 
at 79.09ml, and peak 2 at 95.68ml, corresponding to 109kDa and 21.2kDa respectively. The 
peaks observed in Figure 2.7 show a marked difference in absorbance compared to that from 
the 2M urea dissociation trial. Peak 1 gave an absorbance of 2.4mAU whereas the 
absorbance for peak 2 was 8.9mAU. Comparison with Figure 2.6 shows a significant change 
in the absorbance, with peak 2 now displaying a higher level of absorbance. Eluted fractions 
B4 and B5 were combined and B7 and B8 combined and concentrated to the appropriate 
volumes for further experimental analysis. An additional, smaller peak was recorded in the 
chromatography trace with an elution volume of 113.2ml. Based on the calculated molecular 
weight of the elution volume, and the absorbance value, it was unknown what this additional 
peak represented. Based on these points, the peak was disregarded as irrelevant within these 
experimental trials and was not pursued any further.  
 
Figure 2.7 A size exclusion chromatography trace for the CRP 2.5M urea dissociation 
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experiment. The sample was run through the system 10 weeks after the initiation of the 
experiment. Both peaks are labelled on the graph (1 and 2). The elution volume for peak one 
is 79.09 and the elution volume for peak 2 is 95.68ml. Fractions that were collected for 
further experimental analysis are also labelled (B4, 5, 7 and 8).  
 
 The corresponding chromatography trace for treatment of pCRP with a 3M urea 
dissociation buffer for 10 weeks is shown in Figure 2.8. As previously observed, two peaks 
were seen at 79.60ml (103kDa), and at 94.97ml (22kDa). Although there are similarities 
with those shown in Figures 2.6 and 2.7, there is a marked increase in absorbance for Peak 
2 which gives a reading at 32mAU. Peak 1 showed an absorbance value of 1.14mAu, slightly 
reduced to Peak one in Figure 2.7.  
 
  
Figure 2.8 A size exclusion chromatography trace for the CRP 3M urea dissociation 
experiment. The sample was run through the system 10 weeks after the initiation of the 
experiment. Both peaks are labelled on the graph (1 and 2). The elution volume for peak 1 
is 79.60ml and the elution volume for peak 2 is 94.97ml. Fractions that were collected for 
further experimental analysis are also labelled (B4, 5, 7 and 8).  
 
 Figure 2.9 shows the final dissociation trial of 4M urea with pCRP when run through 
the size exclusion chromatography column. As demonstrated in previous trials, two main 
peaks were observed (1 and 2) on the chromatogram. Peak 1 was eluted off at 79.27ml 
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(1mAU), which was calculated to be a protein with a molecular weight of around 107kDa. 
Peak 2 was eluted off at 94.90ml (6.01mAU), giving a protein with a molecular weight of 
around 22kDa. It is worth noting that although there is a similar pattern to the peaks observed 
in Figure 2.9 to previous dissociation trials, there is an overall decreased absorbance to that 
of Figures 2.8, 7 and 6 due to a smaller amount of protein being used in this dissociation 
trial. A third unexpected peak is also shown in Figure 2.9, eluting off at 112.25ml, with an 
absorbance of.5mAU. This elution volume was calculated to represent a protein with a 
molecular weight of 4.15kDa. Based on the calculated molecular weight of the peak, the 
sample in question was deemed not relevant to our study and was thus not pursued any 
further.   
 
Figure 2.9 A size exclusion chromatography trace for the CRP 4M urea dissociation 
experiment. The sample was run through the system 10 weeks after the initiation of the 
experiment. All peaks are labelled on the graph (1-3). The elution volume for peak 1 is 
79.27ml, the elution volume for peak 2 is 94.90ml and the elution volume for peak 3 is 
112.25ml. Fractions that were collected for further experimental analysis are also labelled 
(B4, 5, 7 and 8).  
 
 Upon purification via size exclusion chromatography, all urea-induced dissociated 
CRP samples were stored in a standard calcium storage buffer (see Section 2.2.1) at 4oC. It 
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is worth noting that during storage periods, none of the samples from any of the dissociation 
trials displayed any indication of re-association into higher molecular weight aggregates.  
2.3.3  Western Blotting of Monomeric and Pentameric C-reactive Protein 
 
As the size exclusion chromatography system only separates out proteins based on 
their size, further analysis was required to confirm that the observed peaks are pCRP and 
mCRP. Therefore, fractions B4 & 5 and B7 & 8 were collected from all dissociation 
experiments and subject to SDS PAGE and Western Blot analysis. Prior to Western Blot 
analysis, protein quantification (see Section 2.2.5) revealed that up to 50% of the initial 
protein for all four dissociation samples had been lost through the purification and 
concentration process, as described in Section 2.2.3 and 2.2.4. 
  Western Blot analysis was carried out on fractions B4+5 and B7+8 from each of the 
dissociation experiments (2, 2.5, 3 and 4M urea) and the 3M urea dissociated mCRP sample 
which had been run through the PC-bound affinity column (as shown in Figure 2.10 & 2.11, 
also see section 2.3.4). All samples were run on an SDS PAGE then subjected to a Western 
Blot procedure, as described in section 2.2.6 and 2.2.7. Western Blot analysis was performed 
with a CRP specific, Clone-8 antibody produced in a mouse, (Sigma) to be confident that 
the band we had observed was CRP. Figure 2.10 shows the Western Blot results for the B4+5 
fractions for each of the dissociation trials. All four samples show a positive band for the 
presence of CRP.  
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Figure 2.10 A Western Blot analyses of the B4+5 fractions for each of the CRP dissociation 
experiments. Lanes 1-4 contain 2, 2.5, 3 and 4M urea-dissociated samples respectively. 
 
Figure 2.11a, shows the Western Blot results for each of the urea dissociated samples 
(2, 2.5, 3 and 4M from fractions B7+8). Each lane contains one band, corresponding to the 
expected mCRP molecular weight of 23kDa. Figure 2.11b is a sample of the 3M urea 
dissociation trial which was run through the PC-bound affinity column (see section 2.2.11 + 
2.3.4). Like that observed in Figure2.11a, the sample displays one positive band for CRP at 
a molecular weight of around 23kDa. Figure ‘c’ contains the molecular weight markers that 
were run with the sample in order to roughly determine their molecular weight.  
23 kDa 
1 2 4 3 
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Figure 2.11 A Western Blot of the dissociated CRP samples. a) A Western Blot of the 
dissociated CRP samples (fractions B7+8) from the urea dissociation trials. Lane 1: 2M urea 
sample, lane 3: 2.5M urea sample, lane 5: 3M urea sample, Lane 7: 4M urea sample. All 
other lanes contained buffer. b) A Western Blot (from the same gel as a) of the 3M urea-
produced mCRP sample which has been run through the PC-bound affinity column. c) 
Molecular weight markers (same gel) which have been stained in Coomassie Brilliant Blue.  
 
 
 
2.3.4 Binding Monomeric and Pentameric C-reactive Protein with 
Phosphocholine 
 
Native, pCRP binds to dead or damaged cells within the human body to generate an 
immune response. When cells become damaged, they express PC on their surface, for the 
recognition and binding of immune proteins. PC is pCRP’s primary ligand, to which it binds 
with the highest affinity (Thompson et al., 1999). To test whether the in vitro produced 
mCRP retained the ability to bind PC, a sample from the 3M urea dissociation trial was run 
through a PC-bound affinity column. The chromatography trace from the column run is 
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shown in Figure 2.12. The mCRP sample used was from the same stock of that produced in 
the 3M urea dissociation trial. Prior to running the sample through the column, it was pre-
equilibrated with standard calcium buffer (see Section 2.2.1), an essential component to 
allow CRP to bind to PC. A total of 250µg was loaded and run through the column at a 
flowrate of 0.5ml/minute. Two main peaks were observed on the chromatography trace; 
these are labelled in Figure 2.12 as peaks 1 and 2. Peak 1 is shown 20 minutes after the 
application of the sample onto the column and gave an absorbance reading of 0.01AU. Once 
the UV absorbance reading had flat-lined, EDTA chelating buffer was run through the 
column. Peak 2 is shown 15 minutes after the chelating buffer was run through the column 
and gave an absorbance reading of 0.03AU. The UV absorbance was measured at 280nm.  
 
Figure 2.12 A chromatography trace of in vitro produced mCRP (from 3M Urea) being run 
through a PC-bound affinity column. A fluctuation in the UV absorbance reading was 
recorded, as shown by peak 1, due to the addition of the sample to the column (see Marker 
1). Peak 2 represents the point at which the protein, mCRP, was eluted off the PC column 
through the addition of the calcium chelator EDTA (see Marker 2).  
 
2.3.5  Precipitation Studies with C-reactive Protein 
 
 CRP was named due to its ability to bind and precipitate out the C-polysaccharide 
that is expressed on the cell wall surface of Streptococcus pneumoniae (McCarthy, 1982). 
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Previous experimental work carried out by Volanakis (1982) demonstrates that the 
precipitation of CRP with CWPS follows a general bell curve. These results are like that 
observed in antibody-antigen complexes; too little or too much ligand results in reduced 
precipitation, with an equivalence zone between the two displaying an increase in 
precipitation (Volanakis, 1982). 
To determine whether the in vitro produced mCRP samples retained an ability to 
bind and precipitate with CWPS and follow the generic precipitation bell curve like that 
observed pCRP, samples were incubated with CWPS, with precipitation levels calculated 
via ELISA analysis on the remaining supernatant. Precipitation experiments were carried out 
on pCRP (SCRIPPS) and in vitro produced mCRP from a 3M urea dissociation experiment. 
Samples were incubated with CWPS to determine whether they would follow previously 
published precipitation trials (Volanakis, 1982). Prior to the precipitation experiments, 
ELISA calibration experiments were conducted for both pCRP and mCRP to determine the 
levels of CRP precipitated when combined with CWPS (as shown in Figure 2.13) 
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Figure 2.13 Monomeric and Pentameric CRP calibration graphs. a) The calibration graph for 
pCRP. Values are expressed in mg/L. The line equation is: y = 1.3587x + 0.0009. The R 
squared value is: 0.996. b) The calibration graph for mCRP. Monomeric CRP used was 
dissociated via a 3M urea trial. Values are expressed in mg/L. The line equation is: y = 
1.2308x + 00332. The R squared value is: 0.9981. Both graphs display a positive correlation 
with an absorbance values below 1.0. This indicates that absorbance is proportional to 
concentration. 
Figure 2.14 displays the levels of precipitation for both pCRP and in vitro produced 
mCRP when incubated with varying amounts of CWPS. The experimental work was adapted 
from the protocol documented by Volanakis, 1982, using radiolabelled CRP incubated with 
C-polysaccharide. Protein concentrations were determined via an ELISA and read at 450nm. 
The level of CRP precipitated was calculated based on the level of protein remaining in 
solution, post CWPS incubation.  
Pentameric CRP displays little precipitation with CWPS at either end of the curve, 
where protein or ligand concentration is in excess, as shown in Figure 2.14. 2µg of pCRP 
precipitated out of solution when incubated with 0.1µg of CWPS, in addition to 5µg of pCRP 
precipitating out of solution when incubated with 300µg of CWPS. There is a clear 
equivalence zone is apparent which demonstrates high levels of protein precipitation. A 
range in the amount of ligand used from 10µg to 100µg shows an increased level in protein 
precipitation, which peaks at 20µg of CWPS, resulting in 16µg out of a total of 20µg of 
pCRP being precipitated. The levels of precipitation that is shown in Figure 2.14 is consistent 
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with what has previously been described when measuring pCRP precipitation (Volanakis, 
1982).   
Unlike that observed for pCRP, in vitro produced mCRP does not follow the general 
bell-shaped curve. The protein maintains a general baseline of precipitation of approximately 
5µg when incubated with all the varying amounts of CWPS. The highest level or 
precipitation peaks at just over 7µg, when mCRP is incubated with 50µg, although these 
levels were still significantly lower than that of pCRP (approximately 15µg). The levels of 
precipitated protein for mCRP were calculated identical to that for pCRP; via ELISA 
analysis of the supernatant.  
 
 
Figure 2.14 Precipitation studies of pCRP and mCRP with CWPS. 20µg CRP was incubated 
with varying amounts of CWPS for 1 hour at 37oC. Samples were freed of precipitate by 
centrifugation (4000 x g for 10 minutes) and protein concentration determined via ELISA. 
The red indicates the level of precipitation for pCRP whilst the blue represents the 
precipitation levels for in vitro produced mCRP (3M Urea).  
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2.4  Discussion 
 
2.4.1  Optimisation of the Size Exclusion Chromatography Column 
 
 Size exclusion chromatography is the principle experimental used in the research 
here to isolate the different forms of CRP. Based on the results from the calibration of the 
column, the theoretical elution volumes for pCRP and mCRP were calculated to be 78.5ml 
and 94.5ml respectively. Although we initially did not have any mCRP to test whether these 
calculations were correct, the commercially available pCRP was run through the column as 
a standard (see Figure 2.5). The CRP sample was eluted off at 79ml, which corresponds to a 
molecular weight of 110kDa.  
2.4.2  Production and Purification of Monomeric C-reactive Protein 
 
 CRP dissociation experiments using 2, 2.5, 3 and 4M urea were set down over a 10-
week period to establish a suitable protocol which would result in the production of mCRP, 
whilst minimising the amount of urea required for dissociation. Although literature suggests 
that dissociation of pCRP is achievable through alternative methods, previous experimental 
work within our lab demonstrated that the treatment of pCRP with heat or acidic conditions 
results in complete denaturation of the protein. We did however aim to minimise the use of 
harsh conditions when dissociating pCRP as we were unclear how this would affect the 
protein’s structure and function (Potempa, 1983). One thing that is essential when 
dissociating native pCRP is the removal of calcium ions; treatment with urea alone (without 
removal of calcium) is not sufficient to result in a high yield of dissociation. It is not entirely 
clear why this is the case, although the absence of calcium induces a major conformational 
change within the protein. Residues 140-150 form a large loop away from the body of the 
molecule, exposing hidden sites susceptible to proteolysis (Ramadan et al., 2002). This 
structural changes suggest that the calcium ions are crucial when maintaining the protein’s 
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structural integrity, and an absence of these ions may weaken the inter-protein contacts 
which can then make it more liable to dissociation through urea treatment (Ramadan et al., 
2002).  
 Partial dissociation was observed for all the urea concentrations used. The results 
show that the higher the concentration of urea used, the greater level of dissociation observed 
within the same timeframe, which agrees with previous dissociation experiments (Potempa, 
1983). Eluted fractions (from all elution profiles) B4 and B5 corresponded to pCRP whereas 
the eluted fractions B7 and B8 were thought to be an in vitro produced form of mCRP based 
upon molecular weight calculations made from the calibration graph and Western Blot 
analysis. The lower concentration of 2M urea resulted in very little dissociation even after 
10 weeks of incubation, based on the absorbance readings, around 90% of the protein eluted 
off was pCRP. Increasing the concentration to 2.5M suggests an increase in dissociation with 
higher levels of mCRP being eluted. There is however, still approximately 75% of the 
sample still being eluted off into fractions B4 and B5.  
Both 3 and 4M urea dissociation trials resulted in almost complete dissociation 
(>90% total protein) of pCRP (see Figures 2.8 and 2.9). In contrast to previous dissociation 
experiments, a slight ‘shouldering’ effect was observed on the peaks representing pCRP 
(peak 1) on both chromatograms. These two ‘shoulders’ in Figures 2.8 and 2.9, based on the 
calculated molecular weights, were thought to signify a small level of un-dissociated or 
partially-dissociated pCRP (see Table 2.12). In several dissociation experiments, up to 50% 
of the initial CRP sample was recorded to be lost through the size exclusion chromatography 
and protein concentration processes. A slower flow-rate whilst purifying samples through 
both procedures was found to increase the protein yield, although significant losses was still 
recorded. As size exclusion chromatography is essential in the development of a sound 
methodology for the purification of in vivo CRP, it was important that where possible, 
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protein losses were reduced. Alongside optimisation of the column flowrate at 0.5ml/min, 
the centrifugation of samples was carried out at a reduced ‘g’ and the concentrate flow-
through was quantified as described in section 2.2.5 to check for protein.  
One of the main aims when producing an in vitro form of mCRP was to avoid using 
harsh conditions when dissociating the sample. When dissociating pCRP, it is expected that 
a small proportion will always remain in the pentameric form. Based on the 10-week period 
chosen it was decided that 3M urea would be the optimum concentration when dissociating 
pCRP for use in the remaining work described here.  
Sample Elution Volume (ml) 
Calculated Molecular 
Weight (kDa) 
2M Urea (B4+5) 79.00 110.23 
2M Urea (B7+8) 95.65 21.35 
2.5M Urea (B4+5) 79.09 109.26 
2.5M Urea (B7+8) 95.68 21.28 
3M Urea (B4+5) 79.60 103.90 
3M Urea (B7+8) 94.97 22.83 
4M Urea (B4+5) 79.27 107.34 
4M Urea (B7+8) 94.90 22.99 
Table 2.12 Elution volumes and their corresponding molecular weight values for each urea 
dissociation experiment. B4 and B5 corresponded to the elution of pCRP whilst B7 and B8 
corresponded to the elution of mCRP.  
 
It is unclear by what method urea dissociates proteins, and in turn, CRP. Furthermore, 
without further studies such as X-ray crystallography to determine the atomic structure, it is 
unclear what modifications urea-dissociation may have on the protein’s structure and 
function. Due to its ability to disrupt non-covalent bonds within proteins, urea is one of the 
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most common denaturants used in proteomic studies (Sun et al., 2014; Zou et al., 1998). 
Urea can interact with both polar and non-polar components, which makes it such a powerful 
denaturant (Rossky, 2008). Interactions with hydrophilic groups are thought to occur by the 
formation of hydrogen bonds or other polar interactions, whereas it is thought to weaken 
hydrophobic interactions of a protein (Rossky, 2008; Zangi et al., 2009).   
There are two main mechanisms that have been postulated underlying urea-induced 
dissociation. The first, indirect mechanism involves urea disrupting the first shell of water 
molecules hydrating the protein. This change in the structure of water’s hydrogen bond 
network around hydrophobic regions of the protein increases its solubility, weakening their 
hydrophobic effect and driving protein unfolding (Hua et al., 2008; Stumpe & Grubmiller, 
2007; Vanzi et al., 1998). The second theory, or ‘direct mechanism’ postulates that urea 
interacts directly with hydrogen bonds, or electrostatic interactions within the protein 
through more favourable attractions, compared with water (Hua et al., 2008) Interactions 
with urea and protein backbones and/or sidechains is stronger than for water, giving rise to 
an intrusion of urea into the protein’s interior. These alterations to the protein’s structure and 
stability are thought to be the initial driving force for the denaturation and protein unfolding. 
The latter theory is suggested to be the more widely accepted model for urea-induced 
dissociation, although it could potentially be a combination of the two (Stumpe & 
Grubmuller, 2007).  
 When in an aqueous solution urea can spontaneously dissociate to form cyanate and 
ammonia; this results in the formation of isocyanic acid. This in turn can then result in the 
carbamylation of the N termini of proteins and peptides, or side chain groups of lysine and 
arginine residues. Temperature, pH, concentration and incubation time are all known to 
affect the rate of urea dissociation and the degree of protein carbamylation (Sun et al., 2014). 
Interprotomer contacts within pCRP’s structure are majorly involved within the 115-123 
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loop of one protomer with residues from 40-42 and 197-202 on the next protomer. Salt 
bridges are formed between Glu101- Lys201, Lys123 – Glu197 and Arg118 to the carbonyl 
region of Pro202. These salt bridges between CRP promoters may be susceptible to 
carbamylation and could potentially explain why urea-dissociated CRP may not be able to 
re-associate. Furthermore, the removal of calcium dramatically results in a shift of the 140-
150 loop, in addition to rearrangement of several side chains (Shrive et al., 1996). This 
change in structure may also explain why removal of calcium is necessary for urea-induced 
CRP dissociation. Alterations in the protein’s stability may aid denaturation by urea through 
one of the previously discussed mechanisms.  
2.4.3 The Binding of Monomeric C-reactive Protein to the Phosphocholine-
bound Affinity Column 
  
 To determine whether the in vitro produced mCRP retained its ability to bind PC, a 
sample from the 3M urea dissociation trial was run through a PC-bound affinity column. As 
samples were dissociated in a urea and EDTA containing buffer, they were eluted off the 
size exclusion column in a calcium containing buffer; crucial for CRP when binding to PC 
(Shrive et al., 1996; Thompson et al., 1999). Figure 2.12 shows the chromatography trace 
for when the mCRP sample was run through the column. Two main peaks were observed on 
the chromatogram (1 & 2). Peak 2 was subject to Western Blot analysis (as described in 
section 2.3.3), with mCRP confirmed from the eluted fraction (peak 2). The first peak was 
suggested to be an anomaly in the UV absorbance during sample loading. The second peak 
just 15 minutes after the addition of the chelating buffer displayed a marked increase in 
absorbance, reaching 0.03AU; a reading more indicative of the amount of protein loaded 
compared to peak 1(250µg). Our results disagree with previous studies that find dissociation 
through urea results in a complete loss to the binding of CWPS (which contains PC to which 
CRP would bind). This could be due to differences within the experimental conditions used 
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or due to CWPS being a much larger structure than PC, creating difficulties for protein 
binding. Although, Potempa, in addition to other published research does state they used 
concentrations of urea up to 8M (Potempa, 1983). Using such high concentrations of urea 
may result in alterations to the proteins structure and therefore loss of binding and/or protein 
function. This is shown through their reporting of mCRP’s loss of ligand binding when 
dissociating the protein at these high concentrations.  
 What we have achieved through this experimental research is a set of optimum 
dissociation conditions, which uses the lowest concentration of urea possible, that results in 
almost complete dissociation of pCRP. Furthermore, we have demonstrated that the in vitro 
produced mCRP retains an ability to reversibly bind to PC, something that was previously 
established not to be possible when dissociating pCRP with urea. These results may not 
provide a direct confirmation of any structural modifications that may occur through urea-
induced dissociation, but give an overall insight into stability and biological properties of 
the dissociated protein.  
2.4.4  Western Blot Analysis of Monomeric and Pentameric C-reactive 
Protein Samples 
 
 Western Blot analysis was performed on the proposed pCRP and mCRP fractions 
from all the urea dissociation trials, and on the 3M urea sample which was run through the 
PC-bound affinity column. This confirmed the presence of CRP from the samples, alongside 
assessing the sample’s purity. Pentameric CRP was confirmed to be present in all the trials, 
indicating that none of the dissociation trials induced complete dissociation of pCRP. All 
four samples of the proposed mCRP component from the dissociation trials gave a single 
band as expected. Comparison with molecular weight markers shown that all four samples 
corresponded to a protein with a molecular weight of around 23kDa, which fits in line with 
the molecular weight of mCRP (Shrive et al., 1996). All samples appeared free from any 
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impurities with only one band being visible in each lane. The mCRP sample (peak 2, Figure 
2.12) which had been run through the PC-bound affinity column was also subject to Western 
Blot analysis, to confirm whether the eluted protein peak was in fact CRP. As expected, the 
sample was positive for CRP, with a molecular weight of around 23kDa. Based on this 
experimental evidence it was concluded that the urea dissociation experiments successfully 
dissociated pCRP into its constituent subunits; an in vitro produced form of mCRP and that 
it retained its PC-binding ability.  
2.4.5  Precipitation Studies with C-reactive Protein 
 
 One of the roles of pCRP within the human body is the activation of the classical 
complement pathway to provide a first line defence to the host. This is achieved through 
multiple interactions including; PC present upon the surface of dead or damaged cells and 
the C1q complement protein (Volanakis, 1982). Section 2.3.5 describes how the in vitro 
produced mCRP displays an ability to bind both PC and CWPS, although less successfully 
with the latter. 
Figure 2.14 displays precipitation levels of pCRP and mCRP when incubated with 
increasing amounts of CWPS. As expected, pCRP follows the usual bell-shaped curve which 
fits in line with previous published work (Volanakis, 1982). A clear equivalence zone is 
shown ranging from around 10µg to 100µg of CWPS with levels of precipitated protein 
being reduced at either ends of the scale. It is believed that at this concentration range of 
ligand (and protein) that the two can form lattices, or aggregates, with cross-linking 
occurring resulting in the precipitation of the whole complex (Murphy et al., 2008; 
Volanakis, 1982). Monomeric CRP displays a much lower level of precipitation. There is no 
clear equivalence zone, where precipitation of the protein is increased, but with more of a 
general baseline level of precipitation at around 5µg. This could be due to several reasons; 
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firstly, the monomeric form may be unable to form cross-linkages or large aggregates as 
there is only one PC binding site, compared to the five sites on pCRP. Secondly, treatment 
with urea could have altered the binding capacity of the protein with CWPS, or alternatively, 
diminished the effect of hydrophobic regions during dissociation. Although mCRP does not 
follow an identical trend to that of pCRP, the results from the precipitation curve do display 
an ability to bind and precipitate out low levels of CWPS.  
2.4.6  Conclusions and Future Work 
 
 The experimental work discussed here provides a working protocol to produce a 
structurally and biologically stable in vitro form of mCRP. Evidence provided from both PC 
and CWPS binding studies show that mCRP retains an ability to interact and bind with these 
ligands; in contrast to previous research in the field. Dissociation with lower concentrations 
of urea can still produce almost complete dissociation of the pentameric molecule, but over 
a longer period. Furthermore, our results raise questions as to what effects such harsh 
conditions, like 8M urea, may have on the protein, which has been used in previous published 
research. Any potential future work involving either mass spectrometry or X-ray 
crystallography would be able to determine whether dissociation through urea treatment 
alters the protein in any way. Finally, the research that has been used within this chapter will 
be used to help develop and drive forward a sound methodology when testing human serum 
for an active form of mCRP. 
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Chapter 3.0 – Analysis of Human Serum Samples 
3.1  Introduction 
 
3.1.1  Overview 
 
 The role of pCRP within the human body is to bind to dead or damaged cells, 
opsonise particles for phagocytosis and regulate the immune response by the induction of 
cytokine synthesis (Pepys & Baltz, 1983). Rise in levels of this plasma protein is induced by 
interleukin (IL) 6, which elevate transcription levels of the CRP gene within hepatocytes 
(Mackiewicz et al., 1990). Normal, healthy baseline levels of CRP can range from 1-3mg/L, 
but during an infection can increase up to 100-fold within 24-72 hours. It is therefore not 
surprising that CRP is routinely used as a clinical biomarker for injury, infection and 
inflammation (Pepys & Baltz, 1983; Shine et al., 1981).  
3.1.2  Measurement of C-reactive Protein in Human Serum 
 
There are a wide range of standard clinical and immunochemical techniques which 
can be employed when measuring CRP levels within serum. These immuno-techniques 
utilise antibodies specific to their target antigen (in this case CRP) providing rapid and 
sensitive results which are applicable for routine analysis within a clinical laboratory 
(Koivunen & Krogsrud, 2006). Standard measurement of CRP levels for the evaluation of 
infection or inflammation within a clinical setting used to use enzyme-linked immunosorbent 
assays (ELISA). These are rapid and sensitive tools used for the measurement and detection 
of antigens among other components, within a serum sample. With modern day technology 
advancing at such a pace, these manual techniques can be quite time consuming and are 
usually only performed for anomalous samples that require a more in-depth analysis. 
Currently assays have moved to a more automated based system, such as latex-enhanced 
immunoturbidimetry assays. This is typically seen within the National Health Service 
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(NHS), which has an ever-increasing volume of samples to process whilst trying to make 
efficiencies within their workforce (Koivunen & Krogsrud, 2006; Rifai et al., 1999; 
Siemens, 2014).  
 Measuring CRP levels in a clinical setting has been typical for assessing the severity 
of inflammation within an individual for many years. It is believed that elevated baseline 
levels (>3mg/L) can be a strong predictor for the development of diseases later of in life 
(Pepys & Hirschfield, 2003). Recent years has seen the development of high-sensitivity CRP 
tests which can detect subtler rises in the overall baseline levels of an individual, compared 
to levels commonly measured with standard CRP tests. As inflammation plays a major role 
in diseases such as cardiovascular disease, hypertension, atherothrombosis and even 
diabetes, the high-sensitivity measurement of inflammatory markers, such as CRP, over a 
period is thought to be a novel method of assessing an individual’s risk of developing such 
conditions (Ridker, 2016; Rifai et al., 1999; Sung et al., 2003). It is crucial when performing 
high-sensitivity CRP tests that the patient is not suffering from infection or inflammation, as 
significantly raised levels of CRP will prevent accurate measurement of baseline CRP levels. 
The increase in sensitivity is based on the development of light-scattering immunoassays, 
sometimes called ‘nephelometric assays’. Light is scattered from antigen-antibody 
complexes and measured based on the principle that a higher concentration of antigen results 
in an increase in the amount of light scattered (Krogsrud, 2006; Ridker, 2016; Rifai et al., 
1999; Sung et al., 2003).  
Shine et al., (1981) recorded that in young, healthy volunteers, the median baseline 
concentration of CRP is 0.8mg/L. The 90th centile of the population has a CRP reading of 
3.0mg/L and the 99th centile measures at 10mg/L or over (Pepys & Hirschfield, 2003; Shine 
et al., 1981). Genetic polymorphisms are known to be partly responsible for increased 
baseline levels of CRP. Guanine and thymine repeats within the intron of the CRP gene are 
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connected to alterations in CRP levels in normal, healthy individuals and patients with 
systemic lupus erythematosus (Pepys & Hirschfield, 2003). 
3.1.3  Monomeric C-reactive Protein within the Human Body 
 
 Research provided within Chapter 2 described previous documented literature for the 
in vitro production of mCRP and the development of a methodology which will be used to 
test human serum for this protein. Within this chapter the focus will also be on the more 
recent experimental work, which suggests that a monomeric form of CRP may be present 
within the human body. The biological relevance and production of this protein is yet to be 
fully established, but there is increasing evidence within the literature which suggests 
biological interactions with phosphocholine (PC), bound to the membranes of larger 
structures (cells, platelets), will readily dissociate the pentamer (Eisenhardt et al., 2009; 
Habersberger et al., 2012; Ji et al., 2007; Ji et al., 2009; Li et al., 2012; Molins et al., 2008; 
Slevin & Krupinski, 2009; Zhao & Shi, 2010).   
  It has also been proposed that mCRP imposes pro-inflammatory effects throughout 
the human body, contributing to various auto-inflammatory diseases. Activation of the 
classical complement pathway through binding to either native, or low-density lipoproteins 
alongside the complement protein C1q, has shown to result in intensified states of 
inflammation throughout the body (Ji et al., 2006). Activation and dysfunction of endothelial 
cells has also been linked to mCRP; upregulation of monocyte chemoattractant protein, IL-
8 and cell-cell adhesion molecules (ICAM-1 & VCAM-1) and E-selectin are just some 
examples. Furthermore, a study by Molins et al., (2008) demonstrated how mCRP has shown 
to upregulate P-selectin, which stabilises platelet-platelet and platelet-leukocyte interactions. 
Coupled with the increase of tissue factor expression and alterations in fibrin clotting 
properties, it is clear these results are likely to be a contributing factor towards pro-thrombin 
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events routinely seen in the pathology of auto-inflammatory diseases (Li et al., 2012; Molins 
et al., 2008).   
 It is worth noting that several of these studies display pro-inflammatory effects for a 
membrane-bound form of mCRP, in addition to the experimental evidence being produced 
with in vitro dissociated CRP, as discussed in Chapter 2. Only previously has evidence come 
to light which suggests that mCRP may be able to be transported throughout the human 
body. In 2013, Habersberger et al proposed a model by which pCRP may dissociate and be 
transported around the body to areas of localised inflammation. They suggested lipids 
present on the surface of activated platelets mediate the binding and dissociation of pCRP. 
Upon activation, lipid membranes then undergo rapid changes within their membrane 
composition, resulting in the shedding of micro-particles (MP) (Eisenhardt et al., 2009; 
Habersberger et al., 2013; Owens & Mackman, 2011; Verma et al., 2004). These MP were 
demonstrated to bind and dissociate CRP following severe cardiovascular events (such as 
myocardial infarction), which can thus allow mCRP to interact with other cells within the 
body and impose a pro-inflammatory stimulus (Habersberger et al., 2012).  
More recently a study by Crawford et al., (2016) has demonstrated the presence of 
mCRP and pCRP on the surface of circulating MP derived from endothelial cells. These two 
forms of CRP both displayed alternative biological effects within a vascular model, with 
mCRP inducing endothelial shedding and acting as a pro-inflammatory mediator, whereas 
pCRP induced anti-inflammatory effects through the reduction and regulation of migrating 
inflammatory immune cells (Crawford et al., 2016). They also state that not all current 
clinical tests may be able to measure levels of CRP that are bound to MP. High sensitivity 
CRP tests failed to detect correct levels, whereas flow cytometry did. This potential failure 
of standard plasma assays to detect sequestered levels of CRP could potentially have a 
knock-on effect for a patient’s treatment within a clinical setting. Although, this is only a 
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suggested model, with mCRP used within their study being produced through 8M urea 
induced dissociation.   
To our knowledge, there is only one experimental study which has claimed to have 
detected in vivo mCRP from human serum. Wang et al., (2015) tested for mCRP within the 
serum of patients who had recently suffered acute myocardial infarction (AMI), alongside 
patients suffering with unstable angina pectoris, stable angina pectoris and a control group. 
Their analysis revealed significantly increased levels of mCRP in AMI patients compared to 
other groups (20.96 ng/ml ±1.64). Their results also showed that circulating mCRP had 
considerable diagnostic accuracy for AMI, with nine patients who died before a 30-day 
follow up displaying plasma mCRP concentrations significantly higher than those who 
survived (36.70 ± 10.26 vs. 19.41 ± 1.43 ng/ml, P = 0.002). Wang and colleagues also 
discovered that mCRP levels were raised within patients who displayed raised levels of 
pCRP (Wang et al., 2015). Their results came from a group of six patients with their plasma 
mCRP levels ranging from 5.73 - 122.74 ng/ml. Their methodology consisted of testing neat 
serum (via an ELISA) by using a monoclonal antibody specific to mCRP. As encouraging 
as these results are, pCRP has been documented to spontaneously dissociate upon binding 
to the bottom of an ELISA plate, which may expose hidden epitopes that would allow 
binding of a mCRP specific antibody (Eisenhardt et al., 2011).  
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3.1.4  Experimental Aims 
 
The robust, established methodology that was used to analyse human serum, was 
developed from our previous experimental research (Chapter 2) coupled with scientific 
evidence within the literature. Our methodology is capable of detecting both pCRP and 
mCRP from human serum. By distinguishing whether mCRP can be isolated and detected 
from human serum may provide a much-needed insight into current misconceptions 
concerning the protein. More important, if mCRP is found to be present within human serum, 
this may provoke further research by clinicians, to re-evaluate the current routine clinical 
care of patients when measuring their CRP levels. Steps may need to be taken to 
accommodate a monomeric form of CRP, which could display an entirely unique set of 
circumstances compared to that of its pentameric form.  
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3.2  Materials and Methods 
 
3.2.1  Ethical Application 
 
Prior to any experimental analysis, for our research to be legal and scientifically sound, 
approval was required by a peer review and ethical research committee respectively. This 
allowed the feasibility and risks of our study to be assessed, protecting both the researchers 
and participants.  
3.2.1.1  Peer Review of the Ethical Application  
 
 An ethical application for peer review of our study was submitted to Keele 
University. The peer review system at Keele University is a local research community who 
assess the quality of the research. The panel scrutinises the supplementary scientific content 
provided, to ensure the research is viable, backed with sound knowledge. In addition, the 
system assesses the feasibility of the study and whether the methodology proposed is 
sufficient and scientifically accurate. The application was approved in April 2015. 
3.2.1.2  The Integrated Research Application System  
 
 An application for the Integrated Research Application System (IRAS) was then 
submitted. The IRAS is an online system which provides regulation and governance for 
research applications. This ensured that the risks of the study were acknowledged, and all 
participants were provided with a detailed knowledge about the study, to make informed, 
autonomous decisions. IRAS was used for preparing applications to Research Ethics 
Committees and the NHS Research & Development offices. The application was approved 
in May 2015. The project was approved by: NRES Committee South Central – Oxford B / 
REC ref: 15/SC/0179.  
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3.2.1.3  Ethical Application Project Title and Research Question 
 
 The full title of the research project was: 
‘Do the current clinical methods, used for the evaluation of raised and baseline levels of C-
reactive protein (CRP), allow for the potential presence of a monomeric form of CRP which 
could potentially display an alternative biological role within the human body, compared to 
that of pentameric CRP?’ 
 The project was submitted as a student project and pilot study. The chief investigator 
(CI) was Dr. A. K Shrive. Other members of the study included Robert Williams (PhD 
student), Professor Trevor Greenhough (Co-supervisor) and Professor Anthony Fryer 
(collaborator at the University Hospital of North Midlands). The principal research question 
was: 
‘Is monomeric CRP found within the serum of patients with raised levels of CRP 
(>100mg/L)? 
 To reduce the risk of the study, inpatients at the University Hospital of North 
Midlands (UHNM), who were due to undergo a routine blood check, were recruited for the 
study. The unused serum from these blood tests would be used for our study, as opposed to 
being discarded after the routine tests were complete. This therefore means that no samples 
were specifically taken for our study.  
3.2.1.4  Identification of Participants 
 
 The identification of participants took place at the University Hospital of North 
Midlands – The Royal Stoke University Hospital Participants eligible for the study were 
identified by Professor A. Fryer, or a member of his research team at UHNM. A criterion 
for participants eligible for the study was created. The inclusion criteria included: 
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i. Male or female over the age of 18 years. 
ii. They are a case with a raised CRP level of >100mg/L 
iii. They are inpatients at UHNM (Royal Stoke University Hospital) and are due to 
undergo a routine blood test as part of their routine clinical care.  
iv. The exclusion criteria for the study were: 
v. Any patient with a serum CRP <100mg/L will not be included. 
vi. Patients under the age of 18 were not included. 
3.2.1.5  Recruitment of Participants 
 
 All participants recruited for our study were inpatients at the UHNM. The 
participants who were eligible for our study were identified by either Professor A. Fryer, or 
a member of his research team. Eligible participants were approached by a research nurse or 
by a member of the participant’s clinical care team and given a brief verbal explanation of 
our study. All participants who showed an interest in taking part in our study were guided 
through a participant information sheet (PIS, see Appendix 1). 
 The PIS outlines the risks, benefits and aims of our study. The research nurses 
explained to all participants that they will have the right to withdraw from the study at any 
time, without giving a reason. All participants were given as much time as required to decide 
if they wished to partake within our study. All participants were informed that as they were 
due to undergo a routine blood test, they would not have to undergo any procedures that 
would not be part of their routine clinical care, therefore making the research study very low 
risk. All participants were also informed that the information generated from this study was 
anonymous, and that none of them would be identifiable from the results generated. 
 If the participants were happy to take part in our study, and the research team member 
was happy that the participant had fully understood everything that had been discussed, the 
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participants were presented with a participant consent form (PCF, see appendix 2). All 
participants were given a PCF and asked to sign and date them. All PCF were stored at the 
UHNM in accordance with standard NHS procedures. Only members of the research team, 
or the participants clinical care team would have access to the PIS or PCS. Research 
members based at Keele University, carrying out the scientific analysis, would not have 
access to this information. All participants were informed that if they were to lose their 
mental capacity to make informed consent before, or during the study, they would be 
immediately removed from the study with their samples being destroyed.  
3.2.2  Acquisition of Human Serum Samples  
 
Once a participant had agreed to take part within our study, and the PCF had been 
signed and dated, venous blood was taken by a fully trained phlebotomist at the Royal Stoke 
University Hospital as per their routine clinical care. A standard phlebotomy technique was 
used and blood was collected into BD Vacutainer SST gel tubes without anticoagulant. The 
sample was then left for up to 30 minutes to allow the blood to clot. The sample was 
transferred to a centrifuge (Hettich Rotanta 460 Robotic Centrifuge, model number: C5680) 
and centrifuged at 3,500 x g at 25oC for 7 minutes to separate out the serum from other 
components within the blood. The serum was stored in the hospital cold room at 4oC until 
the routine analysis had been carried out. Once the analysis had been completed, 1-1.5ml, 
depending on the volume left over of the sample, was transferred into a cryovial tube and 
labelled. The sample was then stored in the cold room at 4oC until collected and transferred 
to Keele University by Mr R. Williams. 
The Human Serum samples were provided by UHNM with a unique code (e.g. CRP 
001). These samples would not be in any way identifiable to the participant who provided 
them. Samples were taken and stored at Keele University, Huxley Building, Structural 
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Biology Research Group. All information generated from the study was stored on a password 
protected computer, with only the named investigators having access to the information.  
 Once the serum samples had been collected at UHNM they were transported in a 
chilled, sealed container to the Structural Biology Research Lab at Keele University. All 
serum samples were provided in a 1.5ml cryovial tube and stored at 4oC (cold room 
temperature at Keele University). Samples were never frozen as it was unknown how this 
may affect the proteins within the serum. Sodium azide (0.02% v/v) was added to all samples 
upon arrival to Keele University. CRP and where possible, calcium levels, were provided by 
UHNM via an Excel Spreadsheet. A total of >1ml was provided per sample. Detailed records 
were kept for the sample collection date, sample ID, sample volumes, CRP and calcium 
concentrations, sample analysis and dates of when samples were discarded. Although the 
biological samples do not come under the jurisdiction of the Human Tissue Act 2004, Keele 
University requested a detailed account of the collection, storage and disposal of all human 
serum samples throughout our study. All relevant information was passed on to the relevant 
authorities at Keele University.  
3.2.3  Purification of the Human Serum Samples 
 
 The affinity chromatography column system and software used were the same as 
described in section 2.2.3. Prior to the application of each human serum sample through the 
column, 10 column volumes of regeneration buffers 1 & 2 (see Table 3.1) were run through 
it. As serum contains many different proteins, it was important to ensure that any remnants 
residing in the column from the previous run were removed. The regeneration buffers were 
used to clean the column, ensuring that all CRP present within the serum could bind. The 
absorbance was measured at 280nm for all chromatography runs. The ultra-violet (UV) 
absorbance baseline was blanked prior to the addition of the regeneration buffers. 
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10 column volumes of equilibration buffer (see Table 3.1) were run through the 
column at a flowrate of 0.5ml/min. 0.9ml of each serum sample was diluted up to 10ml of 
equilibration buffer (see Table 3.1). The 10ml of diluted human serum was then passed 
through the column at a flowrate of 0.5ml/min. When the entire sample had been applied to 
the column, equilibration buffer was passed through and collected in a 50ml tube (Fisher 
Scientific) until the UV reading had returned to 0AU. 
The chelating buffer (Table 3.1) was then run through the column at a flowrate of 
0.5ml/min. The eluted protein was collected in a 50ml tube (Fisher). Once all the bound 
protein had been eluted from the column, 20 column volumes of equilibration buffer was 
run through the column until the absorbance reading had flat-lined to 0AU. The column was 
then ready for storage.  
Buffer/Solution Components Concentration 
Regeneration Buffer 1 pH 
7.4 
Sodium Chloride 500mM 
Tris 200mM 
EDTA 10mM 
Regeneration Buffer 2 pH 
7.4 
Sodium Chloride 500mM 
Tris 50mM 
Calcium Chloride 10mM 
Equilibration Buffer pH 7.4 
Calcium Chloride 10mM 
Tris 50mM 
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Sodium Chloride 150mM 
Sodium Azide 0.01% 
Chelating Buffer pH 7.4 
EDTA 10mM 
Tris 50mM 
Sodium Chloride 150mM 
Sodium Azide 0.01% 
Table 3.1 A list of all the components for the buffers used on the phosphocholine-bound 
affinity chromatography column when purifying the human serum samples. Concentrations 
are also given for all the components used.  
3.2.4  Concentration of the Eluted Fractions 
 
 The eluted fractions from the phosphocholine-bound affinity column were 
concentrated as described in section 2.2.4. Samples were concentrated to volumes that were 
appropriate for application onto the size exclusion column (0.1-2% of the column volume, 
see section 2.2.2).  
3.2.5  Size Exclusion Chromatography of the Eluted Fractions 
 
The size exclusion chromatography system and software used are the same as those 
described in section 2.2.2. The buffers used for preparing the column are outlined in Table 
3.2. The column is stored in 20% ethanol and was purged with three column volumes of 
deionised water (one column volume is 120ml). The column and tubing were equilibrated 
with four column volumes of elution buffer (see Table 3.2). The pH of the elution buffer was 
adjusted by the addition of HCl. All buffers and solutions used on the column were filtered 
through a 0.2µm cellulose acetate filter (Sartorius Stedim Biotech, Geottingem, Germany) 
to remove any particulate matter that may clog the system and de-gassed, to avoid 
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introducing air into the system. All buffers and solutions were stored at 4oC and allowed to 
equilibrate to room temperature before use. 
Buffer/Solution Components Concentration 
Storage Solution Ethanol 20% 
Wash Solution Deionised H2O 100% 
Elution Buffer pH 7.4 
Tris 20mM 
Sodium Chloride 280mM 
Calcium Chloride 
Hexahydrate 
5mM 
Table 3.2 A list of all the components for the buffers used on the size exclusion column when 
purifying the human serum samples. Concentrations are also given for all the components 
used. 
The eluted samples were loaded onto the column via a 2ml sample injection loop. 
Based on the user guidelines, the sample volume did not exceed 0.1-2% of the column 
volume to obtain the best resolution and was accounted for when concentrating the sample. 
A flowrate of 0.5ml/min was used for all samples, with the absorbance measured at 280nm. 
Sample fractions of 5ml were collected up to one column volume (120ml) at room 
temperature. The size exclusion column was then prepared for storage. Four column volumes 
of wash buffer were run through the column, followed by four column volumes of 20% 
ethanol.  
3.2.6  Concentration of the Eluted Fractions  
 
Samples from the size exclusion column were concentration as described in section 
2.2.4. The eluted fractions B4 & B5 and B7 & B8, for each serum sample, were combined 
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respectively. The fractions were concentrated to give final volumes varying between 50 and 
800 µL. Protein concentrations subsequently determined will need to account for this 
variation. 
3.2.7  Protein Quantification of the Eluted Serum Fractions 
 
The protein content of the CRP samples was determined using a spectrophotometer 
as described in section 2.2.5. 
3.2.8  SDS PAGE of the Eluted Serum Fractions 
 
SDS PAGE gels were cast as described in section 2.2.6. All gels used for the analysis 
of the serum samples consisted of a 12.5%T resolving gel, a 4%T stacking gel at 0.75mm.  
All samples were added to a non-reducing, SDS buffer at a ratio of 1:1. Samples were 
heated at 95oC for a total of five minutes prior to loading on the gel. A total volume of 15µl 
was added to each well to maximise the total amount of protein run through the gel for each 
sample. Low range molecular weight markers were run alongside samples, but not 
transferred onto a Western Blot. Lanes containing the molecular weight markers were 
carefully cut off and stained with Coomassie Brilliant Blue, as described in section 2.2.6. 
B4+5 fractions eluted off the column were all run on separate gels to the B7+8 fractions. 
Positive pCRP controls (1µg) which had been subject to the same procedures as the samples 
were run alongside all B4+5 fractions. Positive in vitro produced mCRP (via 3M Urea) 
controls (1µg), which had been subject to the same procedures as the samples were run 
alongside all B7+8 fractions. Negative controls, which contained no protein sample and just 
running buffer, were included in all gels (not included in Figures). Gels were run on the same 
system as described in Chapter 2. 
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3.2.9  Enzyme-linked Immunosorbent Assay of the Eluted Serum Fractions 
 
A calibration graph for known amounts of pCRP & mCRP were produced, to 
determine CRP levels within the human serum samples. Buffers and solutions used for the 
calibration experiments are the same as described are shown in Table 3.5. Both primary and 
secondary antibody dilutions used were as recommended by the supplier SCRIPPS. The 
ELISA was carried out on a sterile, 96-well plate (Costar). The plates were flat bottom plates, 
with a low evaporation lid, high binding affinity and made from polystyrene. All results from 
the experiment were triplicated. 100µl of calcium buffer was added to columns 2-10, rows 
A-C. 100µl of either pCRP or mCRP was added to column 1, rows A-C (0.75µg, 
0.0075mg/ml). 100µl of either pCRP or mCRP was added to column 2, rows A-C. The 
contents of column 2, rows A-C was then mixed thoroughly, with 100µl being transferred to 
column 3, rows A-C. This process was repeated to column 9, rows A-F, where the additional 
100µl was discarded to waste, leaving only calcium buffer in column 10, rows A-F (negative 
control). The plate was left to incubate overnight at 4oC on the rocking machine (see Table 
3.3). 
 The plate was washed thoroughly with wash buffer 3 times. Wash buffer consisted 
of phosphate buffered saline (PBS) and Tween (see Table 3.4). All components of wash 
buffer were purchased from Sigma. Any remnants of wash buffer within the wells were 
‘flicked’ out into the waste. 100µl of blocking solution was then added to all wells. Blocking 
solution consisted of a 3% bovine serum albumin (BSA) solution in PBS-Tween (see Table 
3.4). The BSA was purchased from Sigma with all blocking solution being made fresh prior 
to use. The plate was left for 2 hours at 4oC on the rocking machine. The plate was washed 
thoroughly with wash buffer 3 times (see Table 3.4). Any remnants of wash buffer within 
the wells were ‘flicked’ out into the waste. The primary monoclonal antibody was thawed 
out prior to use. The primary antibody was diluted at 1:40,000 (the recommended dilution 
Chapter 3. Analysis of Human Serum Samples  Materials & Methods 
 
131 
 
from the supplier SCRIPPS) in wash buffer. 100µl of the diluted antibody was added to each 
well. The plate was left for 5 hours at 4oC on the rocking machine.  
 The plate was washed thoroughly with wash buffer 3 times. Any remnants of wash 
buffer within the wells were ‘flicked’ out into the waste. The secondary antibody was thawed 
out prior to use and was diluted at 1:40,000 in wash buffer (dilution based on 
recommendation from supplier SCRIPPS). 100µl of the diluted antibody was added to each 
well. The plate was left for 2 hours at 4oC on the rocking machine. The developing substrate 
used was 3,3’,5,5’ Tetramethylbenzidine (TMB) liquid substrate purchases from Sigma. The 
TMB is stored at 4oC, and prior to use allowed to equilibrate to room temperature. 100µl of 
TMB was added to all columns and developed for 10 minutes, or until the required colour 
intensity was reached. 100µl of 2M Sulphuric Acid was added to all columns. The tray was 
then read at 450nm on a BioTek EL800 plate reader using the Gen5 Software. 
Pentameric and Monomeric CRP Calibration 
  
1 2 3 4 5 6 7 8 9 10 
A 
pCRP 
(µg) 
0.75 0.38 0.19 0.09 0.05 0.025 0.0125 0.00063 0.00021 Control 
B 0.75 0.38 0.19 0.09 0.05 0.025 0.0125 0.00063 0.00021 Control 
C 0.75 0.38 0.19 0.09 0.05 0.025 0.0125 0.00063 0.00021 Control 
D 
mCRP 
(µg) 
0.75 0.38 0.19 0.09 0.05 0.025 0.0125 0.00063 0.00021 Control 
E 0.75 0.38 0.19 0.09 0.05 0.025 0.0125 0.00063 0.00021 Control 
F 0.75 0.38 0.19 0.09 0.05 0.025 0.0125 0.00063 0.00021 Control 
Table 3.3 A Table showing the amounts of pentameric and monomeric CRP used in the 
ELISA calibration experiments.  
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Buffer/Solution Components Concentration 
PBS pH 7.4 with HCl 
Sodium Chloride 137mM 
Potassium Chloride 2.7mM 
Disodium Phosphate 10mM 
Monopotassium Phosphate 2mM 
PBS – Tween (Wash 
Buffer) 
PBS 1L 
Tween 0.5ml 
PBS-Tween with 3% BSA 
(Blocking Solution) 
PBS – Tween 20ml 
BSA 0.6mg 
Calcium Buffer pH 7.4 with 
HCl 
Tris 20mM 
Sodium Chloride 280mM 
Calcium Chloride 5mM 
Primary Monoclonal 
Antibody 1:4,000 Dilution 
Primary Antibody 1µl 
PBS - Tween 39.999ml 
Secondary Antibody 
1:40,000 Dilution 
Secondary Antibody 1µl 
PBS – Tween 39.999ml 
Table 3.4 A list of all the components used in the ELISA calibration experiment for 
pentameric and monomeric CRP. The concentration for each component used is also given.  
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The purified pCRP fractions (B4+5) fractions were subject to an ELISA to determine 
the levels of pCRP present, post-purification. The purified fractions were diluted in calcium 
buffer at 1:100. 50µl of each serum sample was added, in triplicate, to a 96-well plate. The 
blocking, washing, addition of antibodies and reading of the ELISA plates were carried out 
as described above for the calibration experiment. The primary and secondary antibody 
dilution used was 1:40,000. Positive controls were included.  
The purified mCRP fractions (B7+8) fractions were subject to an ELISA to 
determine the levels of mCRP present, post-purification. The purified fractions were diluted 
in calcium buffer at 1:10. 50µl of each serum sample was added, in triplicate, to a 96-well 
plate. The blocking, washing, addition of antibodies and reading of the ELISA plates were 
carried out as described above for the calibration experiment. The primary and secondary 
antibody dilution used was 1:40,000. Positive controls were included. 
Controls of pCRP (SCRIPPS) and mCRP (dissociated via 3M Urea) were included 
in all ELISA experiments. Both forms of CRP had been subject to the same purification 
methods as described in Sections 2.2.2, 2.2.3 and 2.2.4. Eluted fractions B4/5 were used for 
the positive pCRP control whilst fractions B7/8 were used for the negative control. Eluted 
fractions B7/8 were used for the positive control for mCRP, whilst fractions B4/5 were used 
for the negative control.  
3.2.10  Western Blotting of the Eluted Serum Fractions 
 
Samples which were used within the Western Blot transfer had previously been 
subject to SDS PAGE. Components and buffers used for the Western Blotting of human 
serum samples are the same as described in section 2.2.7.  
Membranes were washed as described in section 2.2.7. The primary monoclonal 
antibody (mAb) was defrosted, prior to the addition to the nitrocellulose membrane. The 
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primary mAb was diluted in BLOTTO. For the purified pCRP fractions (B4+5), a 1: 1,000 
mAb dilution was used. For the purified mCRP fractions (B7+8) a 1:400 mAb dilution was 
used. To increase the chances of detecting mCRP on the WB, a maximum volume of 15µL 
from each sample was loaded onto the gel. The primary antibody was left on the membrane 
overnight. A volume sufficient to completely immerse the membrane was used (>20ml). The 
secondary antibody was diluted in BLOTTO at 1:40,000. The secondary antibody was added 
to the nitrocellulose membranes for a minimum of 1 hour (for both fractions). A volume 
sufficient to completely immerse the membranes were used (>20ml).  
 The Clarity ECL Western Substrate was then added for a minimum of five minutes. 
The reagent was added at a 1:1 ratio of Clarity peroxide reagent and Clarity luminol/enhancer 
reagent, to a total volume of 7ml. All steps were carried out at 4oC on the rocking machine, 
to encourage gentle agitation of the solution with the nitrocellulose membrane. The 
membranes were removed from the reagent and wrapped in Saran Wrap (protein side up) to 
prevent drying out. The membrane was then viewed on a digital image detector and exposed 
for up to 30 minutes, depending on the intensity of the band required. Control bands that 
fluoresced too brightly compared to that of the experimental samples were carefully cut off, 
with the remainder of the membranes exposed for a longer period of time.   
3.2.11  Statistical Analysis  
 
All graphs and Tables produced from the data generated from our research were 
created on Microsoft Excel 2010.  
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3.3  Results 
 
3.3.1  Experimental Design 
 
 This sub-chapter highlights the experimental planning, design and initiative that was 
required during the preliminary stages of the study, and was thus used as a guide throughout 
its duration by all parties involved. 
3.3.1.1  Ethical Application Approval  
 
Prior to serum sample analysis, ethical approval was required by both Keele 
University and the online IRAS. Figure 3.1 displays an overview of the process that was 
required to obtain ethical approval for the project.  
 
 
Figure 3.1 A flow diagram highlighting a step-by-step process used to obtain ethical 
approval through both Keele University, and IRAS. Preliminary questions provided through 
IRAS resulted in the generation of three separate forms, all which needed to be approved 
and signed off by the relevant bodies before sample collection could commence. 
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3.3.1.2  Determining the Sample Size Required for the Study 
 
 The primary outcome of this study is to determine whether human mCRP can be 
located within the serum of patients with raised levels of CRP (>100mg/L). For our study to 
be representative of the population alongside sample size calculations being a prerequisite 
for ethical approval, a sample size needed to be chosen to reflect this. To our knowledge, 
there is no readily available data for the average distribution of mCRP levels throughout the 
population in addition to very little information on whether mCRP is located within human 
serum. This therefore meant that we were unable to perform a sample size calculation, or 
generic power analysis for our study that would accurately represent the population. 
We hypothesised that if mCRP were to be located within the serum of patients with 
raised levels of CRP (>100mg/L), then only a small portion of this total CRP would be 
mCRP, with the rest being native pCRP. This proportion was hypothesised to be 15%. From 
this, we were then able to calculate a confidence level (at 95%) for a chosen sample size. 
This was calculated with the following equation: 
 
Confidence Level = (?̂? − 𝑍 
√𝑝 ̂(1−𝑝)
𝑛
, ?̂? +  𝑍 
√𝑝 (1−?̂?
𝑛
 ) 
 
Equation 3.1 The equation used to determine the Confidence Level for a sample size. 
Equation 3.1 highlights how the confidence level for a sample size was calculated 
for this study. The p̂ symbol represents the expected proportion of mCRP (15%), n represents 
the sample size a Z represents the critical value for the 95% confidence level. For the 
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confidence level to be determined for a chosen sample size, the critical value needed to be 
determined.  
3.3.1.3  Calculation of the Critical Value for a Confidence Level 
 
 In statistical analysis, the critical value is the value given which corresponds to the 
chosen level of significance. This critical value, sometimes known as a ‘cut off’ value, is the 
boundary between the samples, in a test statistic, which can result in the decision to either 
reject, or fail-to-reject a null hypothesis. The calculation of the critical value for a two-tailed 
test is as follows (Chosen level of confidence = 95%): 
i. Subtract the confidence level from 100%: 100% - 95% = 5%. This 5% represents 
both tail ends of the graph. These are the areas of the graph which are not included 
in the 95% confidence level. 
ii. Convert the value from step 1 into a decimal: 5% = 0.05. This is usually denoted as 
the α value. 
iii. Subtract α from 1: 1-0.05 = 0.95. This 0.95 represents that we are 95% confident that 
any one value will lie throughout the distribution of samples. 
iv. Divide the value from step 3 by 2 as this is a two-tailed test: 0.95/2 = 0.475. A two-
tailed test allows the test to be two sided, and to determine whether the sample is 
either greater or less than a certain range of values.  
v. Input 0.475 into a Z-Table (see appendix), this gives a critical value of 1.96 (see 
appendix for Z Table).  
3.3.1.4  Calculation of the Confidence Level 
 
Equation 3.1 shows the equation used with Table 3.1 displaying the meaning and value 
of each symbol. This was calculated as follows: 
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i. Proportion = 15% 
ii. 15% of 40 (n) = 6 
iii. 6/40 = 0.15 = p̂ 
iv. = (0.15 − 1.96 √0.15(1−0.15)
40
, 0.15 +  1.96 
√0.15 (1−0.15
40
 ) 
v. = -0.039, +0.026 
vi. = +/- 11.1% 
vii. This therefore means that with a sample size of 40, we can be 95% confident that 
15% of the serum samples analysed will contain mCRP +/-11.1%.  
3.3.1.5  Overview of the Human Serum Sample Analysis Methodology 
 
Once ethical approval had been granted, sample collection could begin. Human 
serum analysis was based on a three-step process; CRP purification from human serum via 
affinity chromatography, separation of potential CRP isoforms by use of size exclusion 
chromatography, followed by identification and quantification via Western Blot and ELISA 
analysis (see Chapter 2).  
Human serum contains crude a mixture of components, including proteins, antigens, 
hormones and antibodies (Murphy et al., 2008). We were therefore required to purify out the 
CRP within the serum, prior to application on the size exclusion column. Samples were run 
through a phosphocholine-bound affinity column, to which CRP can readily bind 
(Thompson et al., 1999). Research within the literature demonstrates several models of 
pCRP dissociation, upon which is initiated through binding to the surface of cells at localised 
sites throughout the body, and even circulating platelets, all of which will contain PC 
constituents protruding from their membrane. (Eisenhardt et al., 2009; Habersberger et al., 
2012; Ji et al., 2007; Ji et al., 2009; Li et al., 2012; Molins et al., 2008).  
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Coupled with the experimental evidence provided in Chapter 2, we were confident 
that potential forms of mCRP will be able to bind and interact with the PC column, and allow 
purification of the sample from serum. An overview of the entire purification, identification 
and quantification process for the human serum sample analysis is shown via a flow diagram 
in Figure 3.2.  
 
Figure 3.2 A flow diagram highlighting in a step-by-step process the methodology used for 
the analysis of human serum. Both Western Blot & ELISA analysis was performed on all 
samples.  
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3.3.2  Purification of the Human Serum Samples 
 
A full list of all the CRP codes that were used within our study, their initial CRP 
concentrations based on reading provided by UHNM and their corresponding values (mg/L) 
from the purified serum ELISA results can be found within the appendix. 
To purify all the potential forms of CRP from all other constituents within human 
serum, all samples were run through a phosphocholine-bound affinity column in the presence 
of calcium. This will allow binding of the pentraxins to their natural ligand, PC. A total of 
40 human serum samples were obtained through the University Hospital of North Midlands 
from patients who exhibited raised levels of CRP (>100mg/L). The samples provided were 
anonymised and given a unique sample code (e.g. CRP 001). All 40 samples were analysed 
via the same methodology. Representative traces for the purification of human serum via 
affinity chromatography and size exclusion chromatography are shown in Figures 3.3 and 
3.4 respectively. All the results obtained from both methods followed the same trend as 
shown in Figures 3.3 and 3.4.  
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Figure 3.3 A chromatography trace of human serum ran through a phosphocholine-bound affinity column. Components within the serum which 
did not bind to the column, represented as peak 1, measured an absorbance reading of 0.54AU. Protein samples which bound to the column, peak 
2, had an absorbance reading of 0.05AU.  
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 The first peak gave a maximum absorbance reading of 0.54AU with the absorbance 
reading not returning to baseline levels (0AU) until just over 30 minutes had passed. The dip 
at the apex of peak represents where the entire sample had been loaded onto the column. 
Equilibration buffer was then run through the column until the absorbance reading had 
returned to baseline levels. The second peak on the chromatography trace occurs several 
minutes after the addition of the calcium chelator, Ethylenediaminetetraacetic acid (EDTA), 
which is shown from the second marker at the time point of around 46 minutes. The removal 
of calcium from the column by the addition of EDTA will result in the elution of any calcium 
dependent binding proteins, such as CRP, as they will no longer retain the ability to stay 
bound to phosphocholine. Peak 2 extends over a period of around 10 minutes and appears to 
exhibit a slight ‘shoulder’ before it reaches its apex, at an absorbance of 0.05AU. This 
magnified section is shown in Figure 3.3, which illustrates the ‘shouldering’ observed on the 
left-hand side of the peak, a common characteristic of the second peak in all the 
chromatography traces with human serum.  
 To separate out potential CRP forms based on their size, samples that had been run 
through the phosphocholine-bound affinity column were then run through a size exclusion 
chromatography column. The eluted sample obtained from peak 2 of the chromatography 
trace (see Figure 3.4) is a typical sample that was run through the size exclusion column. As 
all samples were run through the column using the same methodology, only one example 
image will be shown to represent the results acquired for the total cohort. The sample shown 
in Figure 3.4 (and 3.5) is from the sample labelled ‘CRP 052’. Any anomalous results or 
outliers that did not fit with the size exclusion chromatography data would have been 
identified; fortunately, all results obtained from the affinity chromatography purification 
followed the same trend. 
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 The sample was injected into the column at 0ml, with three main peaks observed and 
labelled as peaks 1, 2 and 3. The first peak in Figure 3.4 is broader and smaller than peaks 2 
and 3, and eluted off the column at a volume of 59.05ml with an absorbance of 0.5mAU. 
The elution volume indicates a protein at a size of 787kDa. Due to the peak size and position 
on the trace, coupled with calculated molecular weight of the protein, which does not match 
any previous experimental work or research documented for CRP, it was disregarded as 
insignificant for this experimental study.  
 The second peak in Figure 3.4 was sharper than the first peak and gave an absorbance 
reading of 1.6mAU. The elution volume of the peak was 72.92ml, which equates to a protein 
with a molecular weight of approximately 200kDa. Based on the elution volume and 
calculated molecular weight, the protein was concluded not to be relevant to our research 
and the eluted fraction was not pursued for further experimental research.  
The third peak represents the elution of pCRP from the human serum sample. The 
third peak displays a typical trace of pCRP when eluting off the size exclusion column, and 
is the most prominent and sharpest peak on the trace. The absorbance was measured at 
6.5mAu and was eluted off at 79.01ml. Based on this elution volume the molecular weight 
was calculated to be approximately 110kDa. The elution peak observed within all the human 
serum samples for pCRP is similar to that recorded for the pCRP in the dissociation trials 
and pCRP control from SCRIPPS. Additionally, previous runs on the size exclusion column 
show that the pCRP is eluted off in the B4+5 fraction tubes, with in vitro produced mCRP 
eluting off into the B7 + 8 fraction tubes (see Chapter 2). 
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Figure 3.4 A chromatography trace from the size exclusion column, representing what is a typical trace when running the human serum samples 
through the column. Pentameric CRP, as shown in peak 3, displayed an elution volume of 79.01ml. Peaks 1 and 2 displayed elution volumes of 
59.05 and 72.92ml respectively. It was unclear as to what these peaks represented. 
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Figure 3.5 displays a magnified area of the chromatography trace from elution 
regions of 70ml – 100ml, highlighting the elution volume and absorbance measurement for 
peak 3. Based on previous dissociation trials and size exclusion chromatography runs of 
control samples, markers 1 and 2 draw attention to where pentameric and monomeric CRP 
should elute off the column. Peak 3 is consistent with previous experimental work, as stated 
previously, but the absorbance reading remains at baseline level of around 0mAU at the 
region where mCRP elutes off (typically 94ml, giving a protein with the molecular weight 
of around 25kDa). Fractions B4 and 5, thought to contain pCRP were collected, in addition 
to fractions B7 and 8. Although no peaks were observed where mCRP should elute off, 
eluted fractions B7 and B8 were collected and tested nonetheless. This was to rule out mCRP 
levels being too little that the size exclusion column was unable to detect them, thus inducing 
an elution peak. All samples run through the size exclusion column were run at a flow rate 
of 0.5ml/min and the UV absorbance was measured at 280nm. Each of the pCRP and mCRP 
combined fractions was concentrated to give final volumes varying between 50 and 800µL, 
with this variation considered, when subsequently determining protein concentration of the 
samples. 
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Figure 3.5 A magnified section of the size exclusion chromatography trace from Figure 3.2 
(70-100ml). The region at which pCRP was eluted off the column is represented by marker 
1. The region at which mCRP is expected to elute off, based on previous in vitro studies, is 
represented by marker 2. It is clear from these results that mCRP failed to induce a peak in 
any of the traces when running human serum samples through the size exclusion column.  
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3.3.3 Enzyme-linked Immunosorbent Assay of the Eluted Serum Fractions 
 
 All purified human serum samples (fractions B4 &5 and B7 & 8) were subject to 
analysis via an ELISA. Analysis via an ELISA will allow quantitative determination of both 
pCRP and mCRP levels in all samples. Furthermore, ELISA offers an increase level of 
sensitivity compared to Western Blot analysis, thus being able to detect levels of protein 
which may be initially missed. To determine the levels of CRP in both sets of fractions, a 
calibration experiment must first be carried out with both pentameric and monomeric control 
samples.  
Graph a. 
 
Graph b. 
 
Figure 3.6. Calibration graphs for both monomeric and pentameric CRP. a) The calibration 
graph for pCRP. The line equation is: y = 20.712x + 0.0372. The R2 value is: 0.9967. b) The 
calibration graph for mCRP. Monomeric CRP used was dissociated via a 3M urea 
dissociation trial. The line equation is: y = 16.486x + 0.0132. The R2 value is 0.9922 
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Figure 3.6a and 3.6b displays the calibration graphs for both pCRP and mCRP 
respectively. The pCRP samples were purchased from SCRIPPS, whereas mCRP samples 
were produced in vitro from a 3M urea dissociation experiment (see Chapter 2). The R2 
displays a strong positive relationship between absorbance of protein concentration. 
Absorbance values are all below 1, indicating that absorbance is proportional to protein 
concentration for both calibration experiments. Line equations from both graphs were used 
to determine their respective CRP concentrations for the purified human serum samples.  
Figure 3.7 displays the levels of pCRP present within each of the combined fractions 
(B4 and B5) from all 40 human serum samples as determined by ELISA. The values obtained 
from ELISA have been corrected per the appropriate concentrated volume post FPLC (see 
3.3.2 and Appendix 5) to represent the concentration in the initial serum samples. All 40 of 
the samples tested positive for the presence of pCRP. The positive controls tested positive 
for pCRP whereas the negative controls did not (results are not included). Sample 
concentration is expressed in terms of mg/L and all results were triplicated. These results fit 
in line with those observed from the Western Blot analysis, which resulted in a positive band 
for all 40 samples (fractions B4 and B5). The lowest recorded value of pCRP within any of 
the samples was from CRP 021, which was calculated at 2.9mg//L, with the highest being 
recorded at 66.8mg/L for the sample ‘CRP 012’. The average value of pCRP recorded was 
23.3mg/L (SD for all 40 samples: 13.6, SE for all 40 samples ±2.1). As the requirement for 
participating in the study was to display an initial CRP reading of over 100mg/L, this 
indicates a significant loss of protein. This trend is also displayed throughout the main body 
of results, with none of the total forty samples displaying a CRP value >100mg/L, although 
as previously described, steps within the methodology used can result in losses of up to 50% 
of the sample with a poor return post-purification.
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Figure 3.7 Pentameric human serum CRP levels in the serum samples as determined by ELISA of fractions B4 & B5 purified via the FPLC. The 
concentration of each sample is expressed in terms of mg/L. Samples were diluted 1:100 in triplicate. Scores shown are an average value minus 
the average control. Primary and secondary antibody dilutions used were 1:40,000. ELISA plates were developed with TMB and read at 450, n = 
40. Error bars represented by SEM for each sample. 
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Purified pCRP (B4 + B5) samples were subject to additional protein quantification 
via the UV Spectrophotometer machine, as described in Section 2.2.5. The total CRP in the 
initial samples as calculated from the UV spectrophotometer measurements in the purified 
fractions was plotted against the levels calculated via the ELISA analysis to provide a 
quantifiable comparison. This comparison is shown in Figure 3.8 which provides an 
overview of the relationship between the two different techniques. The R2 squared value of 
0.46 indicates a slight correlation between the two sets of data; furthermore, observation of 
the chart clearly portrays a moderate, positive correlation within the data. 
 
Figure 3.8. A comparison of the pCRP levels calculated from the ELISA analysis against the 
data provided through the UV Spectrophotometer. The R2 value of the scatterplot was 
calculated at 0.46 and the line equation was as follows: y = 0.3994x + 9.313 
 
Purified mCRP human serum fractions (B7 & B8) from the FPLC were subject to 
analysis via an ELISA. Figure 3.9 displays the levels determined by ELISA of mCRP present 
within each of these combined fractions (B7 and B8) from all 40 human serum samples. The 
values obtained from ELISA have been corrected per the appropriate concentrated volume 
post FPLC (see 3.3.2) to represent the concentration in the initial serum samples. The 
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positive controls tested positive for mCRP whereas the negative controls did not (results are 
not included). Sample concentration is expressed in terms of mg/L and all results were 
triplicated. The entire 40 samples tested positive for the presence of the monomeric form of 
CRP (denoted as ‘mCRP’). These results show a significant increase in the number of 
positive samples compared to those observed from Western Blot analysis, which only 
detected positive bands for three samples (indicated by ELISA to be the three samples with 
the highest mCRP levels) highlighting the difference in sensitivity of the two techniques. 
Furthermore, this disproves the initial hypothesis that only 10% of the 40 patient samples 
would contain mCRP, when the actual value is 100% based on our results. The largest 
recorded value of mCRP within a sample was 3.5mg/L, with the average value from all 40 
samples being 0.88mg/L (SD for all 40 samples: 0.89, SE for all 40 samples ±0.142). The 
purified mCRP (B7 + B8) was also subjected to additional quantification via the UV 
Spectrophotometer. Unfortunately, as mCRP levels of the purified, concentrated fractions 
were so low, protein levels were undetectable.  
For the total cohort of 40 participants, all mCRP values recorded were significantly 
lower than those recorded for pCRP demonstrating an uneven split of these two proteins 
within serum. This was expected as raised CRP levels were a prerequisite to partake within 
this study and we hypothesised that pCRP would be the predominant form of CRP within 
human serum. It is worth noting that even though all 40 samples were positive for the 
presence of mCRP, some of these results were extremely low. These results are outlined in 
Table 3.5. 
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‘CRP’ Sample Code mCRP concentration (mg/L) 
027 0.08 
051 0.13 
096 0.04 
105 0.06 
Table 3.5 ELISA results from B7 and B8 fractions which recorded the lowest levels of mCRP 
out of those who tested positive. The concentrations are for the initial sample as calculated 
from the ELISA results.   
A comparison of the remaining samples for mCRP highlights several which display 
markedly increased levels of the protein (see Table 3.6). The three highest of these samples 
(115, 148, and 204) are those giving positive results from the Western Blot analysis of the 
mCRP fractions B7 & B8 (see below and Figures 3.11 and 3.12).  
‘CRP’ Sample Code mCRP concentration (mg/L) 
012 2.02 
115 3.52 
148 3.28 
204 3.51 
069 3.07 
Table 3.6 ELISA results from the B7 & B8 fractions which displayed markedly increased 
levels of mCRP compared to the remaining positive results. The concentrations are for the 
initial sample as calculated from the ELISA results.   
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Figure 3.9 Monomeric human serum CRP levels in the serum samples as determined by ELISA of fractions B7 & B8 purified via the FPLC. The 
concentration of each sample is expressed in terms of mg/L. Samples were diluted 1:10 in triplicate. Scores shown are an average value minus the 
average control. Primary and secondary antibody dilutions used were 1:40,000. ELISA plates were developed with TMB and read at 450nm, n = 
40. Error bars represented by SEM for each sample. 
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3.3.4  Western Blot Analysis of the Eluted Serum Fractions 
 
To determine the presence of CRP in the samples collected from the size exclusion 
column, Western Blot analysis was carried out. A commercially available, CRP specific 
monoclonal antibody (Clone 8, Sigma), was used to test the samples for CRP. Previous 
experimental Western Blot analysis, (see Chapter 2) demonstrates that the monoclonal 
antibody can interact with and bind to both pentameric and in vitro produced mCRP. The 
previous successful Western Blot analysis with in vitro produced mCRP indicates that the 
epitope for antibody (Clone 8) binding remains identical and structurally intact when 
compared to that of pCRP. Although potential forms of mCRP within human serum may not 
be structurally identical to that of in vitro produced mCRP, one can assume that the same 
readily available epitope may be present for antibody binding with in vivo samples. Fractions 
B4 & B5, thought to contain pCRP, along with B7 & B8, thought to potentially contain 
mCRP, were combined respectively and concentrated as described in 3.2.6.  
 Figure 3.10 shows a typical Western Blot analysis of the CRP samples from the 
combined fractions B4 & B5. The samples used (going from lanes 1-9) were CRP 108, 109, 
110, 115, 117, 120, 124, 146 and 148. All 9 of the samples tested were positive for the 
presence of pCRP through Western Blot analysis using a CRP specific monoclonal antibody 
(see Figure 3.4). Lane 10 consists of the pCRP control sample (from SCRIPPS), which the 
9 CRP samples were compared against. The control image is separate to that of the serum 
samples as it was exposed for a shorter period (15 minutes), compared to that of the serum 
samples (30 minutes). All 10 of the bands (including the control sample) were present around 
the 23kDa mark when compared to the molecular weight markers (as shown on Figure 3.10), 
which corresponds correctly with the individual subunit size of CRP (Shrive et al., 1996). 
The results shown in Figure 3.10 are typical of the Western Blot analysis seen for all 
combined fractions B4 & B5. Positive bands for pCRP were identified for all the 40 human 
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serum samples. All samples that were analysed via a Western Blot were compared to a 
positive control of pCRP and no anomalous results were found when testing fractions B4 & 
B5 for pCRP.  
 
Figure 3.10 A Western Blot of the size exclusion fractions B4 and 5 for samples; 108, 109, 
110, 115, 117, 120, 124, 146, 148. Samples are in lanes 1-9 respectively. Bands are present 
for all 9 of the serum samples tested. Lane 10 contains pCRP control (0.1µg). The primary 
mAb dilution was 1:1,000. The secondary mAb dilution was 1:40,000. Samples were 
exposed for up to 30 minutes.  
 
 Each of the mCRP samples collected from the size exclusion column were subjected 
to Western Blot analysis. Figure 3.11 and 3.12 shows the WB analysis of selected mCRP 
samples (going from lanes 1-9) 018, 021, 023, 109, 115, 148, 153, 175 and 207, 204, 201, 
200, 196, 191, 182, 171, 146 respectively. These two figures include the only samples from 
combined fractions B7 & B8 from all 40 of the human samples which gave a positive 
Western Blot result for mCRP. Lane 9 and 10 in both Figures 3.11 & 3.12 respectively, 
contains an in vitro produced monomeric control from a 3M urea dissociation trial (as 
described in section 2.2.1). The control sample images are separate images as they were 
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exposed for a shorter period (of 15 minutes), compared to that of the serum samples, which 
were exposed for 45 minutes. As hypothesised in section 3.1.4, we believed that if mCRP 
were to be present within serum, only a small proportion of the total CRP would be mCRP. 
Therefore, a smaller mAb dilution was used to ensure even the smallest amounts of protein 
were detected. Figure 3.11 shows two samples which were positive for a monomeric form 
of CRP; samples 115 and 148. The bands shown were consistent in their migration distance 
with the in vitro mCRP control. Furthermore, the bands were present around the 23kDa mark 
when compared to molecular weight markers, corresponding correctly to the size of an 
individual subunit for CRP (Shrive et al., 1996). 
 
Figure 3.11 A Western Blot of the size exclusion fractions B7 and 8 for samples; 018, 021, 
023, 109, 115, 148, 153 and 175. Samples are in lanes 1-8 respectively. Bands are present 
for samples 115 and 148. Lane 9 contains mCRP control (0.1µg). The primary mAb dilution 
used was 1:400. The secondary mAb dilution used was 1:20,000. Samples were exposed for 
up to 45 minutes.  
 Figure 3.12 shows the WB which gave a positive result for the human serum sample 
204. It is worth noting that WB analysis was performed on all purified mCRP samples. Those 
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which gave a negative result for all samples on one blot were not shown. As stated 
previously, the control samples were from in vitro produced mCRP from 3M urea 
dissociation trials. The band shown in Figure 3.12 is consistent with the control sample in 
its migration distance throughout the gel. The sample is present around the 23kDa mark 
when compared to the molecular weight markers, again corresponding to the size of a single 
subunit of CRP (Shrive et al., 1996). Unlike Figure 3.11, Figure 3.12 contains a considerable 
amount of background staining at the bottom of the membrane. This is due to two factors; 
the length of time which the samples were exposed for, in addition to small amounts of 
acrylamide sticking to the membrane post-SDS PAGE.  
 
Figure 3.12 A Western Blot of the size exclusion fractions B7 and 8 for samples; 207, 204, 
201, 200, 196, 191, 182, 171, 146. Samples are in lanes 1-9 respectively. A band is present 
for sample 204. Lane 10 contains mCRP control (0.1µg). The primary mAb dilution used 
was 1:400. The secondary mAb dilution used was 1:20,000. Samples were exposed for up 
the 45 minutes.  
 To ensure that results were not anomalous, or mistaken for background staining, the 
three samples which gave a positive result for the presence of CRP were tested several times.  
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3.4  Discussion  
 
3.4.1  Overview 
 
Here we describe the purification of human serum, through established procedures 
developed within our laboratory, alongside information provided within the scientific 
literature, to detect mCRP. We have successfully identified mCRP in all the 40 patient 
samples, with protein levels quantifiable via ELISA analysis. It was noted that purified levels 
of both pCRP and mCRP were markedly decreased when compared to the initial CRP 
concentrations provided by UHNM. Finally, we found that mCRP displays an ability to 
reversibly bind to PC through affinity chromatography, with Western Blot and size exclusion 
chromatography calculating the protein to have a molecular weight of approximately 23kDa. 
All CRP ELISA, UV Spectrophotometer and initial UHNM values can be found in a table 
in Appendix 5.  
3.4.2  Human Serum Sample Purification 
 
As human serum contains a crude mixture of proteins, platelets, hormones, among 
other components, a large proportion of the samples passed freely through the column, 
without interacting with the readily available PC units (Murphy et al., 2008). This is shown 
through the large absorbance value of 0.54AU in peak 1 of Figure 3.3. Upon addition of the 
calcium chelator, EDTA, a smaller secondary peak was observed, measuring an absorbance 
of 0.05AU. The second peak exhibited a slight ‘shouldering’ effect, just left to the apex of 
the peak, which was typical for most traces seen when purifying the human serum samples. 
The ‘shouldering’ effect could be a result of the slow progression of various PC-binding 
serum proteins being eluted off the column based on their binding affinity to the ligand. 
Alternative ligands which display higher binding affinities to PC may need to be immersed 
within the chelating buffer before to elicit the elution of the protein; this may explain the 
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common ‘shoulder’ observed on all the serum traces. It was assumed the bulk of peak 2 
represented the elution of CRP from the column, due to samples contained raised levels 
(>100mg/L), although other serum proteins are known to bind PC (Christner & Mortensen, 
1994).  
 Like that shown in Figure 3.3, the chromatography trace in Figure 3.4 was typical of 
that seen for all 40 patient serum samples. Three main peaks (labelled 1-3) were observed, 
representing molecular weights of 787kDa, 200kDa and 110kDa respectively. As we are not 
aware of any serum calcium binding proteins with a molecular weight around 787kDa, we 
concluded that this protein was not relevant to our study, as this did not correspond to any 
of our expected protein sizes. Therefore, sample analysis of this fraction was not pursued. 
Similar to peak 1, it was unclear what peak 2 may represent, based on the elution volume 
and calculated molecular weight. One hypothesis was that this protein may represent 
decameric forms of CRP, or CRP aggregates. As described previously, this peak was 
concluded to be not relevant to our study and the eluted fraction was not pursued through 
additional experimental analysis. Based on the elution volume of peak 3, the molecular 
weight for the protein was calculated to be 110kDa. Coupled with the data provided from 
the dissociation trials in Chapter 2, it was concluded that protein was pCRP. This was 
extended to all B4 & B5 fractions of human serum, when run through the size exclusion 
column. All 40 of the serum samples tested failed to produce a peak for mCRP. Previous in 
vitro trials, alongside the column calibration has allowed calculation of where the monomer 
is expected to elute (~95ml, B7 & B8 fractions). This failure to produce a peak on the 
chromatogram could be down to mCRP levels being too low for detection. Therefore, 
fractions B7 and B8 were collected for each serum sample and tested regardless.  
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3.4.3   Western Blot Analysis 
 
 As expected, the Western Blot results for fractions B4 & B5 gave a positive result 
for all 40 human serum samples. Samples also corresponded with the molecular weight of 
the pCRP control sample. Coupled with the molecular weight calculations from the size 
exclusion column, it was accepted that these samples contained pCRP from human serum. 
Fractions B7 & B8 (thought to contain mCRP) gave a positive band for the presence of CRP 
from three of the human serum samples, despite no peak being recorded on the 
chromatogram (Figure 3.4). The samples which tested positive for CRP were 115, 148 and 
204, the three highest serum mCRP concentrations as indicated by ELISA. The positive 
bands observed in Figures 3.11 and 3.12 corresponded to the molecular weight of the mCRP 
standard that was run alongside them (~23kDa). To our knowledge this is the first isolation 
and positive identification of mCRP through this procedure. Based on the molecular weight 
calculation from the size exclusion column, coupled with the positive bands from the 
Western Blot, these results suggest confirmation of the presence of a ‘monomeric’ form of 
CRP in human serum.  
3.4.4  Enzyme-linked Immunosorbent Assay Analysis 
 
ELISA analysis was carried out on all samples (fractions B4 & B5 and B7 & B8). A 
positive result was confirmed for all the 40 patient samples from fractions B4 & B5, which 
corresponds with the results observed from the Western Blot analysis. The average value of 
pCRP recorded was 23.3mg/L, with the minimum recorded value calculated to be 2.93mg/L 
and the maximum at 66.78mg/L. These results were further backed up by the additional 
quantification of the purified pCRP samples via the UV Spectrophotometer, as a comparison 
of the purified pCRP ELISA results with the quantified UV Spectrophotometer values 
suggested a weak positive correlation between the two sets of data. It is worth noting that 
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one of the main patient criteria for inclusion in this study was to have recorded CRP levels 
of >100mg/L. Comparison of these results with the CRP values provided through UHNM 
therefore suggests a large proportion of the protein within the sample was lost through the 
purification process. We have previously reported that large losses of the protein samples 
may occur through the concentrating and chromatography steps of the purification process 
(up to 50%), as described in Chapter 2.  
 ELISA analysis on fractions B7 & B8 resulted in all 40 patient serum samples being 
confirmed to contain mCRP. Comparison with the Western Blot analysis highlights a 
significantly larger proportion of mCRP samples went undetected; portraying the difference 
in sensitivity of the two different techniques. The average recorded level of mCRP within 
the serum samples was 0.88mg/L, with the minimum recorded value being 0.04mg/L and 
the maximum recorded value being 3.52mg/L (Sample ‘CRP115’). Four out of the 40 
samples which tested positive for mCRP displayed significantly lower results, as shown in 
Table 3.5. This ability of ELISA to detect even these low levels further highlights the 
difference in sensitivity of the two techniques. Overall, our results show that mCRP levels 
are significantly lower than those observed for pCRP, alongside levels being unevenly 
distributed throughout the cohort which tested positive for the protein. Our initial hypothesis 
was that we would expect to detect mCRP within 10% of our sample cohort, whereas ELISA 
analysis has confirmed mCRP to be present within all 40 samples, with Western Blot 
analysis confirming the presence of mCRP in 3 of the samples tested. What is significantly 
apparent, despite all the recorded loses when comparing the levels with those provided by 
UHNM, is that mCRP is still detectable at considerable levels when compared to previously 
published data (Wang et al., 2015). 
Based on the methodology used we can also conclude that the isolated form of mCRP 
retains the ability to reversibly bind to PC. Published literature has previously suggested that 
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pCRP dissociation occurs through membrane insertion, with cholesterol being identified as 
a key lipid component for mediating this interaction (Ji et al., 2009). Pneumococcal C-
polysaccharide (which contains PC units) and polylysine are also other ligands which have 
been identified as being able to bind and dissociate CRP. A hydrophobic microenvironment 
has also been proposed as a key component for CRP dissociation; cell membranes contain 
mild hydrophobic environments which could lead to rapid dissociation of the pCRP subunits. 
The mCRP described here, which has been isolated from human serum, displays an ability 
to bind and interact with its high affinity ligand, PC. Our results are in line with previous 
experimental models whereby CRP binds to cell surfaces to induce dissociation and elicit a 
pro-inflammatory response (Ji et al., 2007; Ji et al., 2009). 
 Previous data published by Wang et al., (2015) describe patients who recently 
suffered with an AMI with an average recorded mCRP serum level of 0.021mg/L (published 
as 20.96ng/ml, n = 101), with deceased patients recording higher levels up to 0.0367mg/L. 
Furthermore, a total of six patients out of 42 with raised levels of pCRP (3-285mg/L) 
displayed increased mCRP levels: 0.0057mg/L – 0.1227mg/. A comparison with the mCRP 
levels recorded from our study is an order of magnitude higher compared to those recorded 
by Wang et al., (2015). Our study however only enrolled patients with raised levels of 
(>100mg/L), whereas Wang et al., do not give details on how many of those 6 positive 
samples displayed initial pCRP levels >100mg/L.  
It is worth noting that a proportion of the protein sample was lost from each sample 
due to our methodology. The protein yields for the purified samples ranged from 5 up to 
30%. This links in with what has been previously reported for the purification of in vitro 
produced mCRP, as described in Chapter 2, with losses of up to 50%, which is thought to 
occur during the concentration and chromatography steps within the methodology. 
Furthermore, purification of in vivo CRP samples must undergo both affinity and size 
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exclusion chromatography, in addition to two concentration steps, which may explain the 
large protein losses reported here. Although it is not clear as to what percentage of pCRP or 
mCRP has been lost for each sample. Overall, our results demonstrate that there is an uneven 
distribution of pCRP and mCRP within the serum samples. If one of the two proteins were 
more susceptible to losses during the purification process, this could explain why some 
results displayed larger losses than others.  
Additional factors may need to be considered when evaluating mCRP levels and its 
production. Specific pathophysiological conditions commonly observed in certain 
inflammatory diseases may play a leading role in providing the essential conditions for the 
proteins formation. Epidemiological evidence associates high levels of CRP with the 
progression and development of inflammatory diseases such as atherosclerosis and heart 
disease. Common pathological features such as activated endothelial cells and platelets, and 
the production of circulating MP are all known to dissociate CRP. The production of reactive 
oxygen species in inflammatory diseases including atherosclerosis can permanently oxidise 
or modify proteins which may alter their biological and structural properties, although this 
is just theorising (Berlett & Stadtman, 1997; Mugge, 1998). Furthermore, mCRP has been 
detected within the serum of patients who have recently suffered an AMI, in addition to 
being identified in the extra-cellular matrix of patients suffering with Alzheimer’s disease 
(Ji et al., 2007; Ji et al., 2009; Khreiss et al., 2004; Salazar et al., 2014; Slevin et al., 2015). 
Alterations to normal physiological conditions during disease may provide the essential 
conditions needed for mCRP’s formation. The human body’s physiological pH range is from 
7.35-7.45. At sites of intensified inflammation, it is known to become slightly more acidic. 
As pCRP is known to bind to a wider range of ligands in acidic conditions, this may also 
provide the stimulus needed for its dissociation (Hammond et al., 2010; Kellum et al., 2004 
Sneck et al., 2005).  
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The evidence provided from our research, alongside the information we have 
discussed within the literature displays a strong consensus for an association between mCRP 
production and inflammatory disease. It is plausible that chronic inflammatory diseases may 
result in the formation of a vicious pro-inflammatory cycle involved around mCRP. The 
half-life of CRP is approximately 18 hours, with levels being determined by the rate of 
production and severity of the stimulus. This therefore means that following an acute 
infection, levels of CRP would drop down to baseline levels relatively quickly. However, 
during prolonged periods of chronic inflammation, this removal of CRP from localised sites 
within the body may be more onerous, thus resulting in the persistence of this cycle of 
inflammation.  
 These results may also have a significant impact in a clinical setting. As described 
previously, mCRP circulating on MP was undetectable through common plasma assays 
(Crawford et al., 2016). As we have shown, a monomeric form of CRP can be purified and 
isolated from human serum, in more samples and at higher levels than we initially expected. 
Raised levels of either protein within a patient may dictate a completely different set of 
circumstances, and require completely different treatment. This is especially shown in 
studies researching the potential diagnostic values and biological properties of mCRP in 
patients suffering with cardiovascular disease and AMI (Crawford, et al., 2016; Eisenhardt 
et al., 2009; Habersberger et al., 2013; Wang et al., 2015). If current standard clinical 
techniques and practice, such as ELISA, immunoturbidimetry and nephelometric assays, are 
unable to distinguish between the two isoforms, this could dramatically impact on a patient’s 
health and the treatment they receive.  
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3.4.5  Conclusions 
 
To our knowledge, these are the first published results which demonstrate clearly the 
isolation and detection, via Western Blot and ELISA analysis, of a monomeric form of CRP 
located within human serum. Experimentally determined levels for both mCRP and pCRP 
differed from those provided by UHNM, highlighting the scale of potential losses which we 
have observed can occur through the methodology used. Quantification of pCRP levels via 
the ELISA was further backed up by the values provided via the UV Spectrophotometer 
machine, with levels recorded displaying a weak, positive correlation with those from the 
ELISA. Furthermore, mCRP displayed an ability to reversibly bind to PC, something with 
has previously been reported not to occur. Previous studies have detected a mCRP in vivo, 
although the possibility of pCRP spontaneously dissociating upon binding to an ELISA plate 
still exists. By use of Western Blot analysis and size exclusion chromatography we could 
independently confirm the presence of mCRP.  
Our research has highlighted the need for development of a new methodology which 
could accurately determine mCRP levels from neat serum and provided several new avenues 
of research involving mCRP which may potentially be pursued. Furthermore, it is possible 
that this could instigate a change in the way we measure CRP levels in a clinical setting as 
increasing evidence for a monomeric form of CRP continues to emerge.  
3.4.6  Future Work 
 
Future work should involve researching into establishing a link between mCRP 
levels and inflammatory disease. It is crucial that we determine what predicts rises in levels 
of mCRP and furthermore what increased levels may correspond too. The formation of 
mCRP in vivo is also an avenue of research that should be pursued. Several research models 
currently exist with each one displaying overlapping elements. If we can uncover the 
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mystery of how this protein forms, it may provide us with an indication as to what biological 
role it may have within the body. 
 Finally, research needs to be focused on establishing a reliable methodology which 
could be used to accurately measure serum mCRP levels, without risk of the previously 
discussed complications. Multi-step methodologies also provide obvious complications such 
as low protein yield. The use of a mAb specifically for mCRP would allow measurement of 
the protein within neat serum; this removing the heavy losses sustained through the 
purification processes. These results highlight significant problems within a clinical setting, 
when measuring CRP, which need to be addressed. This research may provoke healthcare 
professionals to consider re-evaluating the way in which the approach CRP, both as a 
biomarker and mediator of inflammation and consider that research may be required to 
accommodate the testing of mCRP levels within the body. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4. Protein Crystallisation    Introduction 
  
167 
 
Chapter 4.0 – Protein Crystallisation 
4.1   Introduction  
 
4.1.1   The Crystallisation of Proteins 
 
 Protein crystallisation is the formation of a protein crystal, predominately used for 
scientific and industrial research. Proteins can be prompted to form a crystal within a solution 
that is supersaturated. This supersaturation causes protein molecules to form a lattice of 
repeating units (each unit known as a unit cell), held together by non-covalent forces. 
Structural biology researchers grow these protein crystals to determine the protein’s structure 
at an atomic level through X-ray diffraction. Incorporating additional proteins or ligands 
within crystal trials is also common, as this allows investigation into how proteins interact 
and/or bind with other components at an atomic level (Sherwood & Cooper, 2010). It is 
virtually impossible to predict the conditions at which a protein will crystallise, therefore 
suitable conditions must be found by trial and error. The protein solution must be at a 
sufficient concentration to promote crystal growth as well as being in a homogenous solution 
(Sherwood & Cooper, 2010). The protein solution should be ‘pure’, meaning that it is free 
from contaminating materials such as nucleotides, carbohydrates and other small molecules 
which may inhibit crystal growth. To grow protein crystals of sufficient quality that they will 
diffract to a high resolution, each unit cell, which forms the crystal lattice, needs to be 
identical. A homogenous solution promotes diffraction quality crystals as there is a higher 
chance of all the unit cells being identical (Lorber & Giege, 1992).  
4.1.2  The Formation of Protein Crystals 
 
There is no set time for which it takes a protein crystal to form; the crystallisation 
period can range from several hours up to several years. The formation of protein crystals 
occurs when protein molecules within the solution slowly aggregate together, because of 
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changes in energy dynamics, adopting one or a few identical orientations resulting in the 
formation of a three-dimensional lattice structure (Blundell & Johnson, 1976; Rhodes, 
2000). Repeating units of this lattice structure are known as ‘unit cells’, which are the 
smallest possible repeating unit required to generate a protein crystal. Unit cells are held 
together through non-covalent interactions, such as hydrogen bonds with the water 
molecules in between them.  
 To achieve the formation of these ordered crystal lattices, proteins are slowly 
precipitated out of an aqueous solution. The aggregation of the protein sample within a well 
occurs due to the precipitant, usually varying types of salt-based solutions, or large molecular 
weight polyethylene glycol (PEG), which draws water molecules away from the protein. 
Temperature, solution pH, protein concentration, protein purity and ionic strength are all 
factors which can also affect whether a protein will precipitate out and form an ordered 
crystal lattice (Rhodes, 2000). The slow and controlled removal of water molecules by 
evaporation raises both the protein and precipitant concentration, which sometimes gives 
rise to the formation of protein crystals (Rhodes, 2000). Slow precipitation is more likely to 
produce larger crystals, whereas rapid precipitation may result in smaller, poorly formed 
crystals or even an amorphous solid (Rhodes, 2000).  
 Crystal formation occurs in two stages, nucleation and growth. The nucleation step 
consists of the initial formation of molecular clusters from which crystals will grow. This 
stage requires protein and/or precipitant concentrations higher than those optimal for slow 
precipitation. If nucleation conditions persist, it will result in the formation of many nuclei, 
which can result in many smaller crystals, instead of very few larger protein crystals 
(Rhodes, 2000).  
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The solubility of a protein also determines how it will crystallise. If a protein crystal 
were placed in a solvent which is free of protein, this crystal will begin to dissolve; the crystal 
will stop dissolving when the protein concentration within the solution reaches a specific 
value. At this specific value, the rate at which the crystal loses protein molecules is the same 
as the rate at which it gains protein molecules is equal, and is said to be in equilibrium. The 
concentration of proteins in the solution at equilibrium is classed as the solubility (Asherie, 
2004). The solubility of a protein will vary on the solution conditions. Protein crystals will 
dissolve in under saturated solutions – where the protein concentration is below the protein 
solubility, but grow in supersaturated solutions. This supersaturation is needed to overcome 
the large activation energy barrier which exists when forming the crystal (Asherie, 2004). 
This barrier represents the free energy that is required to create the microscopic cluster of 
proteins – known as the nucleus – from which a protein crystal will eventually grow. Due to 
this energy barrier, nucleation rates can range from weeks to even years. If the 
supersaturation is too small, the nucleation rate will be too slow and crystals will not form 
in any reasonable amount of time. The point at which the rate of nucleation is large enough 
that spontaneous nucleation is observable is known as the ‘labile’ or ‘nucleation zone’ (see 
Figure 4.1). When the solution reaches the nucleation zone under the ideal conditions, 
protein molecules begin to aggregate and the concentration of free molecules falls. This 
process is shown in Figure 4.1. 
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Figure 4.1. A diagram adapted from Foelsch, (2015), representing the required conditions 
for protein crystal growth. The process consists of increasing the supersaturation of the 
protein in a solution with an optimum concentration of precipitant. This supersaturation 
increases as water molecules diffuse to the reservoir until a crystal structure is nucleated. 
When this point is reached, the supersaturating should be reduced to allow the crystals to 
grow, as indicated by the south facing arrow.  
 
 This reduction of free molecules within the solution is the point at which the protein 
crystals can then start to grow larger within the metastable zone, as shown by the dotted 
arrow in Figure 4.1. If the nucleation rate becomes too high, small ’showers’ of crystals may 
appear. This can be problematic as the crystals formed are often too small to test for 
diffraction. Finally, if the supersaturation zone is too high, this will result in the formation 
of precipitants or aggregates within the solution. This precipitation zone is unfavourable for 
crystal growth due to the formation as the disordered aggregates and precipitates form faster 
than the crystals (Asherie, 2004, Rhodes, 2000).  
There are several well-known methods in which protein crystals can be grown, such 
as dialysis methods, batch methods or by vapour diffusion. There are also variations to the 
vapour diffusion technique, which differ depending on where the drop, containing the 
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protein solution, sits within the well. These are hanging drop, sitting drop and sandwich drop 
(Lorber & Giege, 1992). The sitting drop method of protein crystal growth is the technique 
used within this research project. The vapour diffusion method is carried out by using a tray 
with wells that contain different crystallisation conditions. Vapour diffusion is the most 
commonly employed diffusion technique used in protein crystallisation. For the sitting drop 
method, a droplet of the purified protein solution, buffer and precipitant are added to a small 
bridge sitting within the well, which contains a reservoir solution of the buffer and 
precipitant. The whole system is sealed, usually with a glass cover slip and vacuum grease. 
Over time, the reservoir solution, which contains a higher concentration of the precipitant, 
will equilibrate with the droplet, until the pressures in both are equal. As the droplet and 
reservoir solutions equilibrate, water within the droplet is removed, raising the concentration 
of the precipitant and protein solution. This system is represented in Figure 4.2. 
 
Figure 4.2. A diagram representing the vapour diffusion method used for the crystallisation 
of proteins. The protein solution is clearly displayed in the bridge, with the reservoir solution 
labelled below. The net diffusion of water molecules from the drop, represented by the 
arrows, to the reservoir slowly increases the protein concentration within the drop. Once 
optimal conditions are reached, protein crystals may form. The whole system is sealed with 
a cover slip and vacuum grease, as labelled above. 
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If the appropriate crystallisation conditions are reached within the droplet, the protein 
molecules within the droplet will slowly aggregate together to form a protein crystal 
(Glusker & Trueblood, 1985). Optimum crystallisation conditions for a protein (or complex) 
are usually unknown. In order to produce diffraction quality protein crystals that can be used 
for X-ray crystallography, many different trials will likely be used. Structure screens are 
commercially available which typically provide a set of 100 conditions that have previously 
been successful when growing protein crystals. When a specific condition produces a protein 
crystal, the condition can be ‘screened’. Two-dimensional screening grids allow alterations 
of two variables (usually precipitant and ionic concentrations) to allow refinement of the 
condition in order to produce the best quality protein crystals (Rhodes, 2000). 
 There is a range of different precipitants that can be used in the formation of protein 
crystals. The most common precipitant used is salt-based precipitant, whereby the ions 
compete with the water molecules within the drop. This process is known as ‘salting out’. 
Ions with a greater charge are usually better at salting out as they provide greater competition 
for the water molecules. As more water molecules are taken up, the proteins are forced closer 
together, which can result in the formation of a protein crystal. Other forms of precipitants 
commonly used for protein crystallisation are methyl pentanediol (MPD) and large 
molecular weight polyethylene glycol (PEG).  
 Other conditions which may affect the growth of protein crystals include pH and 
temperature. Alterations of the pH of a protein can change its solubility, and therefore its 
ability to form a protein crystal. Proteins with a larger charge, compared to those with no net 
charge at all tend to be more soluble, so subtle changes to this could alter both the quality of 
the crystal or even its ability to form. Crystals are often grown at room temperature. Crystals 
that are grown in 4oC (for example) would have to be viewed in the temperature that they 
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were grown in, otherwise the crystal well would be forced to undergo temperature changes, 
adding unnecessary complications to the system (Lorber & Giege, 1992; Rhodes, 2000).  
 Protein crystals are also very fragile. Unlike small molecule crystals, the spaces 
between proteins within the crystal lattice are typically filled with a high percentage of 
solvent. The protein crystals are therefore never removed from their mother liquor for fear 
of drying out. Water loss from these protein crystals can thus result in the crystals cracking 
or even breaking apart, which would result in them being unusable, thus diminishing in their 
quality (Lorber & Giege, 1992). 
 Sometimes, during protein crystallisation trials, protein crystals may crystallise in 
more than one form (Rhodes, 2000). Often these crystal forms will differ in their quality of 
diffraction, ease of reproducibility and potentially in other properties too. Protein crystals 
which take more symmetrical shapes are preferred, as these are the crystals which diffract 
well and require less data collection, although with current advances in crystallography 
research, this is no longer a big issue (Rhodes, 2000). The slow precipitation of organic 
solvents or highly concentrated salt-based solvents within an aqueous solution can form 
crystals known as small molecule crystals (up to 200 atoms). The growth of small molecule 
crystals when trying to crystallise proteins can be problematic for some crystallographers, 
as it is difficult to distinguish between the two. The easiest method of determining a small 
molecule crystal will be upon X-ray diffraction, where diffraction patterns characteristic of 
small molecule crystals will be visible.  
4.1.3  Cryoprotection of Protein Crystals 
 
 Protein crystals are flash-frozen in liquid nitrogen before they are exposed to X-ray 
radiation to provide diffraction patterns. The extremely cool temperatures of the liquid 
nitrogen help reduce the atomic vibration and diffusion as well as the level of radiation 
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damage by free radicals produced by the X-rays, increasing the resolution of the data 
collected (Rhodes, 2000). Prior to freezing the crystals, they must be soaked in a 
cryoprotectant, which displaces the water molecules within the crystal pores. This removal 
of water prevents ice forming within the crystal lattice, which can disrupt the lattice 
formation in addition to the formation of unwanted ice rings on the diffraction pattern 
(Lorber & Giege, 1992). Common cryoprotectants used are sugars including glucose or 
glycerol, as well as precipitants like MPD or a low molecular weight PEG. Once the protein 
crystal has been soaked in increasing volumes of cryoprotectant, it is removed by a loop 
where it is suspended in a thin film of the protectant, as shown in Figure 4.3. This is then 
flash frozen by immersing the loop into liquid nitrogen and kept in a cold stream of liquid 
nitrogen until testing (Rhodes 2000).  
 
Figure 4.3. A diagram of the crystal loops which are used to transfer protein crystals from 
the well in which they were grown to a vial containing liquid nitrogen. Loop sizes will vary 
depending on the size of the protein crystal in question. The above diagram also displays a 
protein crystal immersed in a film of solvent and cryoprotectant. This helps prevent 
degradation of the crystal upon freezing. The crystal is flash-frozen into liquid nitrogen and 
stored until tested at DLS. 
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4.1.4  Monomeric C-reactive Protein in the Human Body 
 
 The atomic structure of native pCRP was first determined by Shrive et al., (1996), to 
a resolution of 3.0Å via X-ray crystallography. Following this, the structure for calcium-
depleted pCRP and pCRP bound to PC was solved (Ramadan et al., 2002; Shrive et al., 
1996; Thompson et al., 1999). These three-dimensional maps of native CRP provide a 
detailed insight into what the structural arrangement of a monomeric form of CRP in vivo 
could be. To our knowledge there are no current studies which have attempted to crystallise 
this native or ligand-bound structure. Doing so may provide an insight into the biological 
role of mCRP within the human body. Published reports within the scientific literature have 
postulated that mCRP is ‘membrane-bound’, ‘modified’ and ‘a monomeric protein’. 
Dissociation models, supported by experimental research, suggest an ability of this protein 
to bind to cell membranes, thus stimulating dissociation of the native pentameric molecule. 
As previously discussed (Chapters 2 & 3), there is also increasing evidence for a pro-
inflammatory role of mCRP within the human body, further linking this protein to the 
progression of disease. (Eisenhardt et al., 2009; Habersberger et al., 2012; Ji et al., 2007; Ji 
et al., 2009; Li et al., 2012; Molins et al., 2008; Slevin & Krupinski, 2009; Zhao & Shi, 
2010). 
4.1.5  The Interactions between C-reactive Protein, C1q GHR and CWPS 
 
The binding mechanism between C1q and CRP has been debated over previous years 
to occur through either the collagen like region (CLR) of the C1q protein, or the globular 
head region (GHR) (Jiang et al., 1991; Jiang et al., 1992). More recent experimental research 
involving protein binding models coupled with amino acid mutagenesis studies provide a 
strong argument for binding to occur through the GHR; although this is still not known for 
certain (Agrawal et al., 2001; Gaboriaud et al., 2003; Kishore et al., 2004). Furthermore, to 
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elicit a sufficient immune response, CRP must additionally be bound to its primary ligand 
phosphocholine exposed on the surface of dead or damaged cells (Shrive et al., 1996; 
Thompson et al., 1999; Volanakis, 1982). It is also unknown whether CRP undergoes any 
conformational changes upon binding to phosphocholine (PC) to provide this immunogenic 
stimulus within the human body. 
4.1.6  Experimental Aims 
 
 The experimental aims of the research within this chapter are focused on the 
crystallisation of two different forms of CRP. The first involved in vitro produced mCRP 
from 3M urea dissociation studies described in Chapter 2. Although structural determination 
of this protein may not directly reflect that of an in vivo form of mCRP it will provide a 
general overview of the arrangement of a monomeric unit of CRP. Furthermore, it will 
uncover any modifications that may have occurred through treatment with urea.  
 The latter part of this research involves the crystallisation of the complex C1qGHR, 
CRP and CWPS. As described above, activation of the classical complement pathway 
requires binding to both C1q and a ligand, such as CWPS. By uncovering any structural 
changes that occur within CRP upon ligand binding, alongside the interactions between CRP 
and C1q will provide a greater understanding of pCRP’s role within inflammation and the 
human body.  
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4.2  Materials and Methods  
 
4.2.1  Preparation of Monomeric C-reactive Protein 
 
 All native human CRP used within the crystallisation trials is purchased in >99% 
purified form from SCRIPPS laboratories, San Diego, California, USA. Human pCRP was 
provided in a solution of: 20mM Tris, 280mM NaCl, 5mM CaCl2, 0.1% NaN3, pH 8.0. The 
protein was stored at 4oC until use. Monomeric CRP used within all the crystallisation trials 
was produced and purified from the purified native human CRP as described in sections 
2.2.1 and 2.2.2 of Chapter 2. 
4.2.2  Crystallisation Trails of Monomeric C-reactive Protein 
 
For the crystallisation trials, the human mCRP was used at a concentration of 
4.3mg/ml (0.187M). All crystallisation trials consisted of mCRP with no ligand. All protein 
used within the crystallisation experiments had been stored at 4oC within the lab for no 
longer than 6 months. Due to the lengthy process of mCRP production, coupled with a poor 
percentage yield from the purification process, a continuous flow of dissociation 
experiments was set up to replenish mCRP stocks. This therefore prevented the total 
exhaustion of the mCRP stocks, in addition to the purified protein being stored in the lab for 
extended periods of time.  
 All crystallisation trials used chemicals purchased from either Sigma or Fisher 
Scientific. Both structure screens 1 and 2 used in the initial crystallisation trials were 
purchased from Molecular Dimensions (cacodylate-free). All stock solutions of buffers were 
filtered through a 0.2µm Ministart Plus filter (Sartorius Vivascience, Hanover, Germany) to 
remove any particulate matter and microorganisms.  
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The sitting drop vapour diffusion crystallisation method was used with Linbro 24 
well plates (MP Biomedicals Inc., Ohio, USA), microbridges (Molecular Dimensions), and 
coverslips (Menzel-Glaser, Braunschweig, Germany) sealed with high vacuum grease (Dow 
Corning, USA). A reservoir of 1ml crystallisation buffer was used per well containing the 
precipitating agent. Droplets of 1:1 ratio for protein to crystallisation buffer were placed in 
the microbridge at a total volume of 2µl, thus meaning the final concentration of mCRP 
within the drop was 2.15mg/ml (0.094M). All crystallisation plates were stored at room 
temperature and monitored for crystal growth using a Leica Mz16 microscope. Photographs 
of crystals were taken using a Pentax digital camera mounted on the microscope. The protein 
crystal dye IZIT (1µL) was added to one of the wells to determine whether the crystals grown 
were protein or small molecule.  
4.2.3  Cryoprotection of Monomeric C-reactive Protein Crystals 
 
 The cryoprotectants used for crystals produced from crystallisation trials with mCRP 
were MPD and PEG 400 as both have previously shown to be reliable cryoprotectants within 
our research group. All cryobuffers were made with the cryoprotectants at 5, 10, 15 and 20% 
in the precipitant buffer specific to each well. The protocol for cryoprotection of crystals 
involved the addition of a 2µl droplet of the 5% cryoprotectant. This is followed by the 
addition of 2µl of the 10, 15 and 20% cryoprotectant at two to five minute intervals 
respectively. A further two drops of 2µl of the 20% cryoprotectant is added sequentially at 
two to five minute intervals. An exchange was then carried out by the removal of 10µl from 
the drop within the microbridge, and a replacement volume of 10µl of the 20% 
cryoprotectant added. Crystals were removed in the loop and immediately flash frozen in 
liquid nitrogen in which they were stored until tested at Diamond Light Source (DLS).  
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4.2.4  Data Collection at Diamond Light Source 
 
  All crystals that were produced from the human mCRP crystallisation trials were 
tested at DLS in Didcot, Oxfordshire. The stations that the crystals were tested were I02 and 
I04. The detector at the DLS stations for I02 and I04 was the ADSC Q315 CCD. 
4.2.5  Production of the C1q Globular Head Region 
 
 Human C1q was purchased in a >99% chromatographically purified and lyophilised 
form from BioRad. Chemicals used for buffers for the digestion of intact C1q are highlighted 
in Table 4.1.  
Buffer Used Chemical Components 
Solubilising Buffer A (pH 7.4) 
0.1M Tris BASE 
0.2M NaCl 
Solubilising Buffer B (pH 7.4) 
0.1M Tris BASE 
0.2 NaCl 
0.05M Calcium Acetate 
Dialysing Buffer 1 (pH 7.4) 0.1M Tris 
Dialysing Buffer 2 (pH 7.0) 
1M Sodium Citrate 
0.2M NaCl 
Table 4.1 A Table listing all the chemical components used in the buffers for the enzymatic 
digestion of intact human C1q with the collagenase enzyme. Concentrations of all the 
chemical components used are also given.  
1mg of lyophilised, intact C1q was dissolved in 5ml of solubilising buffer A and 
dialysed using tubing with 3.5 MWCO against 1L of dialysing buffer 1 overnight. The 
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sample was then removed from dialysis and transferred to a 15ml tube and spun in a 
centrifuge at 4oC, 1000 x g for 15 minutes to collect the precipitate at the bottom of the tube. 
The supernatant was removed and transferred to a separate tube and stored at 4oC. The 
precipitate was re-dissolved in 5ml of solubilising buffer B.  
 1mg of collagenase was dissolved in 1ml of deionised water. The C1q solution was 
heated in a water bath at 54oC for 10 minutes, after which 200µl (0.2mg) of collagenase was 
added to the solution, which was then immediately removed from the water bath. The 
solution was left at room temperature for 1 hour, and then transferred to the cold room, at 
4oC, until a precipitate formed. The precipitate was removed from the digest by 
centrifugation at 4oC, 1000 x g for 15 minutes. The supernatant was removed and dialysed 
in dialysis tubing with a 3.5 kDa MWCO against 1L of dialysing buffer 2 for up to 48 hours 
at 4oC. The resulting precipitate was collected by centrifugation at 4oC, 1000 x g for 15 
minutes and re-dissolved in 100µl of solubilising buffer A. The following sample was 
denoted as C1qGHR. The protein concentration of the solution was determined by UV280nm 
absorbance, as described in section 2.2.5, using the extinction coefficient for C1qGHR 0.982 
(Gaboriaud et al., 2003).   
4.2.6  SDS PAGE of Human C1q Globular Head Region 
 
 Samples were run on a 12.5%T resolving, 4%T stacking SDS PAGE. Gels were cast 
as described in section 2.2.6. Reduced and non-reduced C1qGHR samples of 1µg were 
applied to the gel, alongside 1µg of intact C1q and molecular weight markers. Samples were 
prepared as described in section 2.2.6 in addition to the buffers used in the SDS PAGE.  
Collagenase samples were also run on a separate SDS PAGE gel. 1µg of fresh 
collagenase was run alongside 1µg of collagenase that had been used for the digestion of 
intact C1q and molecular weight markers (all under non-reducing conditions). The 
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components used for the casting, running of the gel and sample preparation are as described 
in section 2.2.6. All gels were run for 45-50 minutes at 200V.  
 Once the enzyme control SDS PAGE had been run, the gel was transferred to 
Coomassie Brilliant Blue total-protein stain and left to develop for up to 30 minutes. The gel 
was rinsed with deionised water prior to imaging to remove any background staining. The 
SDS PAGE gel containing the C1qGHR samples was subject to silver staining, a highly 
sensitive method for staining protein gels compared to using Coomassie Brilliant Blue.  
4.2.7  Silver Staining SDS PAGE Gels 
 
 All components used in the silver staining of SDS PAGE gels were purchased from 
either Sigma or Fisher Scientific. The gel containing the C1qGHR samples was washed 
twice with deionised water to remove any remaining running buffer from the surface of the 
gel. A 10% ethanol solution was added to the gel and left in a dark room on the rocking 
machine for ten minutes. The gel was then immersed in a second 10% ethanol solution of 
left for 30 minutes (the gel can be left overnight at this period). Following this a 0.7% nitric 
acid solution was added to the gel for 6 minutes and then washed thoroughly with deionised 
water. The gel was the immersed in 0.1% w/v silver nitrate and placed in a dark room on the 
rocking machine for 30 minutes. The gel was then rinsed thoroughly with deionised water 
and approximately 100ml of developing solution was then added (250µl of formaldehyde 
per 200ml of sodium carbonate solution, 22.9g/L). Once the developing solution appeared 
to turn a black/grey colour, it was disposed of, with fresh developing solution being added 
to the gel. Once the gel had been developed to the desired intensity the gel was covered 3% 
acetic acid and left for 5 minutes prior to imaging.  
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4.2.8   Initiation of the Complex Crystallisation Trails 
 
All native human CRP used within these crystallisation trials is purchased in >99% 
purified form from SCRIPPS laboratories, San Diego, California, USA. The human CRP 
was provided in a solution of 20mM Tris, 280mM NaCl, 5mM CaCl2, 0.11% NaN3, pH 8.0. 
The protein was stored at 4oC until use. The C1qGHR was purchased and produced as 
described in section 4.2.5. Pneumococcal CWPS was purchased from Statens Serum Institut, 
Copenhagen, Denmark in a lyophilised form. Upon use, CWPS was dissolved in 20mM Tris, 
280mM NaCl, 5mM CaCl2, 0.11% NaN3, pH 8.0 to the appropriate concentration. The CRP 
and C1qGHR samples were concentrated to the appropriate concentration using Amicon 
10kDa MWCO centrifugal filter devices, pre-rinsed with deionised water, at a force no 
higher than 1000 x g at 4oC. The final concentration of the solution was measured using a 
spectrophotometer with UV absorbance at 280nm, as described in section 2.1.5. The protein 
samples (and CWPS) were either used immediately for crystallisation trials or stored at 4oC.  
 Both ProPlex structure screens 1 and 2 used in the initial crystallisation trials were 
purchased from Molecular Dimensions (cacodylate-free). All stock solutions of buffers were 
filtered through a 0.2µm Ministart plus filter (Sartorius Vivascience, Hanover, Germany) to 
remove any particulate matter and microorganisms. For the crystallisation trials, the native, 
human CRP was used at a concentration of 13mg/ml (0.11mM). The C1qGHR was used at 
a concentration of 5.6mg/ml (0.11mM) and the CWPS was used in excess, at a concentration 
of 175mg/ml (26.66mM). CRP and C1qGHR were incubated 24 hours at a volume ratio of 
1:1 prior to the addition of CWPS. The CWPS was then added to the solution at a volume 
ratio of 1:1:1, this was denoted as the complex stock solution. 
 The sitting drop vapour diffusion crystallisation method was used with Linbro 24-
well plates (MP Biomedicals Inc., Ohio, USA), microbridges (Molecular Dimensions), and 
Chapter 4. Protein Crystallisation    Materials and Methods 
  
183 
 
coverslips (Menzel-Glaser, Braunschweig, Germany) sealed with high vacuum grease (Dow, 
Corning, USA). A reservoir of 1ml of crystallisation buffer was used per well containing the 
precipitating agent. Droplets of a 1:1 ratio for the complex stock solution to crystallisation 
buffer were placed in the microbridge at a total volume of 2µl. All crystallisation plates were 
stored at room temperature and monitored for crystal growth using a Leica Mz16 
microscope. Photographs of crystals were taken using a Pentax digital camera mounted on 
the microscope.  
4.2.9  Cryoprotection 
 
The cryoprotectants used for crystals produced from crystallisation trials with native 
CRP, C1qGHR and CWPS were Glycerol, PEG 400 and PEG mono-methyl ether (MME) 
550. The protocol for cryoprotection is as described in section 4.2.3. All cryobuffers were 
made with cryoprotectants at 5, 10, 15 and 20%. All crystals were removed in the loop and 
immediately flash frozen in liquid nitrogen in which they were stored until tested at DLS.  
4.2.10   Diamond Light Source 
 
All crystals that were produced from the complex crystallisation trials were tested at 
DLS in Didcot, Oxfordshire. The stations that the crystals were tested were I02 and I04. The 
detector at the DLS stations used was the ADSC Q315 CCD.  
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4.3   Results 
 
4.3.1   Crystallisation Trails of Monomeric C-reactive Protein 
 
The first half of these protein crystallisation experiments are dedicated to the 
crystallisation of an in vitro produced form of mCRP from our own developed 
methodologies (see Chapter 2). The initial crystallisation conditions involving the in vitro 
produced mCRP were chosen based on a range of conditions which have previously been 
successful in the crystallisation of pentraxins within our research group. These conditions, 
containing PEG, 2-(N-morpholino) ethane sulfonic acid (MES) and calcium chloride are 
shown in Table 4.2 Unfortunately after several months of monitoring these trials, no crystal 
growth was observed.  
 1 2 3 
A 
4% PEG 6K, 10mM 
CaCl2, 50mM MES, pH 
7.0 
7% PEG 6K, 10mM 
CaCl2, 50mM MES pH 
7.0 
10% PEG 6K, 10mM 
CaCl2, 50mM MES, 
pH 7.0 
Table 4.2 Details of the initial crystallisation conditions for in vitro produced human mCRP. 
The conditions used were based on previous pentraxin crystallisation conditions which have 
proved successful in growing protein crystals.  
 
 Following on from the initial crystallisation trials, two structure screens containing a 
total of 50 conditions each, which have been documented to successfully grow protein 
crystals was used. Details for both structure screens used in the mCRP crystallisation trials 
can be found in Appendix 3. All conditions from the structure screens which showed a 
potential to grow protein crystals were further screened for optimisation of growth.  
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 Several weeks after the initiation of structure screen 1, the condition 0.2M 
Ammonium Sulfate, 25% PEG 4000, 0.1M Sodium Acetate pH 4.6, produced two small 
rectangle shaped crystals, as shown in Figure 4.4. 
 
Figure 4.4 Two small rectangle shaped crystals produced from the condition 0.2M 
Ammonium Sulfate, 25% PEG 4000, 0.1M Sodium Acetate pH 4.6 from structure screen 
1.Both crystals are identifiable by the arrows included in the Figure. The scale shown 
represents 200µm. 
 
 The crystal shown on the top right of Figure 4.4 was frozen in liquid nitrogen on the 
13/04/2015 and tested at DLS on 19/04/2015. The crystal was cryoprotected prior to 
freezing. Whilst testing the crystal at DLS, it was noted that the crystal had degraded slightly 
in shape, with the edges appearing rounded. No diffraction pattern was observed from the 
crystal. 
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 Four weeks after the start of the structure screen trial, three shard-like crystals, all 
joined together appeared in the well RW06A4 (see Figure 4.5). The condition of the well 
was 3.4M 1,6-Hexanediol, 0.2M Magnesium Chloride Hexahydrate, 0.1M Tris, pH 8.5.  
 
Figure 4.5 Three shard-like crystals, all joined together from the condition 3.4M 1,6-
Hexanediol, 0.2M Magnesium Chloride Hexahydrate, 0.1M Tris, pH 8.5. The condition is 
from structure screen 1 of the mCRP crystallisation trials.The crystal cluster is identifiable 
via the arrow included in the Figure. The scale shown represents 100µm.  
 
The crystal shown in Figure 4.5 was frozen in liquid nitrogen on the 01/12/2014 and 
tested at DLS on the 03/12/2014. Prior to the freezing of the crystal, it was broken apart into 
three separate pieces. Two out of the three crystals were tested, but unfortunately no 
diffraction patterns were observed. To improve the size and quality of the crystal shown in 
Figure 4.5, the condition was followed up with a three by three screen. The follow up trial 
involved the concentration of magnesium chloride and 1,6-hexanediol being altered by 
increments of 0.1 and 0.2M respectively either way. This is shown in Table 4.3.  
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 A B C 
1 
3.2M 1,6-Hexanediol, 
0.1M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
3.4M 1,6-Hexanediol, 
0.1M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
3.6M 1,6-Hexanediol, 
0.1M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
2 
3.2M 1,6-Hexanediol, 
0.2M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
3.4M 1,6-Hexanediol, 
0.2M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
3.6M 1,6-Hexanediol, 
0.2M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
3 
3.2 M 1,6-Hexanediol, 
0.3M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
3.4M 1,6-Hexanediol, 
0.3M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
3.6M 1,6-Hexanediol, 
0.3M Magnesium 
Chloride Hexahydrate, 
0.1M Tris, pH 8.5 
Table 4.3 The conditions described above are a follow up study from the condition 3.4M 
1,6-Hexanediol, 0.2M Magnesium Chloride Hexahydrate, 0.1M Tris, pH 8.5. See Figure 4.5 
for the crystal produced from the initial crystallisation well. Conditions highlighted in yellow 
were those that further produced crystals in the follow up trial.  
 
After several months of monitoring the follow up crystal trial, as described in Table 
4.3, two rod shaped crystals appeared in the well C2, surrounded by thin spindle-like 
crystals. Both crystals from C2 smaller than previously seen in Figure 4.5. Small rectangular 
shaped crystals surrounded by thin, spindle-like crystals also appeared in C3. Conditions 
which produced crystals in the follow up study are highlighted in yellow (see Table 4.3). 
Images of the crystals grown in both follow up conditions are shown in Figure 4.6a and 4.6b. 
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Figure 4.6. Rod-shaped crystals growing in both wells C2 and C3. a) Two rod shaped crystals 
surrounded by very thin spindle-like structures grown in C2 from the follow up study 
described in Table 4.3 (shown in yellow). b) Small rod shaped crystals, again surrounded by 
spindle-like structures within the well. The crystals shown were grown in C3 from the follow 
up study described in Table 4.3 (shown in yellow). The crystals in question are identifiable 
in both Figures via the arrows. The crystals observed in both Figures were noted to be a 
different form than the crystal grown in the original well (Figure 4.5). The scale in both 
images represents 100µm.  
 
Crystals from both Figure 4.6a and 4.6b were frozen in liquid nitrogen on the 
08/07/2015 and tested at DLS on the 12/07/2015. Due to the conditions that the crystals had 
been grown in, no cryoprotectant was used. One crystal was frozen from well C2 and two 
crystals were frozen from well C3. Unfortunately, when tested, the crystals appeared to be 
small molecule crystals, and not protein crystals based on their diffraction pattern. 
 Four weeks after the start of the first structure screen trial, tiny, rod-like crystals 
started to form (see Figure 4.7). The condition of this well was 70% MPD, 0.1M Sodium, 4-
(2-Hydroxyethyl) Piperazine-1-Ethanesulfonic Acid (HEPES), pH 7.5. The crystal growth 
in the well is shown in Figure 4.7.  
a b 
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Figure 4.7 Small, rod-like crystals dispersed throughout the drop from the condition 70% 
MPD, 0.1M Sodium HEPES, pH 7.5. The condition is from structure screen 1 of the mCRP 
crystallisation trials. The arrow included in the Figure identifies one of the many crystals 
observed within the well. The scale shown represents 100µm.  
 
The rod-like crystals shown in Figure 4.7 were too small for testing at DLS. In order 
to improve the size and quality of the crystals shown in Figure 4.7, the condition was 
followed up with a three by three screen. The concentration of MPD and sodium HEPES 
was varied by an increment of 5% and 0.05M respectively. Details for the crystallisation 
follow up study can be found in Table 4.4. 
 A B C 
1 
70% MPD, 0.1M 
Sodium HEPES, pH 7.5 
70% MPD, 0.1M 
Sodium HEPES, pH 7.5 
70% MPD, 0.1M Sodium 
HEPES, pH 7.5 
2 
70% MPD, 0.1M 
Sodium HEPES, pH 7.5 
70% MPD, 0.1M 
Sodium HEPES, pH 7.5 
70% MPD, 0.1M Sodium 
HEPES, pH 7.5 
3 
70% MPD, 0.1M 
Sodium HEPES, pH 7.5 
70% MPD, 0.1M 
Sodium HEPES, pH 7.5 
70% MPD, 0.1M Sodium 
HEPES, pH 7.5 
Table 4.4 The conditions described above are a follow up study from the condition 70% 
MPD, 0.1M Sodium, HEPES, pH 7.5. See Figure 4.7 for the crystals which were produced 
from the initial crystallisation trial. Wells which are highlighted in yellow were successful 
in growing crystals in the follow up trial.   
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  After a week of monitoring the follow up crystallisation trial described in Table 4.4, 
rod shaped crystals appeared in the well A2. A large proportion of the rod-shaped crystals 
were multiple crystals, in addition, there were also several rhombus-shaped crystals 
dispersed throughout the drop. Both forms of crystals appeared to be larger than those 
previously shown (see Figure 4.7). A blue dye called IZIT (Hampton Research) was added 
to the well, which is known to stain some protein crystals dark blue, however the crystals 
did not take up the dye. An image of the crystals from the well A2 is shown in Figure 4.8. 
Unfortunately, the crystals did not stain through the addition of IZIT. The condition is 
highlighted in yellow in Table 4.4. 
 
Figure 4.8 Small rod and rhombus shaped crystals from the in vitro mCRP trials that were 
dispersed throughout the drop. The crystals were grown in A2 of the follow up study 
described in Table 4.4 (highlighted in yellow). The arrows included in the Figure highlight 
clusters of the rod and rhombus shaped crystals within the well. See Figure 4.7 for the 
crystals which were produced from the initial crystallisation well. The scale shown 
represents 100µm.  
 
 The crystals shown in Figure 4.8 were frozen in liquid nitrogen on the 16/01/2015 
and tested on the 18/01/2015 at DLS. Due to the conditions the crystals had been grown in, 
no cryoprotectant was used. Four crystals in total were frozen from the well A2, with only 
two being tested at DLS. Unfortunately, neither of the crystals that were tested showed any 
diffraction and were both thought to be small molecule crystals. 
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Several months after structure screen 2 had been initiated the well shown in Figure 
4.9 started showing signs of crystal growth. Small, rounded crystalline structures appeared 
throughout the drop. The condition of the well was 4.3M Sodium Chloride, 0.1M Sodium 
HEPES, pH 7.5. The crystals are shown in Figure 4.9. 
 
Figure 4.9 Small, rounded crystalline structures were dispersed throughout the drop from the 
mCRP crystallisation trials. The condition for the well was 4.3M Sodium Chloride, 0.1M 
Sodium HEPES, pH 7.5. The scale shown represents 100µm. The arrow highlights one of 
the small, rounded structures observed in the drop.  
 
 As the crystals were too small and had not formed properly, they were not tested at 
DLS. In order to improve the size and quality of the crystal shape, a follow up trial was 
carried out. The concentration of sodium chloride was altered by increments of 0.3M, with 
the pH of sodium HEPES also being varied. The conditions for the follow up study are 
outlined in Table 4.5.  
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 A B C 
1 
4M Sodium Chloride, 
0.1M Sodium HEPES, 
pH 7.2 
4.3M Sodium 
Chloride, 0.1M 
Sodium HEPES, pH 
7.2 
4.6M Sodium 
Chloride, 0.1M 
Sodium HEPES, pH 
7.2 
2 
4M Sodium Chloride, 
0.1M Sodium HEPES, 
pH 7.5 
4.3M Sodium 
Chloride, 0.1M 
Sodium HEPES, pH 
7.5 
4.6M Sodium 
Chloride, 0.1M 
Sodium HEPES, pH 
7.5 
3 
4M Sodium Chloride, 
0.1M Sodium HEPES, 
pH 7.8 
4.3M Sodium 
Chloride, 0.1M 
Sodium HEPES, pH 
7.8 
4.6M Sodium 
Chloride, 0.1M 
Sodium HEPES, pH 
7.8 
Table 4.5 The conditions described above are a follow up study from the condition 4.3M 
Sodium Chloride, 0.1M Sodium HEPES, pH 7.5. See Figure 4.9 for the crystal-like 
structures which were produced from the initial crystallisation trial. Wells which are 
highlighted in yellow were successful in growing crystals.   
 
Four weeks after the trial had been set down; crystals had started growing in the well 
A2. The crystals appeared on the edge of the drop and appeared very similar to a shard of 
glass, as shown in Figures 4.10a and 4.10b.  
Chapter 4. Protein Crystallisation    Results 
  
193 
 
  
Figure 4.10 Crystals from both wells which resemble small shards of glass. a) The crystal 
grown from A2 appears like a shard of glass. b) Similar to a, the crystal also appears to 
resemble a shard of glass. Both crystals from a and b were grown in the well A2, as described 
in Table 4.5 (highlighted in yellow). Both crystals are identifiable via the arrows included in 
the Figure. Scale represents 200µm.  
 
 Both crystals were frozen in liquid nitrogen on the 09/12/2015 and tested at DLS on 
13/12/2015. Prior to freezing the crystals were cryoprotected. The first crystal tested was 
extremely icy (Figure 4.10a) meaning visibility was poor. A grid scan was performed to 
determine where the crystal was located within the loop. Potential diffraction spots were 
observed from the grid scan, but due to the amount of ice on the loop no more information 
was collected. The second crystal tested (Figure 4.10b) unfortunately produced no 
diffraction spots.  
 
 
 
 
 
b a 
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Structure screen 2 also produced crystals which appeared as poorly formed plates 
that were rough round the edges (see Figure 4.11). The condition that the crystals grew in 
was 2.0M Ammonium Sulfate, 5% 2-propanol. The crystals are shown in Figure 4.11. 
 
Figure 4.11 Poorly formed crystals dispersed throughout the drop from the mCRP 
crystallisation trials. The condition for the well was 2.0M Ammonium Sulfate, 5% 2-
propanol. The scale shown represents 200µm. The two arrows included in the Figure 
highlight two of poorly formed crystals within the well. 
 
 Due to the poorly formed nature of the crystals shown in Figure 4.11 they were not 
tested at DLS. A follow up study was carried out, where the concentrations of ammonium 
sulfate and 2-propanol was varied. These conditions are shown in Table 4.6. Unfortunately, 
after months of monitoring the crystal trial, the follow up study described in Table 4.6 did 
not produced any crystals. 
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 A B C 
1 
1.0M Ammonium 
Sulfate, 3% 2-
propanol 
1.0M Ammonium 
Sulfate, 5% 2-
propanol 
1.0M Ammonium 
Sulfate, 7% 2-
propanol 
2 
2.0M Ammonium 
Sulfate, 3% 2-
propanol 
2.0M Ammonium 
Sulfate, 5% 2-
propanol 
2.0M Ammonium 
Sulfate, 7% 2-
propanol 
3 
3.0M Ammonium 
Sulfate, 3% 2-
propanol 
3.0M Ammonium 
Sulfate, 5% 2-
propanol 
3.0M Ammonium 
Sulfate, 7% 2-
propanol 
Table 4.6 The conditions described above are a follow up study from the condition 2.0M 
Ammonium Sulfate, 5% 2-propanol. See Figure 4.11 for the crystals which were produced 
from the initial crystallisation trial.  
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Analysis of all the conditions that were trialled with mCRP from both the structure 
screens and follow-up studies highlighted three conditions which demonstrated potential for 
growing protein crystals. These are highlighted in the summary Table 4.7. Several of these 
conditions are still being pursued with in vitro produced mCRP. In addition to this, varying 
the concentration of mCRP within the drop and the addition of co-crystallisation with a 
natural ligand is also being considered.  
Condition Figure Reference Diffraction Quality 
4M Sodium Chloride, 0.1M 
Sodium HEPES, pH 7.5 
Figure 4.10a + 4.10b 
 
Too icy to test properly 
at DLS 
 
4.3M Sodium Chloride, 0.1M 
Sodium HEPES, pH 7.5 
Figure 4.9 
Small, rounded crystals 
not high quality enough 
for DLS (2x crystals) 
2M Ammonium Sulfate, 5% 2-
propanol 
Figure 4.11 
Small, rounded crystals 
not high quality enough 
for DLS 
Table 4.7 A list of three conditions out of all those that were trialled which showed promise 
when attempting to crystallise mCRP.  
 
4.3.2   Digestion of Human C1q with the Collagenase Enzyme 
The CLR of C1q had to be removed through enzymatic digestion as the intact 
molecule was too floppy and would struggle to crystallise. Furthermore, digestion of the 
intact molecule helped to solubilise the C1q molecule, for the higher concentrations that 
were required for crystallisation. In addition, this aided in stabilising the complex within the 
crystal lattice, helping promote ordered crystal growth. To produce the GHR a protocol was 
used from established procedures (Paques et al., 1979), which has previously been used 
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within our research group. Alternative protocols have also been trialled. Gaboriaud et al, 
2003, successfully managed to cleave the GHR with the enzyme collagenase for 
crystallisation trials. Unfortunately, this protocol has previously yielded poor results within 
our lab and was not followed up.  
The protocol used by Paques et al, 1979, uses the enzyme collagenase to cleave the 
CLR at specific points along the sequence; at the x-Gly bond within the sequence Pro-x-Gly-
Pro, where x is a neutral residue. This therefore frees the GHR from the CLR, which can 
then be purified out of sample and used for crystallisation studies. The collagenase CLSPA 
used in the protocol is purchased from Worthington Biochemical Corporation (New Jersey, 
USA) and is provided in a chromatographically purified form from Clostridium histolyticum. 
The CLSPA collagenase used has a highly specific collagenase activity with little secondary 
enzyme activity, breaking down the collagen into a single stranded-form. In addition, 
bacterial collagenases can cleave at multiple sites along the chain, whereas mammalian 
collagenases are limited to one specific site. 
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SDS PAGE analysis was run on the C1qGHR sample to assess whether the digestion 
and production of C1qGHR had been a success and to assess the purity of the sample. Figure 
4.12 shows the silver stained SDS PAGE of the C1q molecule post-digest. Molecular weight 
markers are shown in lane 1, with intact C1q in lane 3. Lanes 5 and 7 contain C1qGHR non-
reducing and reducing respectively. As the three subunits of the GHR of C1q are not held 
together by disulfide bonds, the three bands observed in the non-reducing lane (5) displayed 
the same molecular weight as the bands from the reducing sample (lane 7). Molecular weight 
markers were used to estimate the molecular weight of each subunit and is shown on the left 
of the image. This matches the expected molecular weights based on previous experimental 
work that has published and within our lab, alongside previous published results (Gaboriaud 
et al., 2003; Paques et al., 1979).  
 
Figure 4.12 C1q digested by collagenase (silver stained), 12.5%T SDS-PAGE. Lane 1: 
molecular weight markers, lane 2: sample buffer, lane 3: undigested C1q, lane 4: sample 
buffer, lane 5: C1q GHR (non-reducing), lane 6: sample buffer, lane 7: C1q GHR (reducing).  
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Due to reports that the collagenase enzyme used in the digestion experiment has been 
known to degrade into smaller protein fragments once used, a second SDS PAGE was run 
to assess the enzyme’s purity. A positive control of the enzyme alongside native collagenase 
is shown in Figure 4.13. Lanes 4 and 6 in Figure 4.13 both show identical bands whilst 
stained, indicating that the enzyme had not degraded.  
 
Figure 4.13 Collagenase from Clostridium histolyticum, Coomassie stained. Samples were 
run on a 12.5%T SDS-PAGE. Lane 1: sample buffer, lane 2: molecular weight markers, lane 
3: sample buffer, lane 4: native collagenase, lane 5: sample buffer, lane 6: A control sample 
of collagenase which had not been subject to any experimental analysis. 
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4.3.2   Co-crystallisation of C-reactive Protein and C1qGHR with CWPS 
 
 The second half of the crystallisation studies is dedicated to the crystallisation of the 
complex structure involving CRP, C1QGHR and CWPS. Two structure screens purchased 
from Molecular Dimensions called the ProPlex were used in the complex (C1qGHR: pCRP: 
CWPS) crystallisation trials. The ProPlex contained two sets of 50 conditions which are 
known to have previously been successful when trying to crystallise large complexes. Details 
of the structure screens used in the complex trials can be found in Appendix 4. Crystallisation 
trials for the first ProPlex structure screen commenced on 24/06/2014. 
 After several weeks after the initiation of the first ProPlex structure screen trial, a 
large boulder shaped crystal had grown in the well RW01D4. The condition the crystal had 
grown in was 0.15M Ammonium Sulfate, 0.1M MES, pH 6.0, 15% PEG 4000. 
Unfortunately, there are no available images for this crystal. The large boulder shaped crystal 
was frozen in liquid nitrogen on 16/04/2015 after being cryoprotected. The crystal was tested 
at DLS on 05/05/2015 but no diffraction was observed. 
 In addition, long, hexagonal crystals started to grow in the well RW02B1 from the 
ProPlex structure screen trial 1. The condition for this well was 0.1M Sodium Citrate, pH 
5.6, 20% PEG 4000, 20% 2-propanol. Unfortunately, there are no available images for this 
crystal. A long hexagonal shaped crystal was frozen in liquid nitrogen on 16/04/2015 after 
being cryoprotected. The crystal was tested at DLS on 05/05/2015 but no diffraction was 
observed. 
 Small, shard-like crystals appeared in from one of the wells in the ProPlex structure 
screen 1. The condition for this well was 0.2M Lithium Sulfate, 0.1M MES, pH 6.0, 20% 
PEG 4000. Unfortunately, there are no available images for this crystal and during 
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cryoprotection, the shard-like crystals dissolved (5% PEG 400). A follow up trial on this 
condition was therefore initiated, to improve the size, quality and stability of the crystal that 
was initially produced. The concentration of lithium sulfate and pH was varied throughout 
the trial. An additional two wells were also added, which was identical to the initial 
condition, except for the molecular weight of PEG used being changed to 2000 and 6000. 
The details of the crystallisation follow up study are shown in Table 4.8. The trial was 
initiated on 18/12/2015. As of yet, there are currently no crystals growing in the follow up 
wells. The well is being monitored for any sign of crystal growth.  
   1 2 3 
A 
0.1M Lithium Sulfate, 
0.1M MES, pH 5.8, 
20% PEG 4000 
0.2M Lithium Sulfate, 
0.1M MES, pH 5.8, 
20% PEG 4000 
0.3M Lithium Sulfate, 
0.1M MES, pH 5.8, 20% 
PEG 4000 
B 
0.1M Lithium Sulfate, 
0.1M MES, pH 6.0, 
20% PEG 4000 
0.2M Lithium Sulfate, 
0.1M MES, pH 6.0, 
20% PEG 4000 
0.3M Lithium Sulfate, 
0.1M MES, pH 6.0, 20% 
PEG 4000 
C 
0.1M Lithium Sulfate, 
0.1M MES, pH 6.2, 
20% PEG 4000 
0.2M Lithium Sulfate, 
0.1M MES, pH 6.2, 
20% PEG 4000 
0.3M Lithium Sulfate, 
0.1M MES, pH 6.2, 20% 
PEG 4000 
D 
0.2M Lithium Sulfate, 
0.1M MES, pH 6.0, 
20% PEG 2000 
0.2M Lithium Sulfate, 
0.1M MES, pH 6.0, 
20% PEG 6000 
Empty 
Table 4.8 The conditions described above are a follow up study from the condition 0.2M 
Lithium Sulfate, 0.1M MES, pH 6.0, 20% PEG 4000. Additional trials involving PEG 2000 
and 6000 were also set down (D1 + D2).  
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 A year after the ProPlex structure screen 1 has been initiated, shard-like crystals were 
found to be growing in well RW01A5. They were then left for several months to continue 
growing, with regular checks made on the crystals. The crystals had stopped increasing in 
size several months later. The crystallisation condition of the well was 0.1M MES, pH 6.5, 
15% PEG 500 MME. The well contained one large shard, with several smaller shards 
throughout the drop, as shown in Figure 4.14a and 4.14b. 
 
Figure 4.14 Large shard-like crystals grown in the complex crystallisation trials. a) A large, 
shard-like crystal from the complex crystallisation trials. b) A smaller, shard-like crystal 
from the complex crystallisation trials. Both crystals are from the crystallisation condition 
0.1M MES, pH 6.5, 15% PEG 500 MME (well RW01A5). The scale represents 200µm. The 
arrows in both Figures highlight the position of the crystals within the drop. 
The crystals had been grown in 15% PEG 500 MME, which could potentially act as 
a cryoprotectant for the crystal. As previous crystals from the complex trials have dissolved 
due to the addition of cryoprotectant, the largest crystal (Figure 4.14a) was frozen directly 
into liquid nitrogen. 20% of PEG 500 MME was added to the smaller, shard-like crystal as 
an additional cryoprotectant, and then frozen. Crystals were frozen on 09/12/2015. The 
crystals were tested at DLS on the 13/12/2015. The first crystal frozen (Figure 4.14a) was 
tested and diffracted to a resolution of around 9Å. A diffraction image for that crystal is 
shown in Figure 4.15. The second crystal diffracted to a resolution of around 10 Å. 
a b 
Chapter 4. Protein Crystallisation    Results 
  
203 
 
Unfortunately, this resolution for both crystals was not high enough to warrant collection of 
a data set.   
 
Figure 4.15. Enlarged section of one of the diffraction pattern images collected from a crystal 
of the protein complex C1qGHR, CRP and CWPS. The crystal which produced the 
diffraction patterns is shown in Figure 4.13a. Data was collected at DLS. Circles seen in 
black on the image represent approximate resolutions of (from inner to outer) 21.15Å, 
10.60Å and 7.10Å.  
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To improve the size and quality of the crystals shown in Figure 4.14, the condition 
was followed up with a three by three screen. The concentration of PEG 550 MME was 
varied alongside the pH of the MES buffer. Details for the crystallisation follow up study 
can be found in Table 4.9. The trial was initiated on 18/12/2015. As of yet there are currently 
no crystals growing in the follow up wells. The well is being monitored for any sign of 
crystal growth. 
 1 2 3 
A 
0.1M MES, pH 6.2, 
10% PEG 500 
MME 
0.1M MES, pH 6.2, 
15% PEG 500 
MME 
0.1M MES, pH 6.2, 
20% PEG 500 
MME 
B 
0.1M MES, pH 6.5, 
10% PEG 500 
MME 
0.1M MES, pH 6.5, 
15% PEG 500 
MME 
0.1M MES, pH 6.5, 
20% PEG 500 
MME 
C 
0.1M MES, pH 6.7, 
10% PEG 500 
MME 
0.1M MES, pH 6.7, 
15% PEG 500 
MME 
0.1M MES, pH 6.7, 
20% PEG 500 
MME 
Table 4.9 The conditions described above are a follow up study from the condition 0.1M 
MES, pH 6.5, 15% PEG 500 MME. Crystals produced from the initial crystallisation trial 
are shown in Figure 4.14. As of yet, no crystals have been produced from this trial. 
 
Crystallisation trials for the second ProPlex structure screen commenced on the 
29/10/2014. Several weeks after the trial had been initiated; small oval shaped crystals 
started to grow (see Figure 4.16). The crystallisation condition of the well was 1.5M 
Ammonium Sulfate, 0.1M Sodium HEPES, pH 7.0. Unfortunately, there are no images 
available for the crystals produced. Crystals from the well were due to be frozen, but 
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dissolved due to the addition of cryoprotectant (5% MPD). A repeat trial was carried out for 
the same condition. After several weeks of monitoring the wells, a boulder-shaped crystal 
appeared, as shown in Figure 4.16 (top left of the image).  
 
Figure 4.16 Boulder-shaped crystals from the complex structure screen 2. The condition for 
the well is 1.5M Ammonium Sulfate, 0.1M Sodium HEPES, pH 7.0. The scale shown 
represents 200µm. The arrow highlights the position of the crystal within the drop. 
The boulder shaped crystal from Figure 4.16 was frozen on 16/10/2015 after being 
cryoprotected with glycerol. The crystal was tested at DLS on 18/10/2015 and diffracted to 
around 9Å. Data was not collected on the crystal as the resolution was not high enough. The 
well was continuously monitored for further crystal growth. 
Small, oval shaped crystals also appeared in the well for the crystallisation condition 
of 2.0M Ammonium Sulfate, 0.1M Sodium Acetate, pH 5.0. Unfortunately, there are no 
images available for the crystals produced. Crystals from the well were due to be frozen, but 
dissolved due to the addition of cryoprotectant (20% PEG 400). A repeat trial was carried 
out on the same condition. Like the initial trial, small rounded crystals appeared in the well. 
These rounded crystals are shown in Figure 4.17 were too small to test at DLS and were left 
to see if they would increase in size. They are still currently being monitored. 
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Figure 4.17 Small, rounded shaped crystals from the complex structure screen 2. The 
condition for the well is 2.0M Ammonium Sulfate, 0.1M Sodium Acetate, pH 5.0. The scale 
shown represents 100µm. The arrows highlight the appearance of two of the rounded crystals 
within the drop. 
 Several months after the initiation of the second ProPlex structure screen, small, 
rounded oval shaped crystals were found to be growing in the well RW14B4. The condition 
of the well was 1.6M Sodium/Potassium Phosphate, pH 6.5. The crystals produced in the 
well are shown in Figure 4.18. 
 
Figure 4.18 Small rounded shaped crystals from the complex structure screen 2. The 
condition for the well is 1.6M Sodium/Potassium Phosphate, pH 6.5. The scale represents 
100µm. The arrow highlights the appearance of one of the rounded crystals within the drop. 
A follow up study was commenced for the condition 1.6M Sodium/Potassium 
Phosphate, pH 6.5, as the crystals in Figure 4.18 were too small to test at DLS. The follow 
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up trial consisted of variations in the concentration of sodium/potassium phosphate and the 
pH. The conditions used are shown in Table 4.10. 
 1 2 3 
A 
1.4M 
Sodium/Potassium 
Phosphate, pH 6.4 
1.6M 
Sodium/Potassium 
Phosphate, pH 6.4 
1.8M 
Sodium/Potassium 
Phosphate, pH 6.4 
B 
1.4M 
Sodium/Potassium 
Phosphate, pH 6.5 
1.6M 
Sodium/Potassium 
Phosphate, pH 6.5 
1.8M 
Sodium/Potassium 
Phosphate, pH 6.5 
C 
1.4M 
Sodium/Potassium 
Phosphate, pH 6.6 
1.6M 
Sodium/Potassium 
Phosphate, pH 6.6 
1.8M 
Sodium/Potassium 
Phosphate, pH 6.6 
Table 4.10 The conditions described above are a follow up from the condition 1.6M 
Sodium/Potassium Phosphate, pH 6.5. As of yet, no crystals have been produced from this 
trial. 
Unfortunately, the follow up study did not produce any crystals after several months 
of monitoring the trial. Several of the rounded crystals shown in Figure 4.18 (the initial 
crystal well) were transferred to B2 in the abovementioned follow up study (highlighted blue 
in Table 4.10). As the crystals, had not changed in size or form since they were discovered, 
they were transferred to B2 to determine if they would display signs of growth, or develop a 
more ordered form by providing a nucleation point for the protein within the well. Figure 
4.19 shows the crystals that were transferred into B2. The crystal well is still being monitored 
but as of yet show no signs of growth.  
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Figure 4.19 Small rounded crystals that were transferred from RW14B4 to the well B2 in 
the follow up study described in Table 4.10. Crystals were transferred in order to determine 
if they would improve in size or quality in an identical. The scale shown represents 100µm. 
A cluster of the rounded crystals is highlighted via the arrow.  
 Well RW14D1 also displayed signs of crystal growth. Similar to that previously 
observed in the second structure screen, small, rounded oval shaped crystals were identified 
within the well. The condition of the well is 0.1M Sodium Acetate, pH 5.0, 2% PEG 4000, 
15% MPD. The crystals that were grown in the well are shown in Figure 4.20. 
 
Figure 4.20 Small rounded shaped crystals from the complex structure screen 2. The 
condition for the well is 0.1M Sodium Acetate, pH 5.0, 2% PEG 4000, 15% MPD. The scale 
represents 100µm. The arrows highlight the appearance of the rounded crystals within the 
drop. 
 A follow up trial was commenced due to the crystals shown in Figure 4.20 being too 
small and poorly formed to be tested at DLS. The follow up trial consisted of variations in 
the concentration of MPD and buffer pH. The crystallisation conditions for the follow up 
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study are described in Table 4.11. The trial was initiated on 18/12/2015. Currently there are 
no crystals growing in the follow up wells. The well is being monitored for any sign of 
crystal growth.  
 1 2 3 
A 
0.1M Sodium 
Acetate, pH 4.8, 2% 
PEG 4000, 10% 
MPD 
0.1M Sodium Acetate, 
pH 4.8, 2% PEG 4000, 
15% MPD 
0.1M Sodium Acetate, 
pH 4.8, 2% PEG 4000, 
20% MPD 
B 
0.1M Sodium 
Acetate, pH 5.0, 2% 
PEG 4000, 10% 
MPD 
0.1M Sodium Acetate, 
pH 5.0, 2% PEG 4000, 
15% MPD 
0.1M Sodium Acetate, 
pH 5.0, 2% PEG 4000, 
20% MPD 
C 
0.1M Sodium 
Acetate, pH 5.2, 2% 
PEG 4000, 10% 
MPD 
0.1M Sodium Acetate, 
pH 5.2, 2% PEG 4000, 
15% MPD 
0.1M Sodium Acetate, 
pH 5.2, 2% PEG 4000, 
20% MPD 
Table 4.11 The conditions described above are a follow up from the condition 0.1M Sodium 
Acetate, pH 5.0, 2% PEG 4000, 15% MPD. As of yet, no crystals have been produced from 
this trial.   
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 Well RW14A1 also produced crystals which displayed promising signs of growth. 
Small, oval shaped crystals were found within the well. The condition was 1.5M Ammonium 
Sulfate, 0.1M Tris, pH 8.0. The crystals that were grown within the well are shown in Figure 
4.21. 
 
Figure 4.21 Small rounded shaped crystals from the complex structure screen 2. The 
condition for the well is 1.5M Ammonium Sulfate, 0.1M Tris, pH 8.0. The scale shown 
represents 100µm. The arrows highlight the appearance of the rounded crystals within the 
drop. 
To improve the size and quality of the crystals grown in Figure 4.21, a follow up 
study was initiated. The follow up study for this trial was slightly altered to that of the 
previous ones carried out. It was noted, that high salt concentrations have repeatedly 
produced crystals throughout the complex crystallisation trials. This can be seen in the 
conditions which produced crystals in the Figures 4.14, 4.16 – 4.21. Therefore, in this follow 
up trial, high concentrations of ammonium sulfate was used, alongside variations in the pH. 
These conditions can be found in Table 4.12. The trial was initiated on 18/12/2015. Currently 
no crystals growing in the follow up wells. The well is being monitored for any sign of 
crystal growth.  
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 1 2 3 
A 
1.0M Ammonium 
Sulfate, 0.1M Sodium 
Acetate, pH 5.0 
1.2M Ammonium 
Sulfate, 0.1M Sodium 
Acetate, pH 6.0 
1.4M Ammonium 
Sulfate, 0.1M Sodium 
HEPES, pH 6.5, 
B 
1.6M Ammonium 
Sulfate, 0.1M Sodium 
HEPES, pH 7.0 
1.8M Ammonium 
Sulfate, 0.1M Tris, pH 
7.5 
2.0M Ammonium 
Sulfate, 0.1M Tris, pH 
8.0 
Table 4.12 A set of conditions from previous complex crystallisation trials which have 
notably produced crystals from high-salt based buffers/precipitants. As of yet, no crystals 
have been produced from this trial.   
Similar to that observed in the mCRP crystallisation trial. There were several 
conditions which displayed promise during the complex crystallisation trials (see Table 
4.13). In addition, the respective crystal figures and their diffraction quality, where possible 
are given. Several of these conditions are currently being followed up alongside several of 
the wells being monitored due to the length of time previous crystals have taken to form. 
Condition Figure Reference Diffraction Quality 
0.2M Lithium Sulfate, 0.1M 
MES, 20% PEG 4K, pH 6.0 
No Figure 
Initially dissolved upon 
addition of cryoprotectant. No 
crystals produced from follow 
up 
0.1M MES, 15% PEG 550 
MME, pH 6.5 
Figure 4.14 
1 crystal to 10 Å 
1 crystal to 9 Å 
1.5M Ammonium Sulfate, 
0.1M Sodium HEPES, pH 
7.0 
Figure 4.16 1 crystal to 9 Å 
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2M Ammonium Sulfate, 
0.1M Sodium Acetate, pH 
5.0 
No Figure 
Initially dissolved upon 
addition of cryoprotectant. No 
crystals produced from follow 
up 
1.6M Sodium Potassium 
Phosphate, pH 6.5 
Figure 4.18 
Initial crystals not high enough 
quality for DLS. No crystals 
produced from follow up 
0.1M Sodium Acetate, 2% 
PEG 4K, 15% MPD, pH 5.0 
Figure 4.20 
Initial crystals not high enough 
quality for DLS. No crystals 
produced from follow up 
Table 4.13 A table of all the conditions from the complex crystallisation trials which 
displayed promise. Crystallisation conditions and their respective crystal Figures are 
displayed in addition to whether the crystals diffracted if grown.  
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4.4   Discussion 
 
4.4.1   Crystallisation Trials of Monomeric C-reactive Protein 
 
 The crystallisation trials for mCRP failed to produce any crystals that were sufficient 
in size and quality that they could have been tested at DLS. Although no protein crystals 
were produced of sufficient quality, the crystal trials discussed here provide a basis of 
potential conditions which may be refined for future follow up crystallisation trials. These 
conditions are summarised in Table 4.7, whereby the well conditions, and quality of the 
crystals produced are given.  
 Several of the crystal trials involving mCRP produced crystals which either produced 
no diffraction spots at all, or were determined to be small molecule, based on the diffraction 
observed when tested at DLS. These crystals are highlighted in Table 4.14.   
Condition Figure Reference Diffraction Observed 
0.2M Ammonium Sulfate, 
25% PEG 4000, 0.1M 
Sodium Acetate pH 4.6 
Figure 4.4 
No Diffraction Pattern 
Observed 
3.4M 1,6-Hexanediol, 0.2M 
Magnesium Chloride 
Hexahydrate, 0.1M Tris, pH 
8.5 
Figure 4.5 
No Diffraction Pattern 
Observed 
3.6M 1,6-Hexanediol, 0.2M 
Magnesium Chloride 
Hexahydrate, 0.1M Tris, pH 
8.5 
Figure 4.6a (Follow on 
from Figure 4.5) 
Confirmed Small 
Molecules Crystal 
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3.6M 1,6-Hexanediol, 0.3M 
Magnesium Chloride 
Hexahydrate, 0.1M Tris, pH 
8.5 
Figure 4.6b (Follow on 
from Figure 4.5) 
Confirmed Small 
Molecules Crystal 
70% MPD, 0.1M Sodium 
HEPES, pH 7.5 
Figure 4.8 (Follow on from 
Figure 4.7) 
No Diffraction Pattern 
Observed 
Table 4.14 Crystallisation trials involving mCRP. Crystallisation conditions and their 
respective crystal Figures are shown for trials which produced small molecule crystals or 
crystals which did not diffract.   
Initially, those crystals which displayed no diffraction upon testing with X-rays were 
suggested to potentially be poorly formed crystals. For proteins, X-rays are an ideal choice 
because their typical wavelength is 0.15nm, the approximate distance of the bond length in 
protein molecules. In principle, a single object will diffract X-rays; however, the use of a 
single molecule would produce too little intensity to observe any measurable diffraction. 
Consequently, scattering from many molecules is required to obtain a sufficient signal. Not 
only are a significant number of molecules required for the formation of a protein crystal, 
but an ordered orientation of the repeating units within the crystal lattice is also important. 
The quality of the diffraction patterns (and resolution) produced from protein crystal mirrors 
the symmetry and arrangement of the unit cells within the crystal. Thus, the formation of a 
poorly ordered lattice within the crystal structure will result in little or no diffraction at all 
(Merz Jr. et al., 2010). This can usually be rectified by refining the crystallisation conditions 
or protein concentration, thus promoting the formation of a well-ordered crystal. Additional 
methods are commercially available to help determine whether the crystals grown are 
protein. A protein dye called IZIT, was tested on the rod-shaped crystals that had been grown 
in 70% MPD, 0.1M Sodium HEPES, pH 7.5 (see Figure 4.8). The dye can distinguish 
between small molecule and protein crystals as it can penetrate the pores within protein 
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crystal contacts. As expected, the dye failed to stain the crystals observed in Figure 4.8, 
suggesting they were small molecule. Furthermore, due to the lack of reproducibility of the 
crystals displayed in Figure 4.4, a common trait in small molecule crystals, and lack of 
diffraction within the follow up studies from Figures 4.6 & 4.8, the abovementioned crystals 
were all deemed to be small molecule and were therefore not pursued any further.  
Figure 4.9 displays small, rounded crystals throughout the drop, which were grown 
in the condition 4.3M Sodium Chloride, 0.1M Sodium HEPES, pH 7.5. These were initially 
considered to be protein crystals, due to their poor formation and quality; typical of protein 
crystal formation when initially trialling different conditions. The ‘shower’ of poorly formed 
crystals suggests that the nucleation rate of the crystal formation was too high (see Figure 
4.1 for a graph on crystal growth). This prevents the formation of a well-ordered lattice 
alongside the growth of larger crystals as the concentration of free protein molecules have 
been depleted. Alterations within the proteins concentration or the precipitant used could 
help delay this growth rate, promoting the formation or larger, diffraction quality crystals. 
As they were too small to test at DLS a follow up was initiated (Table 4.5). The follow up 
trial produced two crystals which resembled shards of glass (see Figure 4.10a & b). This 
unique and random formation of the crystals suggested a poor quality of order within the 
crystal lattice structure. This was thus reflected within their diffraction quality. The crystal 
shown in Figure 4.10a showed potential diffraction spots via a grid scan, but due to heavy 
icing, visibility was too poor for any further analysis. The heavy icing also suggests the 
cryoprotectant used on that well (5-20% MPD) did not work. This could explain the poor 
diffraction quality observed as the formation of ice may have disturbed the crystal lattice. 
Unfortunately, the second crystal tested (see Figure 4.10b) produced no diffraction spots at 
all.  
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 Figure 4.11 shows poorly formed crystal plates that were produced from the structure 
screen 2 condition 2.0M Ammonium Sulfate, 5% 2-propanol. Similar to that seen in Figure 
4.9 and 4.10, the poorly formed order of the crystals suggested they may be protein. The 
shape and size of the crystals in Figure 4.11 does not suggest an issue with nucleation as 
previously suggested, but a lacking of order and homogeneity within the crystal lattice. This 
could be for several reasons, such as; the precipitant used was not optimal for mCRP, the 
protein concentration may need altering or the pH and or temperature may have affected the 
crystal growth within the drop (Blundell & Johnson, 1976). A follow up study was initiated, 
but unfortunately no crystals have since grown.  
4.4.2   Future Crystal Trials of Monomeric C-reactive Protein  
 
 The protein crystallisation trials described here, involving mCRP, failed to produce 
any protein crystals of sufficient diffraction quality. The reasoning behind this is still unclear 
as there are several alternative factors which affect crystal growth. In addition, it is unclear 
whether treatment of native pCRP with urea, to induce dissociation, altered the protein’s 
ability to crystallise. Table 4.7 summarises three conditions which provided the most 
promising results. It was noted that all three conditions contained high concentrations of salt 
precipitants. Furthermore, the use of alternative cryoprotectants may be warranted, as MPD 
failed to prevent ice rings when testing one of the crystals (Figure 4.10a). These conditions 
described here could potentially be pursued and refined in future research, when attempting 
to crystallise an in vitro or an in vivo form of mCRP.   
 Future research may also consider one variable that was not altered throughout the 
crystallisation trials; protein concentration. Typically, high protein concentrations (10-
15mg/ml) are used within protein crystallisation trials to allow the formation of a nucleation 
point for crystal growth (Rhodes, 2000). Under-saturated solutions are unable to reach the 
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‘crystallisation zone’ whereby the ordered crystal lattice starts to form. Crystallisation drops 
for mCRP trials all remained relatively transparent, with no protein precipitation occurring 
(excluding the conditions that produced ‘showers’ of crystals). This further suggests an 
increase in concentration of mCRP may drive this nucleation and help form protein crystals 
in several of the trialled conditions. Future studies involving mCRP may also benefit from 
co-crystallisation with a ligand such as PC to which mCRP can bind. Introducing ligands 
within crystallisation trials can both stabilise the protein structure when bound, in addition 
to providing a nucleation point which aids in protein crystal formation (Rhodes, 2000). 
4.4.3  Co-crystallisation Trials Involving C-reactive Protein and C1qGHR 
with CWPS 
 
 The protein crystallisation studies between pCRP, C1qGHR and CWPS aimed to 
provide an insight into the structural interactions between pCRP and C1q; therefore, 
determining which region of the C1q protein binds to pCRP. Currently structural data exists 
for pCRP bound to PC, determined by Thompson et al, but this may not be representative of 
what occurs in vivo. The binding of PC to pCRP, when complexed with C1q is not enough 
to elicit an immune response and activate complement (Volanakis, 1981; Volanakis, 1982). 
It is suggested that PC is required to be bound to the polysaccharide from the cell wall for 
this to occur.  
 Initial crystallisation trials involving the complex produced two crystals, which when 
tested at DLS, produced no diffraction spots at all. These conditions and their corresponding 
crystal Figures are summarised in Table 4.15. 
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Condition Figure Reference Diffraction Observed 
0.15M Ammonium Sulfate, 
0.1M MES, pH 6.0, 15% 
PEG 4000 
No Figure Available 
No Diffraction Pattern 
Observed 
0.1M Sodium Citrate, pH 
5.6, 20% PEG 4000, 20% 
2-propanol 
No Figure Available 
No Diffraction Pattern 
Observed 
 Table 4.15 Crystallisation trials of the complex. Crystallisation conditions and their 
respective crystal Figures are shown for trials which produced crystals which did not diffract.  
 As discussed previously, if a crystal displays no diffraction it does not necessarily 
mean it is a small molecule crystal; the crystal may be a poorly formed protein crystal. 
Although, based on their lack of reproducibility from their follow up trials, and as no 
diffraction was observed from the initial crystals, these were concluded to be small molecule 
and thus we did not pursue them any further. Cryoprotection of complex crystals proved to 
be problematic, as several of the crystals grown from the complex trials dissolved upon 
addition of the cryoprotectant. Table 4.16 highlights the crystallisation conditions of the 
failed cryoprotectants that were used.  
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Condition Figure/Well Cryoprotectant Used 
Follow Up 
Study 
0.2M Lithium 
Sulfate, 0.1M MES, 
pH 6.0, 20% PEG 
4000 
No Figure 
Available – 
RW02A4 
5-20% PEG 400 
No crystals 
grown from the 
follow up study 
(see Table 4.8) 
1.5M Ammonium 
Sulfate, 0.1M 
Sodium HEPES, pH 
7.0 
No Figure 
Available – 
RW13D6 
5% MPD 
Crystals grown 
in follow up (see 
Figure 4.16) 
2.0M Ammonium 
Sulfate, 0.1M 
Sodium Acetate, pH 
5.0 
No Figure 
Available – 
RW14A2 
5-20% MPD 
Crystals grown 
in follow up (see 
Figure 4.17) 
Table 4.16 A table highlighting crystallisation conditions of the complex trials which 
produced crystals that dissolved upon addition of the cryoprotectant. Information regarding 
crystal growth in the respective follow up studies is also provided.  
 
 Table 4.16 highlights two different common cryoprotectants which proved to be 
damaging to the crystals grown in the complex crystallisation trials. A follow up study from 
the well RW13D6 (described in the above Table 4.16) produced a boulder shaped crystal, as 
shown in Figure 4.16. Cryoprotection of this crystal with glycerol proved successful with 
the crystal diffracting to 9Å when tested at DLS. Furthermore, one the two crystals from 
RW01A5, shown in Figure 4.14a & b was successfully cryoprotected with PEG 550 MME 
and diffracted to 10Å (with the other crystal diffracting to 9Å). The cryoprotectants used 
here were sufficient in helping protect the crystal from ice formation and radiation damage, 
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but unfortunately this was not high enough resolution from either trial to warrant data 
collection. These conditions clearly need to be refined in further follow up studies to improve 
their diffraction quality. The addition of various cryoprotectants to crystals can result in said 
crystal dissolving prior to being frozen, as demonstrated in Table 4.16. The protein and the 
precipitant and buffer solution can largely dictate what cryoprotectant is used. Certain 
cryoprotectants will disrupt the hydrogen-bond network that runs through the crystal 
contacts when attempting to displace the water molecules. This can therefore result in the 
crystal structure breaking apart, and thus dissolving the crystal into solution (Blundell & 
Johnson, 1976; Chayen, 2004; Glusker & Trueblood, 1985; Heras & Martin, 2005)  
 The follow up study for the trial RW14A2, as described in Table 4.16, produced a 
‘shower’ of small rounded crystals throughout the drop (see Figure 4.18). Alongside this, 
several other complex crystallisation trials produced similar crystals. These are summarised 
in Table 4.17. 
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Condition Figure 
Crystal 
Description 
Follow Up Study 
2.0M Ammonium 
Sulfate, 0.1M 
Sodium Acetate, pH 
5.0 
Figure 4.17 
Small Rounded 
Crystals  
No Further Crystals 
Produced 
0.1M Sodium 
Acetate, pH 5.0, 2% 
PEG 4000, 15% 
MPD 
Figure 4.20 
Small Rounded 
Crystals 
No Further Crystals 
Produced 
1.6M 
Sodium/Potassium 
Phosphate, pH 6.5 
Figure 4.18 
Small Rounded 
Crystals 
Crystals transferred 
to additional well 
(see Table 4.10, 
Figure 4.19). No 
Further Crystal 
Growth 
1.5M Ammonium 
Sulfate, 0.1M Tris, 
pH 8.0 
Figure 4.21 
Small Rounded 
Crystals 
No Further Crystals 
Produced 
Table 4.17 A summary of all the crystallisation conditions from the complex trials which 
produced small rounded crystals of poor quality. Their respective Figures and follow up 
information is also given.  
  Table 4.17 summarises a list of conditions from the complex crystallisation 
trials which resulted in the growth of small, poorly formed, rounded crystals. The results 
described here in Table 4.17 are like the crystals growth observed in Figure 4.9 from the 
mCRP crystallisation trials. This poor crystal quality described above could be due to several 
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reasons. Firstly, the nucleation rate during crystal growth could be too high, thus forming 
the small ‘showers’ of crystals throughout the drop, therefore the crystals are to form an 
ordered lattice and grow to a larger size. Secondly, poorly formed crystals could be due to 
refinement needed in the concentration of precipitant and buffers used. A more realistic 
option would be a combination of several variables which require refining, including 
changes to the pH, or the concentration of buffer, precipitant or protein sample used. The 
crystals produced from the condition 1.6M Sodium/Potassium Phosphate, pH 6.5 (Figure 
4.18) failed to produce any crystals in their follow up study (Table 4.10). A process adopted 
from the seeding technique was attempted, whereby fragments of protein crystals are 
transferred from one well to another identical well, which thus acts as a nucleation point for 
the protein within that well (Blundell & Johnson, 1976; Chayen, 2004; Stura & Wilson, 
1991). Unfortunately, after several months of monitoring the well, no crystal growth was 
observed. Looking forward, alternative micro/macro seeding techniques such as adding 
crushed crystals to a well at the start of the experiment could be employed to promote crystal 
growth (Rhodes, 2000).  
 The follow up trial for the condition 1.5M Ammonium Sulfate, 0.1M Tris, pH 8.0 
(see Figure 4.21), which produced small rounded crystals (Table 4.17) was slightly altered 
to that of previous follow-up experiments. Previous crystallisation trials which had yielded 
protein crystals which diffraction to low resolution data, alongside those described in Table 
4.17 all had one variable in common: high salt-based precipitant. A follow up trial was 
therefore carried out containing a range of ammonium sulfate concentrations (1-2M, 0.2M 
increments) and a range of different pH’s (5.0-8.0) to accommodate this observation. Any 
visible crystals are yet to appear from these trials, but are being closely monitored. This 
could be due to several reasons. The temperature within the lab may have had an effect of 
crystal formation within the well. In addition, the range of conditions covered may not be 
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suitable for the complex, with more follow up trials required. Although, it is worth noting 
that initial trials did take up to 12 months for crystals to form (Blundell & Johnson, 1976; 
Chayen, 2004; Rhodes, 2000) 
4.4.4  Future Crystal Trails of the Complex: C-reactive Protein, C1qGHR 
and CWPS 
 
 Protein crystallisation for the complex of C1qGHR, CRP and CWPS produced 
several crystals which diffracted to a low resolution of 9-10Å. Unfortunately, no crystals 
were produced which diffracted to a higher resolution. Common cryoprotectants which have 
provided successful previously within our research group failed to successfully cryoprotect 
three of the complex crystals. Moreover, this highlights two cryoprotectants (PEG 550 MME 
and Glycerol) which could also be used in future studies. A typical feature observed within 
these trials was poorly formed rounded crystals. Future experimental work should address 
this issue of a more ordered crystal growth by through further follow up studies. Fortunately, 
the trials described here have highlighted several key areas which could be pursed for future 
crystallisation studies. Conditions which have been highlighted in Table 4.17 show a range 
of high salt-based conditions which could be further pursued and refined to grow diffraction 
quality crystals. Furthermore, alterations in the proteins concentration may be a key area to 
address for further experimental work.  
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Chapter 5.0 – Discussion, Conclusions and Future Work 
5.1   General Overview 
 
 CRP was initially classed as a biological marker for the presence of infection, 
inflammation or tissue damage within the body (Baltz et al., 1982; Pepys & Hirschfield, 
2003). Since its discovery, experimental research has highlighted conflicting roles for the 
acute phase protein. Published research has postulated that molecular variations of CRP can 
exert pro-inflammatory stimuli within the body, exacerbating the pathology commonly 
observed in inflammatory diseases (Pepys & Hirschfield, 2003; Torzewski et al., 1998; 
Zhang et al., 1999; Zhang et al., 2012). Furthermore, it is widely accepted that raised 
baseline levels of pCRP is a strong indicator for the development of said diseases later in life 
(Pepys & Hirschfield, 2003). Alternative evidence has suggested an immune-regulatory role 
of CRP within the body, helping to manage and control not only inflammation, but other 
components of the immune system (Skoglund et al., 2008).  
The main aims of this research include the purification & identification of molecular 
variations of human CRP from serum, alongside determination of the structural interactions 
occurring between native CRP and its natural ligands. Here we provide experimental 
evidence which contributes towards our overall understanding of CRP within the human 
body. We describe the identification of a monomeric form of CRP from human serum, 
through both Western Blot and ELISA analysis within our laboratory. Furthermore, based 
on our crystallisation studies, we can report a set of experimental conditions to which one 
may follow up to refine the crystallisation of mCRP and a complex of CRP, C1qGHR and 
CWPS. 
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5.2   Production, Purification and Characterisation of Monomeric C-
reactive Protein  
 The experimental evidence provided in Chapter 2 discusses the production, 
purification and characterisation of in vitro produced mCRP. A large proportion of the 
research documented within the literature, which describes the potential pro-inflammatory 
effects of mCRP, uses similar methods of urea-induced dissociation to produce mCRP for 
their experiments. Our dissociation trials helped determine the optimum conditions required 
to produce mCRP within the most realistic timeframe possible for our research. Although 
we could not be certain of any modifications urea-induced dissociation may have on the CRP 
protein, additional characterisation experiments carried out provide an insight into the 
structural and biological stability of the protein. Interestingly, re-introducing mCRP into a 
standard storage calcium buffer for extended periods of time did not result in re-association. 
We hypothesised this is due to urea-induced modifications to the lysine residues involved in 
the non-covalent interactions occurring between the CRP protomers; fortunately, this did not 
seem to alter structural or biological properties of the protein. Confirmation of this could be 
achieved through successful crystallisation of the mCRP protein.  
 Dissociation trials within our research group demonstrated that urea alone was not 
sufficient to induce dissociation of the native CRP molecule; EDTA, a calcium chelator was 
required. The dependence on the removal of calcium highlights its importance in maintaining 
structural integrity of the protein. Moreover, Shrive et al., (1996), have previously 
demonstrated the removal of calcium results in structural changes and exposure of sites 
which are susceptible to proteolysis (Ramadan et al., 2002; Shrive et al., 1996). Calcium 
was also shown to be crucial in maintain the protein’s biological activity when interacting 
with ligands. 
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 Purification of the mCRP samples via size exclusion chromatography not only 
provided us with a method of assessing the level of dissociation, but also allowed calculation 
of the elution volume for mCRP. Due to the lower levels of mCRP that we discovered within 
serum compared to that of pCRP, the protein failed to produce any elution peak when being 
run through the size exclusion column. The elution volume established through previous 
dissociation trials proved to be crucial when calculating where potential in vivo mCRP 
samples may elute off the column. Furthermore, identification of in vitro produced mCRP 
via Western Blot analysis suggested that the commercially available mAb could detect 
similar epitopes present on an in vivo form of mCRP. The experimental evidence from the 
precipitation studies highlighted several important features regarding mCRP. Firstly, the 
protein failed to follow the generic precipitation curve, like pCRP. This may be due to mCRP 
only displaying one binding site to phosphocholine (PC), whereas pCRP contains five. This 
therefore prevents mCRP forming ‘cross-linkages’ with the ligand in an equivalence zone, 
which generates large levels of precipitation; a reaction commonly seen in antibody-antigen 
agglutination reactions. Alternatively, mCRP displayed an ability to bind and precipitate in 
smaller amounts, to larger, PC-bound ligands. As there are large volumes of literature 
referring to a ‘membrane-bound CRP’ form, one may assume that an in vivo form of mCRP 
could exhibit similar features (Ciubotaru et al., 2005; Ji et al., 2009; Li et al., 2012; Zhao & 
Shi, 2010). 
5.3   Analysis of Human Serum Samples 
 
 We tested 40 patient’s serum samples for the presence of mCRP, who displayed 
raised levels of pCRP (>100mg/L). We hypothesised that to increase our chances of 
detecting mCRP; we would recruit participants who already displayed significantly raised 
levels of pCRP. Additionally, we hypothesised that out of the 40 human samples that we 
tested, 15% (6 participants) would test positive for the presence of mCRP. Analysis of the 
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serum from all participants revealed that all 40 samples tested positive for mCRP. To our 
knowledge, this is the first report of the presence of mCRP identified through both Western 
Blot and ELISA analysis, post-serum purification.  
 Previous research has reported the detection of mCRP within the serum of patients 
who had suffered a myocardial infarction (20.96 ± 1.64ng/ml) (Wang et al., 2015). 
Furthermore, they also described the isolation of mCRP within patients with raised levels of 
pCRP (>3mg/L). The clinical data provided from this study, coupled with our experimental 
research, further contributes towards the hypothesis that mCRP is present within the human 
body. Comparison between levels detected within both studies highlights differences in the 
mean levels detected, although these figures are only provided from 6 participants, with 
further research needed. Dissimilar to our research, Wang et al, identified and measured 
mCRP levels through ELISA analysis of neat serum, which may encounter complications as 
pCRP has been reported to dissociate upon binding to ELISA plates (Eisenhardt et al., 2011). 
In our study, we have overcome this by providing a unique additional analysis which 
demonstrates ability for PC binding, alongside molecular weight determination through size 
exclusion chromatography and Western Blot analysis.  
We provide here evidence of a monomeric form of CRP within serum through two 
separate established procedures. We also conclude that standard quantitative tests, such as 
ELISA can measure levels of both in vitro mCRP and pCRP, but do not distinguish between 
the two isoforms. The same is plausible for the automated systems used within clinical 
practice, as these also rely on the same formation of the antigen-antibody complex. This 
research should therefore provoke clinicians to consider re-evaluating the methods in which 
they measure CRP levels within serum. Scientific evidence suggests a pro-inflammatory role 
for mCRP, with others suggesting raised levels acting as a biomarker in life-threatening 
circumstances (Wang et al., 2015). This inability for current automated systems to 
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differentiate between levels of pCRP and mCRP may result in patients receiving the wrong 
care and/or treatment. Monomeric CRP has also been detected on the surface of various cells 
within the body (Habersberger et al., 2012). As we have shown, in vitro mCRP can bind to 
PC; it is entirely plausible that membrane-bound CRP also exists, with membrane binding 
potentially contributing to its formation.  
5.4   Crystallisation Trials 
 
The crystallisation trials involving mCRP failed to produce any protein crystals of 
sufficient diffraction quality, we do however provide a list of potential conditions which may 
be followed up. High salt-based precipitants were found to be the most successful in 
producing small crystal-like structures which may have acted as nucleation points to allow 
crystal growth. Successful crystallisation of these conditions may eventually allow us a 
greater understanding of this proteins atomic structure. Although it may not be identical to 
that located within the human body, it will provide a more detailed structural knowledge of 
a monomeric unit of CRP, in addition to any modifications sustained through urea-induced 
dissociation.  
Crystallisation studies with the complex involved pCRP, C1qGHR and CWPS. 
Similar to that observed within the mCRP crystallisation trails, we failed to produce any 
protein crystals which would diffract to a high enough standard for structural determination. 
The complex itself is extremely large which can sometimes prove difficult when trying to 
crystallise proteins within a uniformly organised lattice. That said, what we have achieved 
is a set of conditions which one could refine, and follow up, to promote the growth of 
sufficient, diffraction quality crystals. A series of high salt based precipitants were found to 
be the most successful when producing crystals, an observation which was common in both 
complex and mCRP crystallisation trials. Small, poorly formed showers of crystals were also 
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commonly seen in these trials, suggesting alterations are required in the concentration of 
proteins used.  
As previously stated, CRP precipitates out with CWPS. Based on established 
precipitation studies (Volanakis, 1982) we managed to determine the ratio of CRP and 
CWPS which would result in low levels of precipitation when combining the samples. 
Furthermore, incubation of CRP with C1qGHR was thought to stabilise this interaction, 
further reducing precipitation levels. Several of the crystals which were produced dissolved 
upon the addition of cryoprotectant, with glycerol proving to be the most stable. This 
additional knowledge could also be used in the future studies; alongside the conditions we 
have provided should more follow-up conditions be trialled.  
5.5   Conclusion 
 
The research described here provides evidence for a monomeric form of human CRP 
through both ELISA and Western Blot analysis. The identification of mCRP through two 
separate procedures was crucial within our research as it not only synergistically backed up 
our experimental methodology but also provided us with both the molecular weight and 
quantifiable levels of the protein. Our methodology was further supported by samples which 
recorded the highest values through ELISA analysis also displaying positive bands on the 
Western Blots. Furthermore, the quantification of pCRP levels via the ELISA analysis was 
additionally reinforced by the UV Spectrophotometer readings of the purified samples. 
Unfortunately, the purified samples did display significant differences to the initial CRP 
concentrations, which could be down to several reasons, such as losses through the 
methodology used, or CRP may already have been ligand-bound, thus resisting purification. 
What is remarkable is that despite these losses, mCRP was still identified within all 40 of 
the human samples at relatively high concentrations compared to previous research, raising 
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the question of what levels of mCRP might be within neat human serum. Interestingly, the 
purified mCRP from human serum displayed similar characteristics to that of in vitro 
produced mCRP. This may provide further insight into the potential characteristics of the 
protein which been used heavily to document its pro-inflammatory properties. The formation 
of mCRP within the human body may not be solely linked to increased levels of pCRP, as 
we initially hypothesised. We speculate that alternative pathophysiological conditions within 
the human body may be required for its formation. In addition, structural determination of 
both mCRP and the complex will further aid in our understanding of both pentameric and 
monomeric CRP, and how they interact with their respective ligands. 
The full clinical significance of this research is yet to be established. Important points 
that have previously been raised need to be addressed before a realistic approach for the re-
evaluation of clinical CRP tests can be considered. What is clear from this research is that 
there is sound justification for further studies involving mCRP. Only through the recruitment 
of larger cohorts from the population can we begin to answer some of these questions and 
fully understand CRP’s role within the human body. 
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Appendix 1. 
 
University Hospitals of North Midlands 
The Royal Stoke University Hospital 
Newcastle Rd, 
Stoke-on-Trent 
Staffordshire 
ST4 6QG 
01782 715444 
PATIENT INFORMATION SHEET 
We would like to invite you to take part in a new research study. Before you decide 
whether to take part, it is important that you understand why the research is being 
done and what it would involve for you. One of the research team will go through the 
information sheet with you and will answer any questions you may have. We expect 
this should take no more than 15 minutes. If you are happy to participate we will ask 
you to sign a written consent form to acknowledge this. 
Study title: Is monomeric C-reactive Protein present within Human Serum? 
What is the purpose of the study? 
 The purpose of this study is to determine whether a specific version of a protein 
(known as C-reactive Protein or CRP) can be found within the serum of patients who 
have already been identified as having raised levels of CRP through a routine blood 
test.  There is evidence that the version of the protein we are looking for may 
contribute to inflammation.  It is thought that current blood tests for CRP do not 
include the version of the protein we are looking for in their measurements.  The 
research will be carried out using the serum left over after all of the routine blood tests 
have been done; there will be no need to collect any extra blood from you. 
Why have I been invited to take part? 
You have been invited to take part in this study because your routine blood tests have 
shown raised CRP levels (>100mg/L).  We would like to use the serum sample that is 
left over following completion of all of your routine blood tests. 
Do I have to take part? 
No, taking part in the study is voluntary. If you do decide to take part you will be 
asked to sign a consent form and you should keep this information sheet for future 
reference. You will retain the right to withdraw from the study at any time. 
 
What will I have to do if I take part? 
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You will not need to do anything other than sign the consent form.  If you decide to 
take part you will: 
(i) Agree to read through, sign and date one of our participant consent forms 
(2x copies). 
(ii) Agree for us to use any excess blood taken from your routine blood test 
procedure (that would normally be discarded), in order to test for a specific 
type of CRP. 
 
You will not be required to undergo any procedure that is not already part of your 
routine clinical care at the hospital. This will complete your role within the study. 
What is the benefit of taking part? 
Although you will not benefit directly from the study, the data we collect will help us 
determine whether a specific type of CRP is located within human blood serum. We 
hope to identify whether current clinical practice, when measuring CRP levels, needs 
to be reconsidered.  
Will taking part change my treatment and care? 
Taking part in the study will not influence your treatment and care. This will continue 
as directed by your Doctor. There will be no further risk to you outside that already 
present in the routine collection of blood. 
Will my information be kept confidential? 
Your name will be included on your consent form, but all other study information and 
data will be kept confidential, anonymous and securely. You will never be identified 
by name in any communications or publications arising from the research. 
What will happen to the samples I donate? 
The samples will be used in a series of laboratory tests to determine whether a specific 
type of CRP is present within the blood. Once our study is completed, serum samples 
will be transferred back to the Hospital and stored for up to five years for potential 
future research. Your sample will remain anonymised and you will never be identified 
in any communications or publications from any research. Information generated from 
this study will be included within the thesis write up by Mr Robert Williams, PhD 
student at Keele University.   
Who is conducting the research? 
The research is led by Dr Annette Shrive (Keele University). Her co-investigators are 
Mr Robert Williams and Professor Tony Fryer (Keele University and University 
Hospitals of North Midlands respectively). The laboratory tests will be conducted at 
Keele University. It is being funded by Keele University. 
Who should I contact for more information? 
Patients can contact the Patient Advice and Liaison service (PALS) by telephone on 
01782 676450/676455 or via email to patient.advice@uhns.nhs.uk for an independent 
contact point where they can seek general advice about taking part in research. 
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In addition, for further information about this study, patients can also contact the 
researchers listed below. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Mr Robert Williams 
Mr Robert Williams 
Postgraduate Researcher 
Huxley Building, Keele University 
Keele 
ST5 5BG 
Tel: 01782 734441 
Dr Annette Shrive 
Structural Biology Researcher & Lecturer  
Huxley Building, Keele University 
Keele 
ST5 5BG 
Tel: 01782 734441 
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Appendix 2.  
 
University Hospitals of North Midlands 
The Royal Stoke University Hospital 
Newcastle Rd, 
Stoke-on-Trent 
Staffordshire 
ST4 6QG 
01782 715444 
PATIENT CONSENT FORM 
 
Title of Project: Is monomeric C-reactive Protein present within the serum of patients with 
raised levels of C-reactive Protein (>100mg/L)? 
Name of Researcher: Dr A. Shrive, Mr R. Williams, Prof T. Fryer, Prof T. Greenhough 
 
Study Centre: Royal Stoke University Hospital / Keele University 
Study Number: CRP1 
Patient ID Number for this study: A001 
Please initial box 
 
1. I confirm that I have been guided through and understand the information 
sheet dated 25th March 2015, version 2, for the above study, and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason and without my medical care or legal 
rights being affected. 
 
3. I understand that sections of my medical notes may be looked at by 
responsible individuals from regulatory authorities, the NHS trust or from 
the Sponsor (Keele University), where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my data. 
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4.  I understand that once the study has been completed, my serum sample will 
be transferred back to the Royal Stoke University Hospital, and kept for up 
to 5 years for potential future research. 
 
5. I agree to take part in the above study. 
 
 
 
  ________________________            ___________   _______________________ 
 Name of Patient Date     Signature 
 
 
  ________________________            ___________   _______________________ 
 Name of Person taking consent Date     Signature 
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Appendix 3. 
Structure Screen 1 
 
 
 
 
 
 
Structure Screen 2 
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Appendix 4. 
ProPlex Structure Screen 1 
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ProPlex Structure Screen 2 
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Appendix 5.  
CRP Concentrations for UHNM and Purified Samples, Volumes of Purified Samples 
and UV Spectrophotometer Readings for the Purified Samples (mCRP & pCRP) 
Sample Code 
Concentration of 
CRP Provided by 
UHNM (mg/L) 
pCRP Concentrations 
in Purified Samples 
(mg/L) 
Volume of 
Purified pCRP 
Samples (ml) 
mCRP 
Concentrations in 
Purified samples 
(mg/L) 
Volume of 
Purified mCRP 
Samples (ml) 
CRP 010 117.20 26.08 0.83 0.66 0.30 
CRP 012 263.90 66.78 0.78 2.02 0.90 
CRP 018 176.00 16.45 0.11 0.20 0.10 
CRP 021 320.90 29.06 0.22 0.36 0.20 
CRP 023 203.50 28.13 0.22 0.37 0.15 
CRP 027 108.40 2.93 0.28 0.08 0.05 
CRP 051 111.20 5.00 0.06 0.12 0.05 
CRP 052 172.10 41.84 0.89 0.75 0.50 
CRP 053 121.70 18.46 0.83 0.50 0.35 
CRP 059 239.60 25.44 0.28 0.87 0.50 
CRP 065 109.90 14.68 0.28 0.98 0.70 
CRP 066 198.70 11.12 0.22 0.58 0.70 
CRP 068 103.20 20.06 0.28 0.34 0.30 
CRP 069 144.90 29.14 0.33 3.07 0.90 
CRP 072 115.80 25.11 0.28 0.22 0.10 
CRP 075 354.30 5.41 0.17 0.31 0.20 
CRP 084 109.10 19.07 0.28 0.26 0.15 
CRP 096 279.80 32.60 0.28 0.04 0.05 
CRP 105 131.10 12.26 0.28 0.06 0.05 
CRP 106 101.70 17.72 0.28 0.71 0.50 
CRP 107 303.00 9.35 0.28 0.55 0.35 
CRP 108 215.40 7.08 0.28 0.72 0.50 
CRP 109 138.40 19.68 0.56 0.58 0.70 
CRP 110 131.00 13.75 0.28 0.62 0.70 
CRP 115 106.90 14.01 0.28 3.52 0.70 
CRP 117 112.50 26.88 0.28 0.32 0.30 
CRP 120 119.20 9.31 0.28 0.79 0.50 
CRP 124 173.90 14.43 0.28 0.79 0.50 
CRP 146 130.80 22.64 0.28 1.07 0.50 
CRP 148 262.10 27.66 0.28 3.28 0.50 
CRP 153 209.80 30.40 0.44 1.15 0.60 
CRP171 149.90 25.24 0.33 0.79 0.50 
CRP175 387.80 27.03 0.44 0.58 0.35 
CRP182 126.70 21.89 0.33 0.58 0.35 
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CRP191 139.40 38.37 0.44 0.74 0.45 
CRP 196 149.20 20.73 0.44 1.03 0.80 
CRP 200 254.50 49.74 0.56 0.75 0.50 
CRP 201 125.40 24.99 0.56 1.02 0.65 
CRP 204 448.60 60.90 0.56 3.51 0.65 
CRP 207 168.00 20.73 0.44 0.43 0.50 
 
Sample Code 
 Purified pCRP 
Concentrations from UV 
Spectrophotometer 
(mg/ml) 
 Purified mCRP 
Concentrations from 
UV Spectrophotometer 
(mg/ml) 
CRP 010 0.040 0.010 
CRP 012 0.050 0.010 
CRP 018 0.010 0.010 
CRP 021 0.140 0.010 
CRP 023 0.120 0.010 
CRP 027 0.010 0.000 
CRP 051 0.010 0.000 
CRP 052 0.040 0.010 
CRP 053 0.040 0.000 
CRP 059 0.010 0.000 
CRP 065 0.090 0.010 
CRP 066 0.060 0.000 
CRP 068 0.090 0.000 
CRP 069 0.080 0.000 
CRP 072 0.070 0.000 
CRP 075 0.050 0.010 
CRP 084 0.080 0.000 
CRP 096 0.200 0.000 
CRP 105 0.060 0.010 
CRP 106 0.060 0.000 
CRP 107 0.040 0.000 
CRP 108 0.030 0.000 
CRP 109 0.040 0.000 
CRP 110 0.060 0.000 
CRP 115 0.050 0.000 
CRP 117 0.050 0.000 
CRP 120 0.060 0.000 
CRP 124 0.070 0.000 
CRP 146 0.020 0.000 
CRP 148 0.050 0.020 
CRP 153 0.010 0.000 
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CRP171 0.070 0.000 
CRP175 0.030 0.000 
CRP182 0.090 0.000 
CRP191 0.080 0.000 
CRP 196 0.060 0.000 
CRP 200 0.040 0.000 
CRP 201 0.040 0.000 
CRP 204 0.150 0.010 
CRP 207 0.060 0.000 
 
 
 
 
 
 
 
 
